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Abstract
Pregestational diabetes mellitus (PGDM) and gestational diabetes mellitus (GDM) are
associated with adverse pregnancy outcomes including increased caesarean section rates,
macrosomia, and perinatal mortality. Despite the high prevalence of GDM and PGDM in
the Eastern Mediterranean Region (EMR), most of the published studies examining the
association between GDM/PGDM and adverse pregnancy outcomes have small sample
sizes, low statistical power, and few adverse outcomes with conflicting results. The
purpose of this study was to determine the association of GDM/PGDM with adverse
pregnancy outcomes among women in the EMR, by using a meta-analysis research
design. Following the conceptual model of the epidemiologic triangle, the research
questions for this study tested whether an association existed between GDM/PGDM and
delivery by cesarean section, macrosomia, and perinatal mortality among women in the
EMR. A random effects model was used for merging the weighted average of the odds
ratios in the 33 primary studies. Pooling of the data showed that, in the EMR, odds of
undergoing caesarean section, of having a macrosomic baby, and of perinatal death
among women with GDM/PGDM were higher than those without GDM/PGDM. This
study contributes to social change by providing a better picture of magnitude and severity
of GDM/PGDM, in creating awareness of the seriousness of the problem, and in helping
inform public health interventions in the EMR. Women with GDM/PGDM receiving
proper health care can have decreased adverse outcomes which, in turn, results in healthy
mothers and children forming a healthy family and leading to a healthy, productive
community.
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Chapter 1: Introduction to the Study
Introduction
Globally, researchers are concerned about an increase in the prevalence of
gestational diabetes mellitus (GDM) and pregestational diabetes (PGDM; Carolan,
Davey, Biro, & Kealy, 2011). Middle Eastern countries are reported to have a high
prevalence of GDM and PGDM, ranging from 4.7% in Iran (Hossein-Nezhad,
Maghbooli, Vassigh, & Larijani, 2007) to 24.9% in the United Arab Emirates (Agarwal,
Dhatt, & Shah, 2010) in comparison to the United States, where the prevalence ranges
from 3.47% to 7.15% (Bardenheier et al., 2013). PGDM and GDM are associated with
adverse fetal and maternal outcomes (Crowther et al., 2005; Metzger et al., 2008).
Adverse fetal outcomes include congenital anomalies, trauma during birth, macrosomia,
and perinatal mortality (Ayaz, Saeed, Farooq, Ali Bahoo, & Hanif, 2009; Ornoy, 2011;
Rosenberg, Garbers, Lipkind, & Chiasson, 2005; Thorpe et al., 2005). Adverse maternal
outcomes include increased rates of caesarean section and increased lifetime risk of
developing type 2 diabetes ( Bellamy, Casas, Hingorani, & Williams, 2009; Langer,
Yogev, Most, & Xenakis, 2005; Rosenberg et al., 2005). Cesarean deliveries may be
associated with a range of morbidities, with complications ranging from mild to serious
(Silver et al., 2006). Wound infection and wound rupture associated with prolonged
hospital stay may follow a caesarean section. Injuries to bowel, urinary bladder or urethra
may occur during the surgical procedure. Repeated caesarean sections may result in
placenta accreta, a serious obstetric complication resulting from deep attachment of the
placenta. Deep venous thrombosis, pulmonary embolism—and in rare cases maternal
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death—may occur (Silver et al., 2006). Generally, maternal morbidity increases with
repeated caesarean sections. The complications of repeated caesarean sections are
especially important in the context of those cultures where large families are a norm, as is
the custom in most countries of the Middle Eastern Region.
There are a few small-scale published studies examining the association between
GDM/PGDM and maternal and fetal outcomes among women in the EMR; many of these
studies do not have adequate sample size and have only a few adverse outcomes
(Abdelgadir, Elbagir, Eltom, Eltom, & Berne, 2003; Al-Dabbous, Owa, Nasserallah, &
al-Qurash, 1996; Misra, Rashid, Grundsell, & Sedagathian, 2001). Due to the rare
occurrence of adverse outcomes and small sample sizes in the published studies, the
estimates of association may not be stable. Because of the increasing prevalence of
PGDM and GDM and the extent of morbidity caused by them, research efforts need to
focus on the magnitude of the problem in the EMR. Determining the magnitude of
association between GDM/PGDM and adverse pregnancy outcomes is an important
initial step in understanding the epidemiology of adverse pregnancy outcomes as they
relate to PGDM and GDM in the EMR.
In this Chapter, I provide the background of the study, problem statement,
purpose of the study, research questions and hypotheses, nature of the study, conceptual
model, assumptions and limitations of the study, delimitations, and significance of the
study. I end the chapter with a summary of the chapter and transition to the next.
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Background
Diabetes mellitus is a chronic condition characterized by increased glucose levels
in the body. The long-term increased levels of glucose, called hyperglycemia, result in
various health complications (International Diabetes Federation [IDF], 2011; Maraschin,
2012). There are three main types of diabetes mellitus; type 1 diabetes mellitus, type 2
diabetes mellitus, and GDM (IDF, 2011). Diabetes during pregnancy can be classified
into two categories; PGDM and GDM (Lawrence, Contreras, Chen, & Sacks, 2008).
Type 1 or type 2 diabetes diagnosed in pregnant women before pregnancy is called
pregestational diabetes mellitus (Lawrence et al., 2008). Women diagnosed with diabetes
for the first time, during pregnancy, are diagnosed with gestational diabetes mellitus
(Bentley-Lewis, Levkoff, Stuebe, & Seely, 2008; Black, Sacks, Xiang, & Lawrence,
2010; Kim et al., 2010; Luoto et al., 2011; Reece, Leguizamón, & Wiznitzer, 2009).
PGDM and GDM are common medical conditions during pregnancy.
There is an increasing trend in the prevalence of PGDM and GDM (Bell et al.,
2008; Carolan et al., 2011; Jiwani et al., 2012; Lawrence et al., 2008). This increase in
prevalence is seen globally, as well as in the EMR. According to the World Health
Organization [WHO], the Eastern Mediterranean Regional Office [EMRO] consists of a
group of WHO member states in one of its six geographical regions and includes 22
Middle Eastern countries, such as Afghanistan, Bahrain, Djibouti, Egypt, Iran, Iraq,
Jordan, Kuwait, Lebanon and Libya. Morocco, Oman, Pakistan, Palestine, Qatar, Saudi
Arabia, Somalia, Sudan, Syria, Tunisia, United Arab Emirates [UAE], and Yemen
(WHO, n.d.). Middle Eastern countries have a high prevalence of GDM and PGDM in
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comparison to other countries of the world (Agarwal et al., 2010; Hossein-Nezhad et al.,
2007). Depending on the diagnostic criteria, the prevalence of GDM in UAE ranged from
7.9% to 24.9% (Agarwal, Dhatt, Punnose, & Koster, 2005). Researchers have also
reported high incidence of GDM. In Yazd, Iran, the incidence of GDM was shown to be
10.2% among 1,071 pregnant women screened for GDM (Soheilykhah et al., 2010). In a
large retrospective cohort study, in Bahrain, the incidence of GDM was found to increase
from 7.2% in 2002 to 12.5% in 2010 (Rajab, Issa, Hasan, Rajab, & Jaradat, 2012). With
this increasing incidence, the burden of adverse pregnancy outcomes is also expected to
increase.
Adverse maternal and fetal outcomes in women having pregnancy with diabetes
have been documented in the EMR. Bener, Saleh, and Al-Hamaq (2011) studied a cohort
of 1,608 pregnant women in Qatar. There was an increased incidence of maternal
complications, such as preeclampsia and cesarean section, in women with GDM. Gasim
(2012) compared pregnancy outcomes in 220 Saudi women with GDM/PGDM and 220
without GDM/PGDM. The researcher found a significantly higher incidence of cesarean
section (p = 0.0019) and macrosomia (p = 0.0186) among women with GDM/PGDM in
comparison to those without GDM/PGDM. However, the difference between congenital
anomalies and perinatal mortality rates was not statistically significant between the two
groups. Several researchers found that GDM/PGDM increased rates of caesarean section
(Badakhsh et al., 2012; Barakat, Youssef and Al-Lawati, 2010; Hossein-Nezhad et al.,
2007; Misra et al., 2001). Additionally, researchers have suggested that GDM/PGDM
increases risk for macrosomia (Al-Khalifah, Al-Faleh, Al-Subaihin, Al-Kharfi, & Al-
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Alaiyan, 2012; Barakat et al., 2010; Hossein-Nezhad et al., 2007; Keshavarz et al., 2005;
Nasrat et al., 1993) and perinatal mortality (Hossein-Nezhad et al., 2007; Keshavarz et al.,
2005; Misra et al., 2001). Contradictory results regarding the association of adverse
outcomes and GDM/PGDM in the EMR have also been documented.
While a positive association of GDM/PGDM and delivery by cesarean section
was seen in some studies (Bener et al., 2011; Gasim, 2012), a non-statistically significant
association between GDM/PGDM and delivery by cesarean section has also been seen
(Nasrat, Augensen, Abushal, & Shalhoub, 1994). Similarly, there is evidence that the
association between GDM/PGDM and macrosomia is not statistically significant. (AlKhalifah et al., 2012; Shirazian et al., 2008). Due to a low number of perinatal deaths in
any single study, estimates of the association between GDM/PGDM and perinatal
mortality were underpowered and unstable (Abdelgadir et al., 2003; Gasim, 2012).
Overall, most studies have had a limited number of participants resulting in low precision
for estimating the association with GDM/PGDM. For example, Abolfazl, Hamidreza,
Narges, and Maryam (2008) included 70 women with GDM and Keshavarz et al. (2005)
were able to include 63 women with GDM in their studies. Many studies conducted to
determine the effect of GDM/PGDM on pregnancy outcomes had low power. For
example, the study conducted by Sobande, Al-Bar, and Archibong (2000) had a power of
41.7% at an alpha level of 0.05, to determine a statistically significant difference of
perinatal deaths between women with GDM/PGDM and those without GDM/PGDM.
Synthesizing the results of these studies by meta-analysis served to increase the sample
size and thus improve the precision of the desired associations to be estimated (The
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Cochrane Collaboration, 2008). Meta-analysis is considered one of the best methods to
inform evidence-based decisions for health care (Lavis et al., 2005; Wallace, Nwosu, &
Clarke, 2012). Meta-analysis is also helpful in planning future research for delivering
optimal health care (Cook, Mulrow, & Haynes, 1997; Roloff, Higgins, & Sutton, 2013).
There is a need for precise and valid estimates of the true association between adverse
pregnancy outcomes and GDM/PGDM among women in EMR.
Problem Statement
Despite the reported high prevalence of GDM and PGDM in Middle Eastern
countries (Agarwal et al., 2010; Hossein-Nezhad et al., 2007), most of the published
studies examining the association between GDM/PGDM and adverse outcomes in this
region are conducted on a small scale with varied and sometimes conflicting results (AlHakeem, 2006; Al-Khalifah et al., 2012; Barakat et al., 2010; Bener et al., 2011; Gasim,
2012; Keshavarz et al., 2005; Nasrat et al., 1994; Shirazian et al., 2008). The true
underlying association may not be well estimated due to small sample sizes, low
statistical power, and few adverse outcomes in any given study. The number of caesarean
sections and macrosomic babies born is low in any given study. Similarly, perinatal
mortality is an uncommon occurrence, and there are nil or few perinatal deaths in any
given study. Studies including multiple countries of the EMR have not been conducted,
thus resulting in a lack of information regarding a broader perspective of the situation in
the EMR. To date, there has not been an attempt to statistically synthesize studies from
countries in the EMR, by meta-analysis, to quantify complications related to pregnancy
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with GDM/PGDM with greater precision or to provide insight into the magnitude of the
association and extent of the problem in the EMR.
Purpose of the Study
The purpose of this study was to determine the association of GDM/PGDM with
adverse pregnancy outcomes among women in the EMR. Measuring the association of
GDM and PGDM with adverse pregnancy outcomes would help in providing a better
picture of magnitude and severity of the problem in the EMR. Given the rising
prevalence of GDM and PGDM in Middle Eastern countries, it is important to be aware
of the severity and seriousness of the problem. Determining the magnitude of association
between GDM/PGDM and adverse pregnancy outcomes is an important initial step for
developing appropriate interventions.
In this meta-analysis, independent variables were PGDM and GDM. The
dependent variable for maternal outcomes was delivery by cesarean section. The
dependent variables for neonatal outcomes were macrosomia/large for gestational age
and perinatal mortality.
Research Questions and Hypotheses
1. Is there an association between GDM/PGDM and delivery by cesarean section among
women in the EMR?
H01 - There is no association between GDM/PGDM and delivery by cesarean section
among women in the EMR
HA1 - There is an association between GDM/PGDM and delivery by cesarean section
among women in the EMR
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2. Is there an association between GDM/PGDM and adverse fetal outcomes among
women in the EMR?
2a. Is there an association between GDM/PGDM and macrosomia among women in
the EMR?
H02a - There is no association between GDM/PGDM and macrosomia among
women in the EMR
HA2a - There is an association between GDM/PGDM and macrosomia among
women in the EMR
2b. Is there an association between GDM/PGDM and perinatal mortality among
women in the EMR?
H02b - There is no association between GDM/PGDM and perinatal mortality
among women in the EMR
HA2b - There is an association between GDM/PGDM and perinatal mortality
among women in the EMR
Conceptual Model
The conceptual model for this study is the epidemiologic triangle— a traditional
model examining the agent, the host, and the environmental factors for an association in
causation of infectious disease (Centers for Disease Control and Prevention [CDC],
2009). The epidemiologic triangle explains disease causation by using a simple paradigm.
It states that the disease is caused by an imbalance among the factors related to host,
agent, and environment. The epidemiologic triangle was originally designed to explain
the cause of infectious diseases, but it has also been applied to noncommunicable
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diseases and other health problems (Huerta & Leventhal, 2002; Peller, LaPlante, &
Shaffer, 2008; Ramirez & Peek-Asa, 2005). The components of the epidemiologic
triangle include host factors related to humans making them susceptible to the agent or
causative factors, agent factors necessary for the causation of disease or health condition,
and environmental factors that are external to the host and agent (CDC, 2012).
The key elements of this study are related to the components of epidemiologic
triangle. The agent factor for GDM/PGDM is the hormone insulin. Adverse outcomes of
GDM/PGDM such as macrosomia, delivery by caesarean section, and perinatal mortality
are associated with insulin resistance during pregnancy (Young & Ecker, 2013). The host
factors consist of both nonmodifiable and modifiable factors including age, race, family
history of diabetes, and lifestyle factors, including diet and physical activity. Regarding
the association of adverse outcomes of GDM/PGDM with host factors, an association
between caesarean delivery and race/ethnicity has been documented (Esakoff, Caughey,
Block-Kurbisch, Inturrisi, & Cheng, 2011). An association between increasing age and
increased prepregnancy BMI with macrosomia as well as cesarean delivery is reported
(Beucher, Viaris de Lesegno, & Dreyfus, 2010; Gutaj, Wender-Ozegowska, Mantaj,
Zawiejska, & Brazert, 2011). Environmental factors that contribute to GDM/PGDM may
be physical, social, and economic. The availability and affordability of healthy food,
cultural values, and accessibility to health care facilities are some of the environmental
factors. In turn, these environmental factors are also related to obesity and maternal and
fetal outcomes of GDM/PGDM, including macrosomia, caesarean delivery, and perinatal
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mortality (El-Chaar et al., 2013; Yogev & Visser, 2009). I discuss the conceptual model
in more detail in Chapter 2.
Nature of the Study
To determine an association between GDM/PGDM and adverse pregnancy
outcomes among Eastern Mediterranean women, quantitative research was conducted.
For the purpose of this study, I used a meta-analysis research design. Meta-analysis is an
appropriate technique for this quantitative research because magnitude of association was
determined by combining results of studies from most countries of the region, conducted
over various periods of time in varied settings. An original study of this extent would
have been resource-intensive and difficult to conduct because of the adverse social,
economic, and political situation of many member countries. Meta-analysis is appropriate
as it statistically combines quantitative estimates from various primary studies (Sutton et
al., 2000). Moreover, meta-analysis may identify gaps in the existing literature (Garg,
Hackam, & Tonelli, 2008). In this meta-analysis, the independent variables were
GDM/PGDM. The dependent variable for maternal outcome was delivery by cesarean
section while the dependent variables for neonatal outcomes were macrosomia and
perinatal mortality.
Search Strategy for Relevant Studies
A review of studies conducted on GDM/PGDM in the EMR was conducted to
systematically identify the relevant literature. A comprehensive literature search was
conducted in several research databases. Explicit criteria for inclusion or exclusion were
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used for meta-analyses. Detailed search strategy, inclusion and exclusion criteria, are
explained in Chapter 3.
Details of the study included in the meta-analysis. The guidelines for reporting
a meta-analysis of observational studies was followed (Stroup et al., 2000). A summary
table was created to record the main elements of each study, such as relevant
bibliographic information, the studies’ design, type(s) of diabetes mellitus, age group/
mean age of women, and outcome data (Glasziou, Irwig, Bain, & Colditz, 2001). To
assess individual observational studies, quality criteria were laid down by selecting
elements from the Strengthening the Reporting of Observational Studies in Epidemiology
(STROBE) guideline (Von Elm et al., 2007). The details of these criteria are stated in
Chapter 3.
Statistical Procedures
The software, Comprehensive Meta Analysis (Version 2) , was used to conduct
the meta-analysis. Statistical procedures included effect size computation, random effects
model, heterogeneity assessment, sensitivity analysis, sub-group analysis, moderator
analysis and publication bias assessment.
An effect size is a number that expresses the magnitude of the association
between two variables (Cooper & Hedges, 2009). To calculate effect sizes in this study,
odds ratio (OR) was the primary metric, because the OR has certain statistical properties
that make it the best index for a meta-analysis (Borenstein, Hedges, Higgins, &
Rothstein, 2009, p. 36). For merging effect sizes, a random effects model was used
because of the presence of a heterogeneous population and potential diversity among the
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studies (Cooper & Hedges, 2009; Petticrew & Roberts, 2006). Statistical significance of
heterogeneity was assessed by Cochrane’s Q statistic and I-squared (Borenstein et al.,
2009). The details of these statistics are provided in Chapter 3.
Sensitivity analyses were performed to assess variation in effect size caused by
study design, sample size, and country of study (Borenstein et al., 2009). The influence of
outliers was also evaluated to determine the affect of their omission on overall results
(Tobias et al., 2010). The possible presence of publication bias was evaluated by funnel
plot (Egger, Smith, Schneider, & Minder, 1997) and Egger’s test (Crombie, & Davies,
2009; Wendland et al., 2012).
Definitions of the Variables
In this study, the independent variables were GDM and PGDM, while the
dependent variables were caesarean section, macrosomia, and perinatal mortality. The
definitions of independent variables and dependent variables are as follows:
GDM - Glucose intolerance leading to hyperglycemia, diagnosed first time in
pregnancy is labeled as gestational diabetes mellitus (Bentley-Lewis et al., 2008;
Black et al., 2010; Kim et al., 2010; Luoto et al., 2011; Reece et al., 2009). In this
research, the study participants labeled by the authors as gestational diabetes was
accepted as GDM cases, irrespective of the diagnostic criteria used.
PGDM - Type 1 or type 2 diabetes diagnosed in pregnant women before pregnancy
is called PGDM (Lawrence et al., 2008). The study participants labeled by the
authors as PGDM were accepted as PGDM cases.
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Cesarean section - Cesarean section is a surgical technique for delivering a baby by
incision through the abdominal wall and uterus of the mother (Mayo Clinic, 2012).
For the sake of this study, the birth labeled by authors as cesarean delivery was
accepted as birth by cesarean section.
Macrosomia or large for gestational age - Macrosomia signifies a newborn with an
excessive birth weight. There are different ways of defining fetal macrosomia. A
birth weight of 4000-4500 g (8 lb 13 oz to 9 lb 15 oz) or more than 90% for
gestational age is labeled macrosomia (Medscape, 2012). For this meta-analysis,
macrosomia and large for gestational age births were included as defined by the
authors of the primary study.
Perinatal mortality - Perinatal mortality refers to fetal (20 or more weeks of
gestation) deaths as well as neonatal deaths (MacDorman, Kirmeyer, & Wilson,
2012). Perinatal mortality included intrauterine fetal death, stillbirth, and early
neonatal death.
Assumptions
The assumptions in this study were mostly related to the primary studies included
in the meta-analysis. It was assumed that the primary studies were conducted rigorously,
taking care of quality measures during study design and data collection. It was assumed
that appropriate statistical analysis was conducted, and that the authors made sound
decisions to reduce the role of bias and confounding in their studies. It was also assumed
that, in spite of different diagnostic criteria used for GDM diagnosis, the effects on the
frequency of adverse outcomes would have been minimal. All of these assumptions were
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necessary in the context of this study because the results of meta-analysis depend on the
scientific rigor of the primary studies from which the data will be drawn (Garg et al.,
2008). Limitations of the primary studies—such as biases, weaknesses in methodology,
and inherent problems in the execution of the primary studies—cannot be rectified in
meta-analysis.
Scope and Delimitations
In this study, I focused on adverse pregnancy outcomes related only to PGDM/
GDM in the EMR women. Specifically, delivery by cesarean section, macrosomia, and
perinatal mortality were the adverse pregnancy outcomes of interest. This focus was
chosen due to the limited number of primary studies conducted in the EMR that had
small sample sizes with few adverse outcomes. The small sample sizes are primarily due
to the uncommon occurrence of macrosomia and perinatal mortality in the EMR. The low
incidence of macrosomia and perinatal mortality in the EMR supported the use of metaanalysis to estimate the associations between delivery by cesarean section, macrosomia,
and perinatal mortality with increased statistical power, greater precision, and improved
internal validity. As a result, other adverse pregnancy outcomes that have been linked to
GDM/PGDM, as well as their causative factors, could not be determined by this study.
This study was delimited to the population of the EMR countries in which the
primary studies were conducted. Thus, the results are valid and generalizable to the
specific set of countries in which the primary studies were conducted. The results may
not be generalized to other populations, such as Europeans or Americans.
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Limitations
This study has limitations which correspond with the limitations of meta-analyses
in general (Garg et al., 2008). The study includes diverse studies with different settings,
designs, and participants. The quality and reliability of the overall effect size and
conclusions of the study depend on the reliability and appropriateness of the methods
used by the primary studies. Meta-analysis of observational studies has certain specific
limitations, which are also reflected in this study. The role of chance, confounding
factors, or biases, may affect the results in primary observational studies which cannot be
rectified in the meta-analysis (Egger, Smith, & Schneider, 2008, pp.213-220). Another
limitation specific to this study is the variability in defining the dependent and
independent variables in primary studies. Variable diagnostic criteria were used for GDM
in various studies. Similarly, the definition of macrosomia/large for gestational age also
varied in primary studies. Variability in these definitions in primary studies might have
affected the results of meta-analysis.
To address the limitations in this study, the following steps were taken: a
comprehensive search strategy was used to avoid bias in study identification and
selection; the quality of the primary studies was assessed; the statistical methods for
calculation of combined effect size were appropriate; the test for heterogeneity and the
assessment for publication bias were carried out(Crombie & Davies, 2009). Standard
guidelines for reporting of meta-analysis including MOOSE (Stroup et al., 2000) and
PRISMA guidelines (Moher, Liberati, Tetzlaff, Altman, & The PRISMA Group, 2009)
were followed in this study.
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Significance
The present study is significant as it provides a broader perspective of adverse
pregnancy outcomes associated with GDM/PGDM among women in the EMR. Filling
gaps in the literature helps in creating positive social change which is an important aspect
of this study. Measuring the association of GDM/PGDM with adverse pregnancy
outcomes helps in providing a better picture of magnitude and severity of the problem in
the EMR, creating awareness about its severity and seriousness. Determining the
magnitude of association between GDM/PGDM and adverse pregnancy outcomes
constituted an important initial step for developing appropriate interventions.
Disseminating the results of this study can lead to measures that policy makers and health
care workers can take to develop intervention strategies for preventing complications
related to GDM/PGDM. Healthy mothers and children form a healthy family leading to a
healthy, productive community.
Summary
The prevalence of GDM/PGDM is rising globally and in the EMR, specifically.
Various studies have been conducted to determine the association of GDM/PGDM and
adverse pregnancy outcomes in this region. However, studies conducted on a large scale
to get a broader perspective of the region are lacking. This study determined a broader
perspective of these outcomes in the EMR by combining the findings of various studies
conducted on a small scale. Determining the magnitude and severity of association was a
necessary step before developing appropriate interventions to deal with the rising
problem of pregnancy with GDM/PGDM in the EMR.
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In this chapter, I discussed the background of the study, problem statement, and
purpose of the study. I identified the research questions, the related hypotheses, and
conceptual model for the study. A brief overview of the assumptions, scope and
limitations was provided. Finally, I concluded with a brief discussion of the significance
of the current study and implications for positive social change. A review of the literature
is presented in Chapter 2. It supports the planned research, including relevant studies on
adverse pregnancy outcomes in women with GDM/PGDM in the EMR.
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Chapter 2: Literature Review
Introduction
Globally, an increase in the prevalence of GDM and PGDM is reported (Carolan
et al., 2011). Middle Eastern countries are reported to have a high prevalence of GDM
and PGDM ranging from 4.7% in Iran (Hossein-Nezhad et al., 2007) to 24.9% in the
United Arab Emirates (Agarwal et al., 2010). PGDM and GDM are associated with
adverse maternal and fetal outcomes (Crowther et al., 2005; Metzger et al., 2008).
Adverse maternal outcomes include increased caesarean section rates and increased
lifetime risk of type 2 diabetes (Bellamy et al., 2009; Langer et al., 2005; Rosenberg et
al., 2005). Adverse fetal outcomes include congenital anomalies, trauma during birth,
macrosomia, and perinatal mortality (Ayaz et al., 2009; Ornoy, 2011; Rosenberg et al.,
2005; Thorpe et al., 2005).
Despite the reported high prevalence of GDM and PGDM in Middle Eastern
countries (Agarwal et al., 2010; Hossein-Nezhad et al., 2007), most of the published
studies examining the association between adverse outcomes and GDM/PGDM in this
region, were conducted on a small scale and showed varied results. These studies may not
depict the true, underlying association because of small sample sizes, low statistical
power. and few adverse outcomes in any given study. Synthesizing these studies
statistically, by meta-analysis, quantified complications related to pregnancy with
diabetes and provide insight regarding the magnitude of association and the extent of the
problem in the EMR.
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The purpose of this study was to determine the association between GDM/PGDM
and adverse pregnancy outcomes among women in the EMR. Measuring the association
of GDM/PGDM with adverse pregnancy outcomes helps in providing a better picture of
magnitude and severity of the problem in the EMR. Given the rising prevalence of
PGDM and GDM in Middle Eastern countries, it is important to be aware of the severity
and seriousness of the problem. Determining the magnitude of association between
GDM/PGDM and adverse pregnancy outcomes is an important initial step for developing
appropriate interventions.
This chapter will cover the literature search strategy, conceptual model of the
study, description of diabetes mellitus and its complications, followed by description of
pregnancy with diabetes (PGDM and GDM), risk factors and adverse maternal and fetal
outcomes of GDM/PGDM. The chapter also includes an overview of screening,
management, and prevention of GDM. The final section constitutes a review of the
methodologies of research and a rationale for using meta-analysis for this study, followed
by a summary of this chapter and transition to the next.
Literature Search Strategy
Information for the literature review was obtained by searching electronic
databases, journals' websites, theses and dissertations available electronically, and
reference lists of relevant articles and research documents. The electronic databases
included ABI/INFORM, Academic Search Premier, CINAHL, Cochrane Database of
Systematic Reviews (CDSR), Dissertations and Abstracts, Educational Resource
Information Center (ERIC), Emrmedex, Journals at Ovid, Library Information Science
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and Technology Abstract (LISTA), MEDLINE, Proquest, PsycINFO, and publishers’
databases, such as Elsevier and Springer. Google Scholar was also used to supplement
the research databases. The databases were searched from inception to January 2013 to
identify relevant citations. The following keywords were used to search the databases:
diabetes mellitus, type I diabetes, type 2 diabetes mellitus, NIDDM, pregnancy,
pregestational diabetes, gestational diabetes, diabetic pregnancy, diabetes in pregnancy,
pregnancy complications, outcome, macrosomia, cesarean, cross-sectional, case control,
and cohort studies. These terms were also searched in combination and with the names of
individual member countries of EMR. These countries included Afghanistan, Bahrain,
Djibouti, Egypt, Iran, Iraq, Jordan, Kuwait, Lebanon, Libya, Morocco, Oman, Pakistan,
Palestine, Qatar, Saudi Arabia, Somalia, Sudan, Syria, Tunisia, United Arab Emirates,
and Yemen.
I restricted my search to articles published in the English language. The search
limit start-date was chosen as the earliest date the database had been available. These
dates varied for various databases. For example, PubMed included articles published
since 1961 while research databases such asAcademic Search Complete, CINAHL Plus
with Full Text, Cochrane Database of Systematic Reviews, ERIC, Library, Information
Science & Technology Abstracts, MEDLINE with Full Text, SocINDEX with Full Text,
CINAHL Complete included articles published only since 1989. This list provided
access to numerous bibliographic resources on the topic which were examined, reviewed,
and included in this chapter. In addition to electronic database searches, articles cited in
meta-analyses and systematic reviews on PGDM and GDM, were reviewed. The
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reference lists of published literature on PGDM and GDM were also examined to identify
studies eligible for inclusion in this literature review.
Various sources of literature specific for EMR were searched and reviewed. The
medical journals of EMR such as Eastern Mediterranean Health Journal by World
Health Organization, Annals of Saudi Medicine, Saudi Medical Journal, and Saudi
Journal of Family and Community Medicine were hand-searched in the local libraries.
Internet searches were conducted using the keywords mentioned above, through search
engines such as Google Scholar. Websites such as World Health Organization Eastern
Mediterranean Regional Office (WHO EMRO), and websites of Ministry of Health of
member countries of EMRO were also searched for relevant researches. Individual
websites of medical journals of the EMR were explored for relevant articles. A thorough
literature review was conducted to determine the appropriate conceptual model for this
study which is described in the next section.
Conceptual Model
The epidemiologic triangle is a traditional model examining the agent, the host,
and the environmental factors to examine causation of infectious disease (CDC, 2009).
The epidemiologic triangle explains disease causation by using a simple paradigm. It
states that the disease is caused by an imbalance among the factors related to agent, host
and environment. The epidemiologic triangle has also been applied to non-communicable
diseases and health problems. Researchers have applied this model to earthquake-related
traumatic injuries (Ramirez & Peek-Asa, 2005), bio-terrorism (Huerta & Leventhal,
2002), and gambling behavior (Peller et al., 2008). Merrill (2010) suggested an advanced

22
model of the epidemiologic triangle for chronic diseases. The advanced model includes
the causes of chronic diseases in addition to the factors related to communicable diseases.
The advanced model recognizes the complex etiology of chronic diseases. The
components of the model include causative factors, the population group and their
characteristics, the environment, behavior, culture, physiological factors, and ecological
elements (Merrill, 2010). The components of epidemiologic triangle are explained as
follows:
x

Agent factors are those which are necessary for the causation of disease or

health condition. These factors may include a living or non-living substance, or a
force responsible for the event. The agent factors include biological agents such
as bacteria, virus and parasites; chemical substances such as poisons, pesticides,
medications; and physical factors including radiation, noise and heat (CDC, 2012;
Ferng, n.d.).
x

Host factors are related to humans making them susceptible to the agent or

causative factors. These include factors such as age, socioeconomic status,
physiologic factors, psychological factors, and behavioral factors (CDC, 2012).
x

Environmental factors stand for all those factors which are external to the

host and agent. Environmental factors are external factors which influence the
agent and the chances for exposure. These include geologic factors, such as
climate; biologic factors such as plants, animals, parasites,and viruses; and
socioeconomic factors, such as population distribution, housing, and health
services availability (CDC, 2012; Ferng, n.d.).
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For GDM and its outcomes, the epidemiologic triangle can be applied as follows:
Agent. The agent is the cause of the condition. The agent for GDM is insulin.
During pregnancy, some hormones (human placental lactogen, estrogen, and cortisol)
produced by placenta can affect the functions of insulin, causing "insulin resistance." If
the insulin production is not adequate to counter the effect of the placental hormones,
GDM results (Ohio State University, n.d.). Adverse outcomes of GDM/PGDM such as
macrosomia, delivery by caesarean section and perinatal mortality are associated with
insulin resistance during pregnancy (Young & Ecker, 2013).
Host. The host factors comprise of non-modifiable and modifiable factors. Nonmodifiable factors include age (women more than 25 years age are at a higher risk for
developing GDM than younger women); race (Asian American, American Indian,
African-American, or Pacific Islander have a greater risk); family history of diabetes;
having given birth previously to macrosomic baby, a stillbirth, or a child with a birth
defect. Modifiable factors include overweight/obesity; lifestyle factors including diet and
physical activity. Regarding the association of adverse outcomes of PGDM/GDM with
host factors, studies have demonstrated lower odds of caesarean delivery in Asian women
(adjusted odds ratio (aOR) =0.86, 95% CI [0.77–0.96]) as compared to European
American and African-Americans (Esakoff et al., 2011). Asians are also shown to have
lower odds (aOR=0.58, [95% CI 0.48–0.70]) of macrosomia and perinatal mortality as
compared to African-Americans (Esakoff et al., 2011). An association between
increasing age and increased pre-pregnancy BMI with macrosomia as well as cesarean
delivery is reported (Beucher et al., 2010; Gutaj et al., 2011).
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Environment. Environmental factors that contribute to GDM may include
physical, social and economic environment. Availability and affordability of healthy
food; cultural values and accessibility to health care facilities are some of the
environmental factors playing their role in the etiology of gestational diabetes. In turn,
these environmental factors are also related to maternal and fetal outcomes of
PGDM/GDM including macrosomia, caesarean delivery and perinatal mortality.
To sum up, the conceptual model for this study is epidemiologic triangle. Agent,
host and environment play an important role in the causation of diabetes mellitus,
PGDM/GDM, and their adverse maternal and fetal outcomes. The following section of
the chapter discusses burden of diabetes mellitus and its complications.
Burden of Diabetes Mellitus
Diabetes mellitus is a chronic condition characterized by increased glucose levels
in the body due to reduced production of insulin in the body or difficulty in utilizing
insulin effectively (International Diabetes Federation [IDF], 2011d; Maraschin, Murussi,
Witter, & Silveiro, 2010). There are three main types of diabetes mellitus; type 1 diabetes
mellitus, type 2 diabetes mellitus and GDM (IDF, 2011d; Maraschin, 2012). Type 2
diabetes mellitus is considered a global epidemic (Tovar, Chasan-Taber, Eggleston, &
Oken, 2011). Globally, 366 million people had diabetes in 2011. It is projected to rise to
552 million by 2030. Low- and middle-income countries bear the main brunt of the
problem having 80% of people with diabetes. In 2011, a total of 4.6 million deaths
occurred because of diabetes (IDF, 2011c). Rising incidence of diabetes mellitus has been
reported from various parts of the world. In the United States, the prevalence of diabetes
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mellitus is expected to rise from 16.2 million in 2005 to 48.3 million in 2050 (Feig,
Zinman, Wang, & Hux, 2008). Other parts of the world are also reporting rising
incidence of diabetes.
By 2020, an estimated 438 million people are predicted to have diabetes globally;
half of these will be residents of Asia (Hirst, Tran, Do, Morris, & Jeffery, 2012). In
South-East Asia, seven countries occupy almost one-fifth of people with diabetes,
worldwide (IDF, 2011b). The EMR includes six out of the world’s top 10 countries for
highest prevalence of diabetes. These countries are Kuwait, Lebanon, Qatar, Saudi
Arabia, Bahrain and the United Arab Emirates. A notable increase in the prevalence of
diabetes in these countries is attributed to rapid economic development and increased life
expectancy resulting in ageing populations. Moreover, rapid urbanization in wealthy oilproducing countries has caused lifestyle changes such as poor dietary habits and
decreased physical activity leading to obesity which is an important risk factor for
diabetes (IDF, 2011a). The countries with rapid socioeconomic changes have a greater
increase in prevalence of diabetes (Hirst et al., 2012).
In 2011, the prevalence of diabetes in the Middle East and North Africa region
was 9.1%, comprising of 32.8 million people with diabetes in this region (IDF, 2011a). It
is estimated that, in less than 20 years, this number will double reaching approximately
60 million. Majority of these persons have type 2 diabetes. In this region, the prevalence
of diabetes among younger persons is higher as compared to the prevalence recorded
globally. Moreover, 6.7% (24 million people) of the population have impaired glucose
tolerance (IGT) and are at high risk of having diabetes in the future. It is estimated that
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the number will by doubled by 2030. A total of 65,200 children have type 1 diabetes in
the region; Saudi Arabia has the highest number of children with type 1 diabetes (IDF,
2011a). During 2011, an estimated 280,000 deaths in the region, were attributed to
diabetes, which is approximately 10% of all deaths in adults in the region. The number of
deaths is almost similar in both genders; 141,000 in males while 138,000 in females
(IDF, 2011a). In addition to higher mortality, diabetes is also associated with increased
morbidity because of a host of diabetes complications.
Complications of Diabetes Mellitus
Diabetes mellitus results in a number of complications due to continuously
increased blood glucose levels. The complications may affect the heart and blood vessels,
nerves, kidneys or eyes. Heart disease, blindness, renal failure, and amputations may
occur as a result of complications of diabetes. Cardiovascular complications include
stroke, myocardial infarction, heart failure, and peripheral vascular disease (IDF, 2011d).
Diabetes doubles the risk of suffering from heart attack or a stroke. The risk of dying due
to coronary heart disease is 50% greater in women as compared to men (Anna, Ploeg,
Cheung, Huxley, & Bauman, 2008). Chronic kidney disease leading to renal failure is
another serious complication of diabetes mellitus. Diabetic retinopathy can damage
vision and may lead to blindness (IDF, 2011d). Diabetic neuropathies may cause
problems in gastrointestinal, genitourinary systems and the extremities. The extremities
may have pain, tingling or loss of sensation due to nerve damage. Loss of sensation leads
to unnoticed injuries which may result in gangrene leading to amputations. Persons with
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diabetes have an increased risk of gingivitis and a possible enhanced risk of obstructive
sleep apnea (IDF, 2011d). Women with diabetes face special risks during pregnancy.
Pregnancy with Diabetes Mellitus
Diabetes during pregnancy can be classified into two categories: PGDM and
GDM (Lawrence et al., 2008). A brief description of PGDM and GDM is provided as
follows:
Pregestational Diabetes Mellitus
Type 1 or type 2 diabetes diagnosed in pregnant women before pregnancy is
called PGDM (Lawrence et al., 2008). An increasing trend in the prevalence of PGDM is
reported by various studies. In a retrospective study of 175,249 pregnancies, the
prevalence of PGDM increased from 0.81 percent in 1999 to 1.82% in 2005. The study
included 209,287 deliveries with 20 or more weeks of gestation. These deliveries took
place during 1999 to 2005 in Kaiser Permanente hospitals, in southern California. Rising
prevalence was observed among all ages and all ethnic groups. Among all deliveries to
women with diabetes, 10% were due to PGDM in 1999, increasing to 21% in 2005
(Lawrence et al., 2008). Similar trend of increasing prevalence is reported from the
United Kingdom. A regional population-based survey in all maternity units in the North
of England included 1,258 pregnancies in women with PGDM delivered between 1996
and 2004. The study revealed that the prevalence of PGDM increased from 3.1 per 1,000
births in 1996-98 to 4.7 per 1,000 in 2002-04 (test for linear trend, p < 0.0001) (Bell et
al., 2008). Eastern Mediterranean Region is also reported having an increasing trend in
the prevalence of PGDM (Wahabi, Alzeidan, Bawazeer, Alansari, & Esmaeil, 2010).
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Pregestational diabetes has various adverse maternal and fetal outcomes. Poor
glycemic control during early pregnancy results in an increased incidence of spontaneous
abortions and congenital abnormalities (American Diabetes Association, 2004). It also
results in increased risk of macrosomia if hyperglycemia persists later in pregnancy. The
risk of preterm delivery and perinatal death is reported to be higher in women with type 1
diabetes (American Diabetes Association, 2004). PGDM is found to be associated with
disturbances of intrauterine growth and post-natal neurobehavioral abnormalities in the
offspring. In some studies, delayed brain maturity, inattention or hyperactivity is
observed in newborns of women with diabetes (Ornoy, 2005). Thus, PGDM may result in
substantial morbidity among women and their newborns.
Gestational Diabetes Mellitus
Glucose intolerance leading to hyperglycemia, diagnosed for the first time in
pregnancy is labeled as gestational diabetes mellitus (Bentley-Lewis et al., 2008; Black et
al., 2010; Kim et al., 2010; Luoto et al., 2011; Reece et al., 2009). Generally GDM
resolves after pregnancy. It is the most commonly diagnosed medical condition during
pregnancy (Moses & Cheung, 2009). Several risks are associated with GDM. Women
diagnosed with GDM are at higher risk of developing diabetes later in life. It is associated
with increased perinatal morbidity and mortality. Metabolic disorders may occur in the
children of mothers with GDM (Moses & Cheung, 2009). It is the most common
pregnancy complication leading to fetal mortality and perinatal morbidity (KautzkyWiller et al., 2008).
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An increasing prevalence of GDM is reported worldwide (Carolan et al., 2011). In
a survey administered in 173 countries, GDM prevalence estimates ranged from <1% to
28% (Jiwani et al., 2012). Middle Eastern countries are reported to have a high
prevalence of GDM and PGDM ranging from 4.7% in Iran (Hossein-Nezhad et al., 2007)
to 24.9% in the United Arab Emirates (Agarwal et al., 2010). In Yazd, Iran, the incidence
of GDM was 10.2% among 1,071 pregnant women screened for GDM at 24-28 weeks of
gestation (Soheilykhah et al., 2010). In Bahrain, an increase in the incidence of GDM
from 7.2% in 2002 to 12.5% in 2010 (p < 0.01), was observed (Rajab et al., 2012).
Because of higher birth rates in Middle Eastern countries, this increasing incidence of
GDM has more implications on the burden of GDM and its complications. While
comparing burden of GDM between various regions or various periods of time, it is
important to take into account the diagnostic criteria used for GDM.
Diagnosis of GDM. The basis for diagnosis of GDM is to identify the women at
risk of both adverse obstetrical outcomes, and the future development of type 2 diabetes
mellitus. In 1964, O’Sullivan and Mahan suggested the initial glycemic thresholds for
diagnosis of GDM on oral glucose tolerance test (OGTT) to identify women at risk of
developing type 2 diabetes mellitus (O’Sullivan & Mahan, 1964). Since then, there has
been a debate on the diagnostic criteria for GDM. The debate mainly focuses on the
identification of fetal overgrowth and its associated obstetrical complications, resulting in
different sets of diagnostic criteria proposed by various organizations such as the
National Diabetes Data Group, the American Diabetes Association, and the WHO
(Retnakaran et al., 2009).
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Currently, international consensus is lacking about the diagnostic criteria for
GDM. Although OGTT is commonly used, the dosages of glucose challenge vary, and
there are different diagnostic thresholds. GDM is diagnosed either on the basis of 100
gram 3-hour test (used in the USA) or the 75 gram 2-hour WHO test (IDF, 2009). In
some countries, a two-stage diagnostic procedure is conducted comprising of a nonfasting glucose challenge test (GCT) followed by OGTT for women who test positive for
GCT (IDF, 2009). According to American Diabetes Association (ADA) guidelines, GDM
is diagnosed if at least two 75-g or 100-g OGTT values meet the following thresholds:
≥95 mg/dl FPG, 1-h glucose ≥180 mg/dl, 2-h glucose ≥155 mg/dl, and 3-h glucose ≥140
mg/dl (Black et al., 2010). Various international organizations have tried to develop a
consensus on GDM diagnostic criteria.
After discussions in 2008–2009, the International Association of Diabetes and
Pregnancy Study Groups (IADPSG), an international professional group with
representatives from several obstetrical and diabetes institutions produced revised
recommendations for the diagnosis of GDM. The primary focus of IADPSG Consensus
Panel was to recommend diagnostic threshold values that identified clinically significant
risk for adverse pregnancy outcome (Metzger et al., 2010). The group recommended that
all women not having a history of diabetes undergo a 75-g OGTT at 24–28 weeks of
gestation (“Standards of Medical Care in Diabetes--2012,” 2011). The diagnostic criteria
proposed for the 75-g, 2-hour OGTT are that any of these following thresholds be met or
exceeded: fasting plasma glucose 92 mg/dL (5.1 mmol/L); one-hour plasma glucose 180
mg/dL (10 mmol/L); or two-hour plasma glucose 153 mg/dL (8.5 mmol/L) (Coustan et
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al., 2010; Royal College of Obstetricians and Gynaecologists, 2011; Mahdavian et al.,
2010).
As various international organizations have recommended different criteria for
diagnosis of GDM, epidemiologic studies have been conducted to compare and determine
the appropriateness of these criteria. Agarwal et al. (2010) conducted a study to compare
IADPSG criteria with the ADA criteria and the fasting plasma glucose (FPG) to predict
GDM. A total of 10,283 pregnant women were studied including 80.1% Arab and 15.5%
South Asian women. The researchers found that the IADPSG and ADA criteria identified
GDM in 3,875 (37.7%) women and 1,328 (12.9%) women, respectively (p < 0.0005).
FPG thresholds of ≥5.1 mmol/l diagnosed GDM in 2,975 (28.9%) women with a
specificity of 100% while <4.4 mmol/l excluded GDM in 2,228 (21.7%) women with
95.4% sensitivity. The authors concluded that IADPSG criteria increased the prevalence
of GDM almost threefold (Agarwal et al., 2010). In contrast, on investigating the impact
of IADPSG guidelines in a cohort of pregnant women from the general population,
Mahdavian and colleagues (2010) concluded that these guidelines offered a unique
opportunity for a unified and global approach to GDM. Thus, an international consensus
on diagnosis of GDM is still lacking. Risk factors for GDM play an important role in the
diagnostic criteria. The following section elaborates the risk factors for GDM.
Risk Factors for GDM
Risk factors for GDM can be classified into modifiable and non-modifiable risk
factors. The non-modifiable risk factors include age, ethnicity, family history of diabetes
and past obstetric history (Ferrara, 2007). The modifiable risk factors include obesity,
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weight gain during pregnancy, diet and physical activity (Iqbal, 2005). A description of
modifiable and non-modifiable risk factors is provided in the following sections.
Non-Modifiable Risk Factors
The risk for GDM rises with age, and incidence rates differ by race/ethnicity
(Anna et al., 2008; Ben-Haroush, Yogev, & Hod, 2004; Hunt & Schuller, 2007). In a
prospective cohort study, The Nurses' Health Study II, 14,613 women without previous
GDM or other known diabetes were included. The researchers found that the risk for
GDM increased significantly with increasing maternal age (p for trend < 0.01) and family
history of diabetes mellitus (Relative Risk [RR] = 1.68; 95% confidence interval [CI]
[1.39-2.04]). African-American, Hispanic or Asian women had significantly increased
age-adjusted relative risk for GDM in comparison to white women (Solomon et al.,
1997). Similarly, in a study of 4,566 parous women participating in the National Health
and Nutrition Examination Survey III, women with a maternal (Odds Ratio [OR] = 3.0;
95% confidence interval [CI] [1.2-7.3]), paternal (OR = 3.3; 95% CI [1.1-10.2]), or
sibling (OR = 7.1; 95% CI [1.6-30.9]) history of diabetes had higher odds of having
GDM in comparison to women without a family history of diabetes (Kim, Liu, Valdez, &
Beckles, 2009). A hospital-based case-control study of 6,032 women in Australia,
revealed statistically significant association of GDM with age ≥ 25 years (OR = 1.9; 95%
CI [1.3-2.7]), family history of diabetes mellitus (OR = 7.1; 95% CI [5.6-8.9]) and
ethnicity (high-risk racial heritage) (OR = 2.5; 95% CI [2.0-3.2]) (Davey & Hamblin,
2001). Thus, age, family history of diabetes, and ethnicity are found to be associated with
GDM in various studies.
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Studies have reported ethnic differences in the prevalence of GDM. In the U.S.,
Native Americans, Asians, Hispanics, and African-American women were found to be at
higher risk for GDM than non-Hispanic white women. Similarly, in Europe, GDM was
reported to be more prevalent among Asian women than among European women
(Ferrara, 2007). In a systematic review of 13 studies, non-White race/ethnicity was the
most important predictor for recurrence of GDM in future (Kim, Berger, & Chamany,
2007). Similar results were shown in a cohort study conducted among members of the
Northern California Kaiser Permanente Medical Care Program, including 267,051
pregnancies screened for GDM. The women diagnosed with GDM were more likely to be
from ethnic groups such as African American, Asian and Hispanic (Ferrara, Kahn,
Quesenberry, Riley, & Hedderson, 2004). High prevalence of GDM is reported in South
Asian, black Carribean and Middle Eastern including women from Saudi Arabia, Kuwait,
United Arab Emirates, Qatar, Oman, Egypt, Jordan, Syria, Lebanon, or Iraq (National
Collaborating Centre for Women's and Children's Health, 2008).
Previous history of GDM and family history of diabetes are important risk factors
for GDM. The probability of recurrence of GDM is reported as 30–84% (National
Collaborating Centre for Women's and Children's Health, 2008). A prospective
population-based study conducted in Sweden included 3,616 women. Along with other
risk factors, important risk factors were history of GDM (OR = 23.6; 95% CI [11.6 48.0]) and family history of diabetes (OR = 2.74; 95% CI [1.47 - 5.11]) (Ostlund &
Hanson, 2003). Similarly, in a cohort of 3,950 Italian women, GDM diagnosis was
significantly associated with age (p < 0.0001), and family history of diabetes (p < 0.01;
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(Di Cianni et al., 2003). These findings were supported in a case- control study including
510 pregnant women with GDM (cases) and 1,160 pregnant women with normal glucose
tolerance (controls), where age (30.1 vs. 27.2 years; p < 0.0001) and family history of
diabetes (40.0 vs. 25.7%; p < 0.01) were significantly associated with GDM (Cypryk,
Szymczak, Czupryniak, Sobczak, & Lewiński, 2008). Thus, age, family history of
diabetes, and previous history of GDM are important non-modifiable risk factors
identified in research studies conducted globally.
Various studies conducted in Middle Eastern countries have revealed similar risk
factors. A prospective cohort study of 1,310 pregnant Iranian women revealed age more
than 30 years, family history of diabetes, and previous macrosomia as statistically
significant (p < 0.001) risk factors for GDM (Keshavarz et al., 2005). In a prospective
study carried out among 2,000 Kashmiri women, the researchers found increasing rate of
GDM with increasing age; from 1.7% in women below 25 years to 18% in women 35
years or older. In this study, GDM occurred more frequently in women who had GDM
during previous pregnancies, had given birth to a macrosomic baby, or had a family
history of diabetes mellitus (Zargar et al., 2004). In Bahrain, in a study of 4,982 women
with GDM, maternal age was associated with GDM (OR = 1.094; 95% CI [1.081-1.107])
(Rajab et al., 2012). Similar risk factors were found in a cross-sectional study at primary
health care centers in Qatar, including 4,295 pregnant women. Age 35 years or more (OR
= 3.8; 95% CI [2.4-6.4]) and multigravida with 4 or more pregnancies (OR = 2.7; 95% CI
[1.7-4.2]) were found to be significant predictors of GDM in this study (Al-Kuwari & AlKubaisi, 2011). Among Iranian women, a significant association between incidence of
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GDM and age, family history of diabetes, history of GDM, parity, macrosomic baby and
still birth during previous pregnancies was identified (Garshasbi, Faghihzadeh,
Naghizadeh, & Ghavam, 2008; Rahimi, Dinari, & Najafi, 2010; Soheilykhah et al.,
2010). Thus, studies in Middle Eastern countries have demonstrated maternal age, parity,
family history of diabetes, and previous history of GDM as important risk factors of
GDM. In addition to the non-modifiable factors, modifiable factors also play an
important role in occurrence of GDM.
Modifiable Risk Factors
Overweight and obesity are recognized risk factors for diabetes (Lawrence et al.,
2008; Kim et al., 2010; Narayan, Boyle, Thompson, Gregg, & Williamson, 2007), and
are designated as the major modifiable risk factors of GDM (Bowers et al., 2011). A
systematic review conducted to assess and quantify the risk for GDM according to prepregnancy maternal body mass index (BMI) included observational studies published in
the last 30 years. Compared with women with a normal BMI, the unadjusted pooled OR
of an underweight woman developing GDM was 0.75 (95% CI [0.69 - 0.82]). The OR for
overweight, moderately obese and morbidly obese women were 1.97 (95% CI [1.77 2.19]), 3.01 (95% CI [2.34 - 3.87]) and 5.55 (95% CI [4.27 - 7.21]) respectively (Torloni
et al., 2009).
Various studies conducted in developed countries have demonstrated an
association between overweight/obesity and GDM. In a hospital-based case-control study
of 6,032 women in Australia; the researchers found statistically significant association
between GDM and body mass index (BMI) ≥ 27kg/m2 (OR = 2.3; 95% CI [1.6-3.3];

36
Davey & Hamblin, 2001). In Sweden, a prospective population-based study including
3,616 women found that weight ≥ 90 kg or more (OR = 3.33; 95% CI [1.56 - 7.13]) and
BMI ≥ 30 kg/m2 (OR = 2.65; 95% CI [1.36 - 5.14]) had statistically significant
association with GDM (Ostlund & Hanson, 2003). Similarly, a cohort study including
women with pregnancies between 16 and 18 weeks, classified women as underweight
(BMI<18.5), normal (BMI 18.5–25), overweight (BMI 25–30), and obese (BMI>30)
women. Compared to other groups, obese women were more likely to develop GDM
(p<0.001; Doherty, Magann, Francis, Morrison, & Newnham, 2006). A case- control
study comprising of 510 pregnant women with GDM and 1,160 pregnant women as
controls also showed an association between BMI and GDM. The study found BMI > 25
kg/m2 (OR = 4.14) a risk factor for GDM (Cypryk et al., 2008). In The Nurses' Health
Study II, relative risks for GDM were 2.13 (95% CI [1.65-2.74]) for pregravid BMI of 25
to 29.9 kg/m2 and 2.90 (95% CI [2.15-3.91]) for BMI of 30 kg/m2 when compared to
BMI of <20 kg/m2. Risk for GDM rose with greater weight gain (RR = 3.56; 95% CI
[2.70 - 4.69]) for weight gain of 20 kg or more] (Solomon et al., 1997). Thus, increased
BMI, overweight, obesity and extent of weight gain during pregnancy are found to be
important modifiable risk factors of GDM in studies conducted in the developed world.
Association of overweight and obesity with GDM is also found in research studies
from other regions of the world. Out of a total of 9,471 pregnant Chinese women
screened for GDM, 174 women were confirmed to have GDM. Pre-pregnancy BMI and
weight gain in pregnancy before screening were found as risk factors for GDM in this
population (Yang et al., 2002). In a prospective study carried out in 2,000 Kashmiri
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women, the researchers found that women with obesity and hypertension had a higher
prevalence of GDM (Zargar et al., 2004). In a study of 1,720 Iranian pregnant women,
obesity was one of the risk factors for GDM (Rahimi et al., 2010). In another study from
Iran, screening for GDM was performed on 1,804 women. GDM diagnosis was
significantly associated with pre-pregnancy BMI (p = 0.005) (Garshasbi et al., 2008).
Overweight and obesity are closely related to the dietary habits and physical activity of
an individual. Increased physical activity may also play a role in prevention of GDM.
The role of physical activity during pregnancy in reduction of risk of GDM has
been explored in various studies. Data from the 1988 National Maternal and Infant Health
Survey was analyzed for 4,813 women, reporting physical inactivity before pregnancy.
GDM was diagnosed in 3.5 percent of this group. Among previously inactive women,
11.8 percent became physically active during pregnancy. These women had 57 percent
lower adjusted odds of developing GDM than those who continued to be physically
inactive (OR = 0.43; 95% CI [0.20–0.93]). Brisk walking during pregnancy resulted in a
reduced risk of GDM (OR = 0.44; 95% CI [0.19–1.02]) (Liu, Laditka, Mayer-Davis, &
Pate, 2008). Therefore, physical activity is found to be an important factor in the
occurrence as well as prevention of GDM.
In addition to obesity and lack of physical activities, various studies have
demonstrated other risk factors. Twin pregnancies are found to be a risk factor for GDM.
In a cohort of 23,056 pregnant women who gave birth to a live infant; 553 women had
twin pregnancy. Patients with twin pregnancies had a higher rate of GDM when
compared with singleton pregnancies (3.98% vs. 2.32%; p = 0.01) (Rauh-Hain et al.,
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2009). Another risk factor for GDM is periodontal disease. An association of periodontal
diseases with GDM is demonstrated in some studies. A total of 53 pregnant women with
GDM and 106 pregnant women without GDM were studied at Woman's Hospital, Baton
Rouge, Louisiana. The adjusted OR for association of periodontal diseases and GDM was
2.6 (95% CI [1.1 - 6.1]; Xiong et al., 2009). On literature search, researches exploring
association of periodontal disease and GDM in Eastern Mediterranean countries could
not be found. However, certain other risk factors such as polycystic ovarian syndrome are
explored by researchers in Eastern Mediterranean countries.
Polycystic ovarian syndrome (PCOS) is a pathological condition signified by
anovulation, resistance to insulin, and excess of androgen. The women with PCOS have a
higher risk of glucose intolerance and type 2 diabetes (Lo et al., 2006). Commonly the
affected women have insulin resistance and hyperinsulinaemia and consequently, may,
have a higher risk of GDM (Mikola, Hiilesmaa, Halttunen, Suhonen, & Tiitinen, 2001).
Some studies suggest the risk of GDM is higher among PCOS versus non-PCOS women
(Lo et al., 2006). However, in a retrospective case-control study, the researchers found no
statistically significant difference in the prevalence of GDM between the PCOS (22%)
and the controls (17%; Vollenhoven, Clark, Kovacs, Burger, & Healy, 2000). In a study
conducted to determine the impact of PCOS on glucose tolerance during pregnancy, the
researchers compared the pregnancy records of 38 PCOS patients retrospectively with
136 non-PCOS patients. The prevalence of GDM was similar in both groups (Turhan,
Seçkin, Aybar, & Inegöl, 2003). Similarly, a case-control study included 188 pregnant
women; 94 women had GDM (cases) while the other 94 were women without GDM
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(controls). The results of the study showed that the women with GDM had a history of
PCOS more often than the control group of women (15 cases of PCOS in GDM group vs.
6 cases of PCOS in the control group, p = 0.03) (Kashanian, Fazy, & Pirak, 2008). In
another study of the pregnancies of 66 women with PCOS and 66 age- and weightmatched controls, no statistically significant difference was found in the prevalence of
GDM between the group of PCOS patients and the controls (Haakova et al., 2003). In
contrast, in a total of 99 pregnancies retrospectively evaluated in women with PCOS and
compared with the control population, GDM developed in 20% of the PCOS patients and
in 8.9% of the controls (p < 0.001) (Mikola et al., 2001). Although some studies have
shown an association between GDM and PCOS, the results are inconclusive. Some other
risk factors of GDM such as levels of ferritin are explored by few studies.
Some epidemiological studies have documented a positive association of
circulating levels of ferritin (a marker of body iron stores) with circulating levels of
glucose and insulin, and risk of type 2 diabetes mellitus and GDM (Bowers et al., 2011).
In a case-control study, 34 women with diagnosed GDM were compared with 34 nonGDM women in the control group at 24-28 weeks of pregnancy. The results of the study
showed that concentration of serum ferritin, iron and transferrin saturation was
significantly higher in the GDM group (p < .05; Afkhami-Ardekani & Rashidi, 2009).
Similarly, a prospective study suggested an association between increased iron stores and
glucose intolerance in non-anemic women at the third trimester (Lao, Chan, & Tam,
2001).
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To sum up, many modifiable and non-modifiable risk factors are related to GDM.
Some of these factors such as age, family history of diabetes are well-researched while
other factors such as ferritin levels need to be further researched to reach a definitive
conclusion. Information about risk factors of GDM is important not only for the
prevention of GDM but also for reduction in adverse outcomes of GDM/PGDM.
Outcomes of Pregnancy with Diabetes
Pregnancy with diabetes is associated with increased perinatal morbidity (Reece
et al., 2009). It has been associated with maternal, fetal, and infant complications,
including cesarean section, infant macrosomia and birth trauma (Kim et al., 2010). GDM
has many effects on fetal outcomes, maternal outcomes and also there are long-term
health effects on women with a history of GDM (Hedderson, Gunderson, & Ferrara,
2010; Hsu-Hage & Yang, 1999). Epidemiological research suggests that women who
have GDM have an increased risk of type 2 diabetes later in life (Bellamy et al., 2009;
Buchanan & Xiang, 2005; Horvath et al., 2010). To determine the effects of
GDM/PGDM on maternal and fetal outcomes, population databases of all women and
their infants, discharged from hospital following birth in New South Wales (NSW)
between July 01, 1998 and December 31, 2002, were studied. A total of 370,703 women
and their newborns were included. Out of these 1,248 women (0.3%) had PGDM and
17,128 (4.5%) had GDM. The researchers found that, in comparison with women without
diabetes, maternal morbidity or mortality was more frequent in women with PGDM
(7.9%; OR = 3.2; 95% CI [2.6 - 3.9]) and in women with GDM (3.1%) (OR = 1.2; 95%
CI [1.1 - 1.4]). Infant morbidity or mortality was more common in newborns of women
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with PGDM compared with those without diabetes (13.6% vs. 3.1%; OR = 5.0; 95% CI
[4.2 - 5.8]) and in newborns of women with GDM compared with women without
diabetes (3.2% vs. 2.3%; OR = 1.4; 95% CI [1.3 - 1.5]; Shand, Bell, McElduff, Morris, &
Roberts, 2008). Although in general maternal and fetal morbidity are increased, certain
specific adverse fetal and maternal outcomes are associated with PGDM/GDM.
Adverse fetal outcomes include complications such as macrosomia, shoulder
dystocia, birth injuries, neonatal hyperbilirubinemia, while adverse maternal outcomes
include caesarean section, and pre-eclampsia (Metzger et al., 2008). There are certain
factors associated with the adverse maternal and fetal outcomes including racial/ethnic
differences and type of maternal diabetes.
Racial/ ethnic differences have been found in perinatal outcomes, in women with
GDM. Esakoff and colleagues (2011) in a retrospective cohort study included singleton
pregnancies with GDM receiving health care from California Diabetes and Pregnancy
Program (CDAPP) between 2001 and 2004. A total of 26,411 women with gestational
diabetes sub-grouped by four races/ethnicities (Caucasian, African-American, Latina, and
Asian) were included in the study. The results of the study showed that Asians had lower
odds (aOR = 0.58; 95% CI [0.48 - 0.70]) of birthweight > 4000 g. African-Americans had
highest odds of intrauterine fetal death (aOR = 5.93; 95% CI [1.73- 20.29]) as compared
to other races/ethnicities (Esakoff et al., 2011). Other adverse pregnancy outcomes are
also shown to vary in different races or ethnicities and according to the type of maternal
diabetes.
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Type of diabetes during pregnancy influences adverse maternal and fetal
outcomes. In a population-based study conducted in Sweden between 1991 and 2003,
data were obtained from the Medical Birth Registry, including more than 98% of all
pregnancies in Sweden. A total of 5,089 pregnancies with type 1 diabetes and 1,260,207
pregnancies without diabetes were included. The results of the study showed that, in type
1 diabetes, preeclampsia was significantly more frequent (OR = 4.47; 95% CI [3.775.31]) as was delivery by cesarean section (OR = 5.31; 95% CI [4.97-5.69]) compared
with results for the general population. Stillbirth (OR = 3.34; 95% CI [2.46-4.55]),
perinatal mortality (OR = 3.29; 95% CI [2.50-4.33]), and major malformations (OR =
2.50; 95% CI [2.13-2.94]) were more common in women with type 1 diabetes than in
women without diabetes. The incidence of fetal macrosomia was increased in the group
with diabetes (OR = 11.45; 95% CI [10.61-12.36]; Persson, Norman, & Hanson, 2009).
Individual adverse maternal and fetal outcomes are discussed in the following sections.
Adverse Maternal Outcomes
Cesarean Section
Studies from various parts of the world have reported a higher rate of cesarean
section in women having pregnancy with diabetes as compared to those without diabetes.
A study was conducted among women with pregestational type 2 diabetes during the
period between 1992 and 2006 from one center in the Netherlands. Sixty-six singleton
pregnancies were analyzed. Delivery occurred by cesarean section in 42.9% cases (de
Valk, van Nieuwaal, & Visser, 2006). Similarly, in a 12 years' (1990 -2002) outcome
analysis of pregnancies in 182 women with type 2 diabetes, 161 (88%) resulted in a live
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outcome. Fifty-three percent were delivered by caesarean section in this study population
(Dunne, Brydon, Smith, & Gee, 2003).
Higher rate of caesarean section in women having pregnancy with diabetes is
reported by various studies from Eastern Mediterranean countries. Various studies
conducted in this region has demonstrated the rate of cesarean section ranging from 22%
to 84%. In an observational cross-sectional study conducted among infants of women
with diabetes in Pakistan, 40 infants were included. Twenty-two (55%) newborns were
delivered by cesarean section (Alam, Raza, Sherali, Akhtar, & Akhtar, 2006). Another
hospital-based study in Pakistan included 42 pregnant women with diabetes; 45% of
these women were delivered by cesarean section (Hussain, Irshad, Khattak, & Khan,
2011). In a study of 8,000 pregnant women, in Saudi Arabia, 685 women were diagnosed
with GDM, between January 2000 - December 2001. A total of 148 (21.6%) were
delivered by cesarean section (Al-Hakeem, 2006). High rate of cesarean section was
reported in a prospective observational study in Sudan which included 50 infants of
women with diabetes; 42 (84%) infants were delivered by caesarean section (Kheir,
Berair, Gulfan, Karrar, & Mohammed, 2012). In addition to determining the proportion
of deliveries by caesarean section in women with GDM/PGDM, researchers have also
compared these proportions between women with GDM/PGDM and those without
GDM/PGDM.
Epidemiological studies have shown a statistically significant association between
delivery by cesarean section in women with diabetes when compared to women without
diabetes. In a prospective cohort study conducted in Iran, 1,310 pregnant women were
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included in the study. The researchers found that women with GDM had a higher rate of
caesarean section (p < 0.001) as compared to those without GDM (Keshavarz et al.,
2005). Similarly, Hossein-Nezhad et al. (2007) studied 2,416 Iranian pregnant women
and identified 114 women (4.7%; 95% CI [3.9-5.6%]) with GDM in this cohort. The odds
ratio for cesarean section (OR = 2.28, p = 0.0002) was significantly higher in women
with GDM as compared to those without GDM. In another study including 420 Iranian
women referred to Shiraz hospitals in 2006, seventy were pregnant women with diabetes
and 350 were those without diabetes. There was a significant difference between the two
groups in delivery by cesarean section (RR = 1.96, p < 0.05; Abolfazl et al., 2008). In
Qatar, a prospective cohort study included a representative sample of 2,056 pregnant
women attending the antenatal clinics of the Women’s Hospital. From this sample, 1,608
women (78.2%) expressed their consent to participate in the study. Cesarean section rate
(27.9% vs 12.4%; p < 0.001) was significantly higher in women with GDM as compared
to those without GDM (Bener et al., 2011). In a study of 228 pregnant women, higher
rate of cesarean section (68%) was noted among women with GDM as compared to
46.8% (p = 0.009) in those without diabetes (Tahir, Zafar, & Thontia, 2011).
Women with PGDM are reported to have higher rates of caesarean section as
compared to those with GDM. In a one year retrospective review of registry records, of
the 5,394 women registered, 225 had GDM and 56 had PGDM. A statistically significant
greater rate of cesarean delivery was found among women with GDM (OR = 2.70; 95%
CI [1.17-4.03]) and PGDM (OR = 4.39; 95% CI [1.68-11.49]) as compared to those
without diabetes (Barakat et al., 2010). A prospective hospital-based study conducted
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among 100 women with diabetes (27 women with GDM and 73 women with PGDM)
compared fetal/neonatal complications of GDM and PGDM. Women with PGDM had a
higher rate of cesarean section as compared to those with GDM (Akhlaghi & Hamedi,
2005). In another hospital-based study conducted in Abu Dhabi, 129 records of women
with diabetes delivered over a two year period were reviewed. Of these, 82 had GDM,
and 47 had PGDM. Patients with PGDM had a significantly higher rate of caesarean
sections (p = 0.0147) as compared to those with GDM (Misra et al., 2001). Thus, higher
rates of caesarean section is an important adverse outcome in women having pregnancy
with diabetes. Among women having pregnancy with diabetes, women with PGDM are
more at risk of having the delivery by caesarean section than women with GDM. In
addition to higher rates of caesarean section, other adverse maternal outcomes also occur
in pregnancy with diabetes and may also differ in frequency among women with PGDM
and those with GDM.
Other Adverse Maternal Outcomes
Other adverse maternal outcomes of pregnancy with diabetes include pregnancy
induced hypertension, development of type 2 diabetes mellitus and hypertension in the
long term. Hypertension occurring because of pregnancy is called pregnancy-induced
hypertension (PIH), which has two groups: gestational hypertension and pre-eclampsia
(Hossein-nezhad, Mirzaei, Ahmadi, Maghbooli, & Karimi, 2011). In a retrospective
analysis of the record of 1,813 women with GDM, preeclampsia was diagnosed in 9.6%
(174/1,813) women with diabetes (Yogev, Xenakis, & Langer, 2004). In a prospective
observation of pregnancy outcomes among 462 women with PGDM, 92 (20%) had
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preeclampsia. The frequency of preeclampsia increased significantly with increasing
severity of diabetes (Sibai et al., 2000). In another study including women having
singleton births in Victoria during 1996, women with GDM had increased rates of
hypertension and pre-eclampsia [adjusted OR = 1.6, 95% CI, 1.4-1.9; Stone, McLachlan,
Halliday, Wein, & Tippett, 2002). Similarly, in a study of 749 women from the
randomized controlled Diabetes and Pre-eclampsia Intervention Trial (DAPIT), preeclampsia and gestational hypertension occured in 17% and 11% of pregnancies,
respectively. Women with pre-eclampsia had statistically significant higher levels of
HbA1C before and during pregnancy in comparison to the women who did not have preeclampsia (Holmes et al., 2011).
An association between pregnancy induced hypertension and GDM/PGDM is
demonstrated in various studies of the Eastern Mediterranean Region. A prospective
cohort study in Iranian population among 1,310 pregnant women, demonstrated a higher
rate of gestational hypertension (OR = 6; 95% CI [2.3-15.3]) in women having pregnancy
with diabetes (Keshavarz et al., 2005). In another cohort study of 615 Iranian pregnant
women including 293 GDM patients and 322 women without GDM, a significant higher
prevalence of pregnancy induced hypertension (RR = 1.03; 95% CI [1.004-1.06]) was
demonstrated (Hossein-nezhad et al., 2011). Similarly, a significantly higher incidence of
pre-eclampsia (p < 0.0001) is demonstrated in Saudi women with GDM when compared
with those without GDM (Gasim, 2012). In most cases, pregnancy induced hypertension
is a short-term effect and resolves after pregnancy; however, there are also certain longterm effects of GDM such as the occurrence of type 2 diabetes.
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Women with GDM are at increased risk of developing type 2 diabetes later in life.
GDM is found to be a strong predictor of type 2 diabetes. Women with GDM are
approximately six times more prone to develop type 2 diabetes in comparison to women
with normal glucose tolerance in pregnancy (Anna et al., 2008; Cheung & Byth, 2003). In
a systematic review of 675,455 women with 10,859 having type 2 diabetes, women with
GDM had an increased risk of developing type 2 diabetes compared with those who had a
normoglycaemic pregnancy (RR = 7.43; 95% CI [4.79 -11.51]) (Bellamy et al., 2009). To
conclude, adverse maternal outcomes of GDM/PGDM include higher rate of delivery by
caesarean section, pregnancy induced hypertension, and occurrence of type 2 diabetes
later in life. Next section will discuss various adverse fetal outcomes associated with
GDM/PGDM.
Adverse Fetal Outcomes
Macrosomia
Macrosomia signifies a newborn with an excessive birth weight. There are
different ways of defining fetal macrosomia. Birth weight of 4,000-4,500 g (8 lb 13 oz to
9 lb 15 oz) or more than 90% for gestational age is labeled as macrosomia (Medscape,
2013). The most frequent and significant morbidity in pregnancy with diabetes is fetal
macrosomia, which in turn is associated with increased risk of birth injuries and asphyxia
(Persson & Hanson, 1998). A retrospective cohort study was performed on 111,563
pregnancies delivered in 39 hospitals in northern and central Alberta, Canada. Infants
born to mothers with GDM were at higher risk of being macrosomic or large-forgestational-age (Xiong, Saunders, Wang, & Demianczuk, 2001). Svare, Hansen, &
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Mølsted-Pedersen (2001) examined the outcome of pregnancy in 327 women with GDM
and 295 women without GDM. Although not statistically significant, the incidence of
macrosomia was higher, (8% vs. 2%, p = 0.07), in the group with GDM. Incidence of
macrosomia varies according to the type of diabetes in pregnancy. A prospective cohort
study comprising of 682 consecutive pregnancies with diabetes in East Anglia included
408 (59.8%) pregnancies with type 1 and 274 (40.2%) with type 2 diabetes. Women with
type 2 diabetes had fewer large-for-gestational-age infants (37.6 vs. 52.9%, p < 0.0008)
as compared to those with type 1 diabetes (Murphy et al., 2011). Variations in incidence
of macrosomia are also reported in studies conducted in different parts of the world.
Research studies from EMR have shown high proportion of infants with
macrosomia in women with GDM/PGDM. In Pakistan, a hospital-based study of 42
infants of women with diabetes found macrosomia (40.4%) the most common
complication in this study population (Hussain et al., 2011). Haider, Zehra, Anjum, and
Munir (2009) studied 110 pregnant women with diabetes in Pakistan and found
macrosomia in 41.8% newborns. In another study in Pakistan, 50 pregnant women with
GDM were identified among 1,429 delivered women. Most frequent fetal complication
was macrosomia identified in 18 (36%) newborns (Farooq, Ayaz, Ali, & Ahmed, 2007).
Similarly, among 50 infants of Sudanese women with diabetes, 14 (28%) newborns were
macrosomic (Kheir et al., 2012). In Bahrain, in a cohort of 3,443 pregnant women with
GDM, 6.5% newborns had a birth weight of more than 4000 g (Al Mahroos, Nagalla,
Yousif, & Sanad, 2005).
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Researchers from Middle Eastern countries have studied the association between
pregnancy with diabetes and macrosomia. In Iran, a cohort of 1,801 pregnant women,
was classified into four groups according to the results of GCT and OGTT. The groups
included: normal GCT (<130 mg/dl); GCT ≥ 130 mg/dl but normal OGTT; impaired
glucose test (IGT); and GDM. The results of the study showed that the prevalence of
macrosomia in patients with GDM, IGT, only abnormal GCT and normal GCT was
15.8% , 6%, 3.6% and 1.1%, respectively (Khoshniat nikoo et al., 2010). Similarly, in
Iran a prospective cohort of 1,310 Iranian pregnant women demonstrated that women
with GDM had a higher rate of macrosomia (OR = 3.2; 95% CI [1.2-8.6]) as compared to
those without GDM (Keshavarz et al., 2005). In another study in Iran, Hossein-Nezhad et
al. (2007) studied 2,416 Iranian pregnant women including 114 women with GDM in this
group. The odds ratio for macrosomia (OR = 1.93, p = 0.0374) was significantly higher in
women with GDM as compared to those without GDM. Bener et al. (2011) studied a
cohort of 1,608 pregnant women in Qatar. Newborns of women with GDM were at
increased risk of macrosomia (10.3% vs 5.9%; p = 0.01) than those of women without
GDM. In a historical cohort study including 420 Iranian women (70 women with diabetes
and 350 without diabetes), the newborns of women with GDM were seven times more at
risk of being macrosomic [RR = 7.38, p < 0.05] as compared to those born to women
without GDM (Abolfazl et al., 2008). On comparing the strength of association of
macrosomia in women having pregnancy with diabetes, women with PGDM were found
to be more prone to have a macrosomic baby. In a 1-year retrospective review of records
of 5,394 pregnant women registered, 225 had GDM and 56 had PGDM. The risk of
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macrosomia was three-fold among women with GDM (OR =3.03; 95% CI [1.36-6.75])
and approximately seven-fold among those with PGDM (OR =7.20; 95% CI [2.3022.61]) (Barakat et al., 2010). In contrast, some studies have shown statistically nonsignificant association between macrosomia and pregnancy with diabetes. In Saudi
Arabia, 424 pregnant women were studied. Infants of women with diabetes were found to
be heavier than those without diabetes, however, the proportion of babies with birth
weight ≥ 2 standard deviations above the mean, were equal in both groups (Nasrat et al.,
1994). In another study of 185 pregnant women with diabetes in Saudi Arabia, there were
27(14.6%) with type 1 diabetes forming group 1; 19 (10.2%) with type 2 diabetes
constituting group 2 and 139 (75.2%) with GDM making up group 3. The results of the
study showed no statistically significant differences in the three groups regarding the
mean birth weight (p > 0.05) of newborns (Sobande, Eskander, & Archibong, 2005).
Another retrospective cohort study among pregnant women with GDM in Saudi Arabia
including 766 women (419 women with GDM and 347 without GDM), was also not able
to demonstrate statistically significant association between macrosomia and GDM (AlKhalifah et al., 2012). To sum up, macrosomia is one of the most common adverse
outcomes of pregnancy with diabetes. High incidence of macrosomia is reported in
infants of women with GDM/PGDM globally as well as in the EMR. Macrosomia results
in perinatal morbidity and some of its complications may lead to perinatal mortality.
Perinatal Mortality
Perinatal mortality refers to fetal (20 or more weeks of gestation) deaths as well
as neonatal deaths (MacDorman et al., 2012). The Confidential Enquiry into Maternal
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and Child Health in UK reported that perinatal mortality was approximately four-fold in
women with diabetes as compared to the general population (Confidential Enquiry into
Maternal and Child Health [CEMACH], 2005). On a review of pregnancy outcome in
116,303 pregnancies, at the Mercy Hospital for Women, GDM was found to be
associated with an increased risk of perinatal mortality (OR = 1.53; 95% CI [1.13-2.06];
Beischer, Wein, Sheedy, & Steffen, 1996). An analysis of outcomes of pregnancies
among women with type 2 diabetes mellitus, was performed. From a regional
computerized database, data were obtained about 182 women delivered between 1990
and 2002. Infants of women with type 2 diabetes had a twice higher risk of stillbirth, a
2.5 times higher risk of perinatal death, a 3.5 times higher risk of neonatal death and a 6times higher risk of infant death when compared with regional/national statistics (Dunne
et al., 2003). The researchers compared outcomes of pregnancy in women with type 1
diabetes with those in the general population in a prospective multicenter study
conducted in eight Danish centers. The study included 990 women with 1,218
pregnancies. The results of the study showed that the perinatal mortality rate was 3.1% in
pregnancies with type 1 diabetes compared with 0.75% in the general population (RR =
4.1; 95% CI [2.9-5.6]), and the stillbirth rate was 2.1% compared with 0.45% (RR = 4.7;
95% CI [3.2-7.0]) in the general population (Jensen et al., 2004).
The incidence of perinatal mortality is shown to vary according to the type of
diabetes. Data for a duration of 12 years (1985–1997), from a population in Auckland,
revealed 434 pregnancies in women with type 2 diabetes, 160 pregnancies in women with
type 1 diabetes and 932 in women with GDM. The results of the study showed that the
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perinatal mortality in type 2 diabetes was 46.1/1000, significantly (p < 0.0001) higher
than the rates for type 1 diabetes (12.5/1000) and GDM (8.9/1000). A seven-fold greater
rate of late fetal death and 2.5-fold greater rate of neonatal death was also shown in this
study (Cundy et al., 2000). Some studies have reported a worse perinatal outcome in
women with type 2 DM as compared to type 1 diabetes. In a study conducted to compare
the maternal and fetal outcomes in pregnant women with type 2 and type 1 DM, the
researchers found that women with type 2 DM had a higher risk of perinatal mortality
(OR = 1.50; 95% CI [1.15-1.96]; Balsells, García-Patterson, Gich, & Corcoy, 2009). In a
population- based cohort study in 231 maternity units in England, Wales, and Northern
Ireland, 2,359 pregnancies to women with type 1 or type 2 diabetes were studied. Of
2,359 women with diabetes, 652 had type 2 diabetes and 1,707 had type 1 diabetes.
Perinatal mortality in infants of women with diabetes was 31.8/1000 births. Perinatal
mortality was almost similar among women with type 1 (31.7/1000 births) and type 2
diabetes (32.3/1000) and was approximately four times greater than that in the general
population (Macintosh, 2006).
An increased perinatal mortality rate is especially important in settings where
appropriate obstetric care is not accessible to the whole population (IDF, 2009; Schmidt
et al., 2001). Because of poor socioeconomic conditions, some countries of EMR such as
Afghanistan and Pakistan, are not able to provide access to obstetric care to a substantial
proportion of their population. Thus, it is important to determine the perinatal mortality
attributed to pregnancy with GDM/PGDM.
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Studies from Middle Eastern region have shown an increased perinatal mortality
rate in women with GDM/PGDM. A study conducted in Benghazi Diabetic Clinic during
the period from 1984 to 1991 included 988 pregnant women with diabetes. Twelve
women had type 1 diabetes mellitus while 976 women had type 2 diabetes mellitus. Rates
of intra-uterine death and still birth were 3.28% and 2.6%, respectively. Perinatal
mortality was 11.44% (Kadiki, Reddy, Sahli, Shawar, & Rao, 1993). Approximately
similar perinatal mortality rate of 7.5% was found in a cross-sectional study of 40 infants
born to women with diabetes in Pakistan (Alam et al., 2006). In another hospital-based
study, in Pakistan, the mortality rate was 4.7% among 42 infants born to women with
diabetes (Hussain et al., 2011). In Iran, in a prospective cohort study of 1,310 Iranian
pregnant women, babies born to women with GDM had a higher rate of stillbirth (OR =
17.1; 95% CI [4.5-65.5]; Keshavarz et al., 2005). In another cohort study including 420
Iranian pregnant women (70 women with diabetes and 350 without diabetes), statistically
significant difference in still births [RR= 8.87, p < 0.05] between the two groups was
observed (Abolfazl et al., 2008). Misra et al., (2001) reviewed records of 129 women
with diabetes in a hospital-based study in Abu Dhabi. Perinatal mortality rate was 2.5
times higher in the pregnancies with diabetes than in the general population. In a casecontrol study conducted in Sudan, the perinatal mortality rate was significantly higher
among women with diabetes (80.2%) than the total hospital population (23.7%) (p <
0.01). The overall perinatal mortality rate in women with diabetes was 3.5 times more
than that for women without diabetes. Unexplained intrauterine deaths were more
common in PGDM (RR = 18.4; 95% CI [3.9 - 85.7]) than in GDM (RR = 13.4; 95% CI
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[29- 61.6]; Dafallah & Yousif, 2004). Thus, many studies have shown an association
between increased perinatal mortality rate and GDM/PGDM, however, considering the
improvement in health care generally and improved management of GDM/PGDM in
many countries of the world, it is important to look at the trends of perinatal mortality in
women with GDM/PGDM.
Some studies have shown a decreasing trend in perinatal mortality rate among
women having pregnancy with diabetes. A review of 1,528 pregnancies in women with
diabetes mellitus between 1968 and 1987 at National Women's Hospital showed that 571
had PGDM and 957 had GDM. During this period, the perinatal mortality rate for women
with PGDM fell from 15.2% to 2% and for those with GDM from 6.7% to 0.5% (Roberts
& Pattison, 1990). Similar trend was shown in a retrospective survey conducted to
examine changes in perinatal mortality in babies born to mothers with pregestational type
1 diabetes over 40 years in Edinburgh, Scotland. Perinatal mortality were ascertained
from 643 babies born after 28 gestational weeks to mothers with pregestational type 1
diabetes between 1960 and 1999. The results of the study showed that there was a
remarkable improvement in perinatal mortality rate, decreasing from 225 per 1,000 total
births in the 1960s to 102 in the 1970s. It further decreased to 21 in the 1980s, and then
10 per 1,000 total births in the 1990s (p < .001; Johnstone, Lindsay, & Steel, 2006).
Studies showing the trend of perinatal mortality in Eastern Mediterranean countries could
not be found on literature search, however, this meta-analysis will be able to demonstrate
changes in perinatal mortality rates in various countries in different periods of time. In
addition to perinatal mortality, certain other adverse fetal outcomes may occur in
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pregnancy with GDM/PGDM. These adverse fetal outcomes are discussed in the next
section.
Other Adverse Fetal Outcomes
Other adverse fetal outcomes in pregnancy with diabetes include congenital
malformations and long term effects such as increased BMI in adulthood. The excess risk
for birth defects among babies of women with diabetes mellitus is well documented. In
the Atlanta Birth Defects Case-Control Study, 4,929 live and stillborn babies with major
malformations, were included. The study also included 3,029 non-malformed live babies.
The relative risk for major malformations among infants of mothers with type 1 diabetes
mellitus (n = 28) was 7.9 (95% CI [1.9- 33.5]) compared with infants of women without
diabetes. Infants of mothers with GDM who required insulin during the third trimester of
pregnancy were 20.6 (95% CI [2.5-168.5]) times more likely to have major
cardiovascular system defects than infants of women without diabetes (Becerra, Khoury,
Cordero, & Erickson, 1990). The percentage of pregnancies with congenital
abnormalities (12.3% in type 2 vs. 4.4% in type 1; p = 0.002) was found higher in women
with type 2 diabetes as compared to type 1 diabetes in a study of pregnancies with PGDM
(389 type 1 diabetes and 146 type 2 diabetes) from 10 UK hospitals (Roland, Murphy,
Ball, Northcote-Wright, & Temple, 2005). In contrast, in a hospital- based study at the
Gulf Medical College Hospital and Research Center, Ajman, records of 1,222
consecutive live births, the researchers found no statistically significant association of
GDM with congenital anomalies (Aryasinghe et al., 2012). In addition to congenital
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anomalies, certain long term consequences have also been observed in infants of women
with GDM/PGDM.
Maternal diabetes mellitus may have long-term consequences for greater BMI in
offspring. A record-linkage prospective cohort study of 280,866 singleton-born Swedish
men from 248,293 families was conducted to determine the effect of maternal diabetes
mellitus on the body mass index (BMI) of the offspring in early adulthood. It was found
that GDM/PGDM was associated with higher mean BMI in their sons at age 18 (Lawlor,
Lichtenstein, & Långström, 2011). Thus, GDM/PGDM are associated with many adverse
maternal and fetal outcomes. Some outcomes such as macrosomia and perinatal mortality
occur in short-term while other adverse outcomes such as higher BMI in adulthood are
long-term consequences of GDM/PGDM. Considering the magnitude of adverse
outcomes in GDM/PGDM, it is important to manage these conditions optimally.
Screening for GDM/PGDM and appropriate treatment of GDM/PGDM are the
cornerstones of optimal management.
Screening for GDM
The objective of screening for GDM is to identify women at risk of adverse
maternal and fetal outcomes (Rey, 1999). There is continuing debate about whether all
pregnant women should be screened (universal screening), or whether screening should
be done only if risk factors are present (selective screening). Main risk factors for GDM
include increasing maternal age, overweight or obesity, previous GDM, previous
macrosomic baby, family history of diabetes, and belonging to an ethnic group having a
high prevalence of diabetes (Griffin et al., 2000). The pros and cons of selective and
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universal screening are debated (Moses & Cheung, 2009). It is argued that with selective
screening based on risk factors, a substantial proportion of GDM cases might be
overlooked. Studies have found 22% to 53% missed cases of GDM when screening is
conducted through risk factors. However, studies examining broader criteria for risk
factor screening observed that only 3–9% of GDM cases would be missed but it would
require to screen 80–90% of women (Moses, Moses, & Davis, 1998; Moses & Cheung,
2009; Williams et al., 1999). Selective screening has also been found to be challenging
and complex (Moses & Cheung, 2009). Studies have revealed that even well-trained
health care workers may face difficulty in conducting selective screening. A survey
conducted in New Zealand showed that even experienced midwives had difficulty
recalling the recognized risk factors for GDM (Simmons, Devers, Wolmarans, &
Johnson, 2009). The current recommendations for screening of GDM include:
x

Screening for undiagnosed type 2 diabetes at the first prenatal visit in those with
risk factors, using standard diagnostic criteria.

x

In pregnant women not previously known to have diabetes, screening for GDM at
24–28 weeks’ gestation, using a 75-g OGTT, with plasma glucose measurement
fasting and at 1 and 2 hours.

x

The OGTT should be performed in the morning after an overnight fast of at least
8 hours.
Women identified of having GDM on screening need to be managed

appropriately to prevent the occurrence of adverse maternal and fetal outcomes.
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Management of GDM/PGDM
It is well-documented that women with GDM/PGDM are at higher risk of adverse
pregnancy outcomes (Crowther et al., 2005; Landon et al., 2009; Kwik, Seeho, Smith,
McElduff, & Morris, 2007). Proper management of women with GDM/PGDM can
decrease the risk of these adverse outcomes (IDF, 2009). The primary intervention for
women with GDM/PGDM is lifestyle modification, however, medications may be
needed to achieve adequate glycaemic control. Oral hypoglycaemic agents or insulin may
be required (Royal College of Obstetricians and Gynaecologists, 2011). Women should
be made aware of the risk of hypoglycemia, and information about prevention and
treatment should be provided to them (National Collaborating Centre for Women's and
Children's Health, 2008). Continuous glucose monitoring should be emphasized, and
pregnant women with diabetes should be encouraged to self-monitor blood glucose
levels. In addition to self-monitoring of blood glucose, the HbA1c level should also be
measured at intervals of 4 to 8 weeks (IDF, 2009). In addition to management of glucose
levels, lifestyle modifications especially appropriate diet plays an important role in
management of GDM/PGDM.
All pregnant women with diabetes should receive advice about appropriate
nutrition. In most cases, previous nutritional advice for women with PGDM needs to be
revised and altered according to pregnancy requirements. Women who develop GDM
should be provided with nutritional advice. Healthcare professionals should provide
individualized and culturally sensitive nutritional advice. To help control glucose levels,
the carbohydrate intake needs to be regulated, and a change in the types of the
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carbohydrates consumed may prove beneficial (IDF, 2009). Lifestyle modifications
include not only changes in diet but also changes in physical activity. Physical activity
plays an important role in the management of pregnancy with diabetes. A moderate
amount of exercise is beneficial for women with diabetes in pregnancy. A minimum of
30 minutes exercise on most days of the week is recommended (IDF, 2009). Appropriate
communication strategies are needed to convey proper advice about diet and physical
activity in women with GDM/PGDM.
Healthcare professionals should play their role by providing information and
support that will help to decrease the risks of adverse pregnancy outcomes. Healthcare
professionals should provide information about the importance of appropriate diet, body
weight and physical activity; the risks of hypoglycemia; the higher risk of having a large
for gestational age baby which raises the risk of birth trauma, induction of labor and
caesarean section; the importance of appropriate feeding of the newborn; and the chances
of metabolic disturbances during the neonatal period (National Collaborating Centre for
Women's and Children's Health, 2008). The management of pregnancy with diabetes
continues after pregnancy. Women with GDM should have a postpartum OGTT. Women
belonging to high-risk group should have an annual OGTT while those in the low-risk
group may have tests for fasting glucose levels every two to three years (IDF, 2009).
Thus, management of GDM does not stop at the completion of pregnancy rather it
continues to follow- up to identify women at risk of developing long term consequences
of GDM. Provision of information to women for prevention of GDM in subsequent
pregnancies is also an important step in the management of GDM.
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Prevention of GDM
In spite of increasing incidence of GDM, there is lack of evidence on effective
approaches to prevent it. It is suggested that a combined dietary and exercise intervention
may have an impact on insulin resistance leading to prevention of GDM (Callaway et al.,
2010). Some studies have shown that restricting energy and carbohydrates could
minimize gestational weight gain. Thus, weight management through nutritional
prevention strategies could prove successful in reducing the risk for GDM (Morisset et
al., 2010). In contrast, a cluster-randomized trial conducted to examine whether GDM
can be prevented by lifestyle counseling in pregnant women at high risk of GDM, could
not demonstrate positive results (Luoto et al., 2011). Studies conducted to determine the
role of physical activity on prevention of GDM have also shown inconclusive results
(Callaway et al., 2010). Wolff, Legarth, Vangsgaard, Toubro, & Astrup (2008) found that
restriction of gestational weight gain in obese women is achievable through limited
energy intake. Although studies have identified maternal weight and physical activity as
important factors in prevention of GDM, further studies are needed to determine the
influence of these factors as preventive measures.
Review of Methodologies Used in Determining Maternal and Fetal Outcomes of
PGDM/GDM among women in Eastern Mediterranean Region
The literature reviewed includes research addressing the effect of GDM/PGDM
on maternal and fetal outcomes of pregnancy. These studies are observational and
quantitative in nature and are mostly hospital-based. The study designs include crosssectional studies, retrospective review of administrative records, case- control studies,
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and cohort studies. The strengths and limitations of these research designs in the context
of determining maternal and fetal outcomes among women with GDM/PGDM are
discussed below:
Cross-sectional studies
A cross-sectional study describes the health status and the presence or absence of
exposure of a specified population at a defined point in time (Ressing, Blettner, & Klug,
2010). It determines the association between an outcome and an exposure among
individuals in a specified population at a specific point in time (Aschengrau & Seage III,
2008). Thus, the researcher observes the exposure and outcome in the study population,
simultaneously. The strength of this design is that the prevalence of disease or health
outcome in a population can be assessed. Furthermore, these studies are less resource and
time- intensive. However, the cross-sectional design has certain limitations which make it
less scientifically rigorous than case-control and cohort studies (Aschengrau & Seage III,
2008). These studies cannot determine the temporal sequence of exposure and disease,
thus, it is difficult to establish the association between exposure and disease (Aschengrau
& Seage III, 2008). However, temporal sequence is not an issue in the studies for
determining association between PGDM/GDM and pregnancy outcomes, as exposure
always precedes the outcomes. Hossein-Nezhad et al. (2007) conducted a cross-sectional
study and determined the prevalence of GDM and its association with various adverse
pregnancy outcomes in the study population.
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Case- Control Studies
The case-control study compares the individuals with the disease or health
outcome (case) to those without the disease or health outcome (control) (Ressing et al.,
2010). A case–control study examines a single disease in relation to exposure to risk
factors (Aschengrau & Seage III, 2008). The strengths of case- control studies include
their cost-effectiveness and time- efficiency. They are appropriate to study rare diseases
and diseases with long latent periods. Moreover, multiple risk factors can be examined to
determine their association with the outcome. Limitations of case-control studies include
the inability to calculate incidence rates, confounding and bias. Bias may occur due to
inappropriate selection of the control group in the case-control studies (Aschengrau &
Seage III, 2008). Another limitation is the information bias as the study is dependent on
the medical records or study participant's ability to recall events. For example,
Diejomaoh et al. (2009) stated the limitation of inability to calculate body mass index
(BMI) of study participants as height of the pregnant women were not recorded in their
medical records. This may have affected the association of GDM/PGDM with
macrosomia as the confounding effect of obesity could not be ruled out.
Cohort Studies
Cohorts are groups of similar individuals such as all pregnant women registered in
a health care facility during a specified period of time. In cohort studies, the cohort is
followed over a period of time to determine the outcomes in relation to certain risk factor
(Aschengrau & Seage III, 2008). The cohort study begins with the observation of study
participants without outcomes who are either exposed or non-exposed to certain risk
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factor (Ressing et al., 2010). Thus, the cohort under investigation is divided into two
groups on the basis of their exposure status such as women with GDM/PGDM and those
without GDM/PGDM. The researchers observe the study population and follow them
over time to determine the outcome in the exposed and unexposed group. Cohort studies
can be either prospective or retrospective (Lounds Taylor et al., 2012). In a prospective
cohort study, the study population is defined prospectively before outcome occurrence. A
prospective study allows for a more accurate measure of exposure and outcome. In a
retrospective cohort study, the outcome occurs before the start of the study; however, the
study population is classified on the basis of exposure status. The cohort studies are
useful in studying several possible outcomes from a single exposure. Incidence rate of a
disease can be calculated. The prospective cohort studies are time consuming and
resource intensive. The study participants may be lost to follow up resulting in attrition
bias. In case of retrospective cohort studies, information bias may occur. Al-Khalifah et
al. (2012) have discussed the limitations of their retrospective cohort study as information
regarding nutritional status of pregnant women and adherence to treatment regimen was
not available in the medical records. Thus, the confounding effect of these factors on the
association between GDM and adverse pregnancy outcomes could not be controlled.
Summary of Methodological Issues
Most studies of GDM/PGDM in the EMR were case-control studies (Abdelgadir
et al., 2003; Dafallah & Yousif, 2004; Diejomaoh et al., 2009) and cohort studies
(Abolfazl et al., 2008; Al-Khalifah et al., 2012; Bener et al., 2011; Hossein-nezhad et al.,
2011; Keshavarz et al., 2005). Some Eastern Mediterranean studies determined maternal
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and fetal outcomes of GDM/PGDM by using administrative data. Thus, retrospective
review of the administrative records to determine an association between adverse
pregnancy outcomes and GDM/PGDM was conducted (Al Najashi & Al Umran, 1997;
Barakat et al., 2010; Misra et al., 2001). Many of these studies had limited sample sizes
(Abdelgadir et al., 2003; Abu-Heija, Jallad, & Abukteish, 1999; Al-Dabbous et al., 1996).
For example, Abu-Heija et al. (1999) only identified 11 women with PGDM out of their
total sample of 114 women.
Many studies conducted in the EMR have used medical records for data collection
(Barakat et al., 2010; Gasim, 2012; Misra et al., 2001). Use of administrative data is costeffective and time-efficient but has certain methodological limitations. The number of
variables available for analysis is limited in administrative data. For example,
information about certain risk factors which may affect the outcomes of pregnancy such
as age of onset or duration of PGDM may not be available in the administrative records.
Some women with GDM/PGDM may choose to use private health care facilities. Any
single study based on administrative data from public hospital may not represent the
complications in those who got health care services from private institutions; who had
severe complications or those who had complications during home delivery.
An important design issue among the studies reviewed was the duration of the
study. For example, Al-Khalifah et al. (2012) reviewed hospital records of women with
GDM for the duration of one year while other studies reviewed the records for a duration
of two years (Misra et al., 2001; Sobande et al., 2000; Tahir et al., 2011). Data of many
studies were limited because the data were collected from a single health care facility
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(Al-Khalifah et al., 2012; Mazhar et al., 2003; Misra et al., 2001; Sobande et al., 2000).
Some of the above mentioned methodological limitations can be overcome by conducting
meta-analysis. Meta-analysis combines the data from various studies. Combining data of
these studies provided a better perspective by having larger sample size; longer duration
of study; data from multiple countries and multiple health care facilities.
Meta-analysis
Meta-analysis is a statistical method for synthesizing the results of relevant
primary studies (Crombie, & Davies, 2009). While reviewing the literature for my
dissertation, I reviewed various studies in which meta-analysis was conducted on the
topic of PGDM and GDM. Researchers have addressed a variety of topics related to
PGDM and GDM. Purposes of these meta-analyses, number of studies included in the
meta-analysis, publication years of included studies, and the outcomes discussed in these
meta-analysis are illustrated in Table 1. The number of studies included in the metaanalysis ranged from a minimum of seven (Poel et al., 2012) to a maximum of 22 studies
(Mao, Li, & Gao, 2012). The span of time for studies included in meta-analysis varied;
ranging from 3 years (Lepercq et al., 2012) to more than 20 years (Chu et al., 2007;
Horvath et al., 2010; Wahabi, Alzeidan, & Esmaeil, 2012). To synthesize the effects of
treatments on women with GDM, Horvath et al. (2010) included studies conducted over a
span of around 40 years, from 1966 to 2005.
In addition to variation in the time span and number of studies included in metaanalysis, a variety of topics are addressed in these meta-analyses. Associations of various
adverse outcomes with GDM/PGDM are studied, as well. Balsells et al. (2012)
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performed a meta-analysis to determine the association of major congenital
malformations in women with GDM/PGDM in comparison to the general population.
Bellamy and colleagues (2009) determined the strength of association between GDM and
risk of developing type 2 diabetes later in life. However, I could not find a meta-analysis
addressing adverse pregnancy outcome among women with GDM/PGDM in the EMR.
As most of the countries in this region have high birth rate and also prevalence of
GDM/PGDM is higher in comparison to rest of the world, it was important to conduct a
meta-analysis by including studies conducted in this region. Such a meta-analysis
provided a better picture of gravity of the situation in EMR.
This dissertation is a meta-analysis of observational studies conducted on adverse
maternal and fetal outcomes among women with GDM/PGDM in the EMR. Metaanalysis was appropriate for this research because I have tried to explore existence and
magnitude of association between adverse pregnancy outcomes and GDM/PGDM in the
EMR. The meta-analysis included studies from most countries of the Region, conducted
in various periods of time in varied settings. It utilized scientific literature search
strategies and statistical methods for quantitatively summarizing the results of relevant
primary studies addressing a particular research question (Cook et al., 1997). The
quantitative summary provides a broader perspective of relevant findings from research
on a specific topic. Statistical synthesis of data from several primary studies results in a
more precise estimate of the effect size, in comparison to any single primary study. On
combining the samples of primary studies, the overall sample size was enhanced, leading
to increased statistical power, thus reducing the size of the confidence interval and
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increasing the precision of the results. Moreover, systematic reviews and meta-analysis
may identify gaps in the existing literature (Garg et al., 2008). Meta-analysis provides
evidence to make informed decisions for health care. They are also helpful in planning
future research for delivering optimal health care (Cook et al., 1997).
Table 1
Characteristics of Published Meta-analysis on Various Issues related to Pregestational/
Gestational Diabetes Mellitus
Author

Balsells,
GarcíaPatterson,
Gich, &
Corcoy,
2012
Bellamy,
Casas,
Hingorani,
&
Williams,
2009
Chu et al.,
2007

Horvath et
al., 2010

Purpose

To perform a
systematic review
and meta-analysis
of major congenital
malformations in
women with GDM
as compared to
general population.
To assess the
strength of
association between
GDM and risk of
developing type 2
diabetes
To determine the
magnitude of
association between
risk of GDM with
increasing weight
or BMI
To summarize the
benefits and harms
of treatments for
women with GDM

Number
of studies
included
in metaanalysis

Type of
diabetes

17
studies

Publicati
on years
of studies
included
in metaanalysis
19882008

Outcome

20
studies

19912008

GDM

Type 2
Diabetes
Mellitus

20
studies

19802006

GDM

GDM

Pool A: 5
studies
Pool B:
13
studies

19662005

Maternal
GDM
and
PGDM

Congenital
Malformatio
n

Pre-eclampsia
GDM

Fetal

Shoulder
dystocia;
Large for
Gestational
Age
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Author

Purpose

Number
of studies
included
in metaanalysis

Publicati
on years
of studies
included
in metaanalysis
20072010

Type of
diabetes

Lepercq et
al., 2012

To compare use of
insulin
glargine with
human NPH insulin
for efficacy and
safety-related
outcomes during
pregnancy.

8 studies

Mao, Li, &
Gao, 2012

To derive a more
precise estimation
of the association
between common
type 2 diabetes
(T2D) risk gene
polymorphisms,
hence achieve a
better
understanding to
the relationship
between T2D and
GDM.
To examine
association between
vitamin D and
glucose metabolism
in women with
GDM compared
with normal
glucose tolerance
(NGT)

22
studies

19942012

GDM

7 studies

20072011

GDM

Poel et al.,
2012

GDM
and
PGDM

Outcome
Maternal

Fetal

Weight at
delivery,
weight gain,
1st/3rd
trimester
HbA1c, severe
hypoglycemia,
gestation/newonset
hypertension,
preeclampsia,
and cesarean
section

Congenital
malformatio
ns,
gestational
age at
delivery,
birth weight,
macrosomia,
LGA, 5
minute
Apgar score
>7, NICU
admissions,
respiratory
distress
syndrome,
neonatal
hypoglycemi
a, and
hyperbilirubi
nemia

69
Author

Purpose

Tobias,
Zhang,
Dam,
Bowers, &
Hu, 2010

Wahabi,
Alzeidan,
& Esmaeil,
2012

Wendland
et al., 2012

To synthesize the
current
evidence on the
relation between
physical activity
and the
development of
GDM
To evaluate the
effectiveness and
safety of prepregnancy care in
improving the rate
of congenital
malformations and
perinatal mortality
for women with
PGDM
To systematically
review the evidence
for the associations
between GDM and
adverse outcomes

Number
of studies
included
in metaanalysis

Publicati
on years
of studies
included
in metaanalysis
20042010

Type of
diabetes

21
studies

19832010

8 studies

19942010

8 studies

Outcome
Maternal

Fetal

PGDM

HbA1c in the
first trimester
of pregnancy

Congenital
malformatio
n; perinatal
mortality;

GDM

Preeclampsia;
cesarean
delivery

Macrosomia;
large for
gestational
age;
perinatal
mortality

GDM

Summary and Transition
Chapter 2 presented a literature review for GDM/PGDM and their adverse
maternal and fetal outcomes. GDM and PGDM are associated with adverse maternal and
fetal outcomes and may result in serious health complications (Crowther et al., 2005;
Metzger et al., 2008). Increased caesarean section rates, high blood pressure, and
increased lifetime risk of occurrence of type 2 diabetes are adverse maternal outcomes
(Langer et al., 2005; Bellamy et al., 2009). Adverse fetal outcomes include perinatal
complications, still birth, macrosomia, and trauma during birth (Ayaz et al., 2009; Ornoy,
2011; Thorpe et al., 2005).
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Middle Eastern countries are reported to have a high prevalence of GDM and
PGDM (Agarwal et al., 2010; Hossein-Nezhad et al., 2007). There are a limited number
of published studies examining the association between adverse outcomes and
GDM/PGDM among women in Middle Eastern countries. Most of the published studies
are hospital-based and tend to have small sample sizes. Since adverse fetal outcomes,
such as still births are not common occurrences and the number of cases in any given
study is few, the measure of association may not be significant statistically for these
outcomes. These non-significant results are due to smaller sample size and low statistical
power of the study. Synthesizing these studies statistically, by meta-analysis, quantified
complications related to pregnancy with diabetes and provided insight regarding the
extent of the problem in the EMR. This study determined the existence of association as
well as strength of association of adverse pregnancy outcomes with GDM and PGDM
among women in EMR. Measuring the association of adverse pregnancy outcomes with
GDM and PGDM helped in providing a better picture of magnitude and severity of the
problem in EMR. Given the rising prevalence of PGDM and GDM in Middle Eastern
countries, it is important to be aware of the severity and seriousness of the problem.
Determining the magnitude of association between adverse pregnancy outcomes filled the
gap in the existing literature regarding this important topic related to maternal and child
health.
In Chapter 3, I provide the details of the study, including the research design and
its rationale. Description of the population, dependent and independent variables,
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literature search strategy, inclusion and exclusion criteria for studies, and data analysis
techniques will also be described in Chapter 3.
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Chapter 3: Research Method
Introduction
Given the rising prevalence of PGDM and GDM in the EMR ,.determining the
magnitude of association between GDM/PGDM and adverse pregnancy outcomes is an
important initial step that will help provide a better picture of magnitude and severity of
the problem. The purpose of this study was to determine the association between
GDM/PGDM and adverse pregnancy outcomes among women in the EMR. Studies on
pregnancy with diabetes and its outcomes are generally conducted at a smaller scale;
however, this meta-analysis combines the sample sizes of studies from various countries
and analyzes their results to provide an idea about this public health issue at a regional
level .
The first section of this chapter describes the research design and rationale. After
restating the research questions, I describe what is meta-analysis. I then describe the
population used for the study. In the subsequent sections, I describe the independent and
dependent variables, the literature search strategy for identifying studies for inclusion in
the meta-analysis, the inclusion and exclusion criteria for various studies used in this
project, and the data analysis techniques and sensitivity analysis.
Research Questions and Hypotheses
This study was based on two main research questions, each of which generated
related hypotheses:
1. Is there an association between GDM/PGDM and delivery by cesarean section among
women in the EMR?

73
H01 - There is no association between GDM/PGDM and delivery by cesarean section
among women in the EMR
HA1 - There is an association between GDM/PGDM and delivery by cesarean section
among women in the EMR
2. Is there an association between GDM/PGDM and adverse fetal outcomes among
women in the EMR?
2a. Is there an association between GDM/PGDM and macrosomia among women in
the EMR?
H02a - There is no association between GDM/PGDM and macrosomia among
women in the EMR
HA2a - There is an association between GDM/PGDM and macrosomia among
women in the EMR
2b. Is there an association between GDM/PGDM and perinatal mortality among
women in the EMR?
H02b - There is no association between GDM/PGDM and perinatal mortality
among women in the EMR
HA2b - There is an association between GDM/PGDM and perinatal mortality
among women in the EMR
Research Design and Rationale
The purpose of this study was to determine whether GDM/PGDM, as independent
variables, had any association with the adverse pregnancy outcomes among women in the
EMR. Quantitative research is an appropriate methodology as the study is designed to test
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a hypothesis using quantitative data. In order to find any association between the
independent and dependent variables as well as their strengths of association, primary
studies on GDM/PGDM among women in the EMR were collected to conduct a metaanalysis. Generally, a single study cannot answer important questions, and combination
of results from multiple primary studies provides more compelling evidence as compared
to result from a single study (Wilson, 2012). Moreover, combination of results of studies
conducted in different regions with varied populations is expected to be more
generalizable as compared to the results of a single study (Wilson, 2012). Meta-analysis
is a statistical method used for synthesizing the results of relevant primary studies
(Crombie & Davies, 2009). It uses scientific literature search strategies and statistical
methods for quantitatively summarizing the results of relevant primary studies addressing
a particular research question (Cook et al., 1997). The quantitative summary provides a
broader perspective of research findings on a specific topic. Statistical synthesis of data
from several primary studies results in a more precise estimate of the results, in
comparison to any single primary study. On combining the samples of primary studies,
the overall sample size is enhanced, leading to increased statistical power thus reducing
the size of the confidence interval (CI) and increasing the precision of the results (Garg et
al., 2008). Moreover, meta-analysis may identify gaps in the existing literature (Garg et
al., 2008). For example, it was revealed during the literature search for this meta-analysis
that the studies examining the association between GDM/PGDM and perinatal deaths in
the EMR were few with inconsistent results. The reasons for gaps in the research
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identified during meta-analysis include insufficient information, biased information or
inconsistent results (Robinson et al., 2013).
Meta-analysis is an appropriate method for this research because I tried to explore
if there is any association and the strength of that association between GDM/PGDM and
adverse pregnancy outcomes in the EMR. The meta-analysis included studies from most
countries of the region, conducted in various periods of time in varied settings addressing
the research questions of this dissertation. An original study of this extent would have
been resource- intensive and difficult to conduct because of adverse social, economic and
political situation of many member countries in the EMR. Meta-analysis is appropriate as
it statistically combines quantitative estimates from various primary studies (Sutton et al.,
2000). Therefore, my study provided a broader picture of the gravity of the situation in
Middle Eastern countries by combining quantitative estimates from various countries.
The estimates from various studies were combined to provide a pooled estimate.
Meta-analysis of epidemiological studies and the integration of observational data
has become increasingly popular in medicine and health care (Egger, Smith, & O’rourke,
2008). Systematic reviews and meta-analysis can result in the identification of an
important research question, and may help in appropriate sample size calculation for
future studies (Egger et al., 2008, p.12). They are also helpful in planning future research
for delivering optimal health care (Cook et al., 1997). My study provides scientific
information for informed decision by the policy makers in the EMR. Moreover, it helps
in identifying gaps in the available literature and in planning future research in this
important area of maternal and child health care.
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Time and Resource Constraints
There were certain time and resource constraints in conducting this study.
Acquiring all relevant research documents was not possible within the available time
frame. It was difficult and time consuming to get access to unpublished researches related
to the study topic. Thus, only published journal articles were included. Although there
were resource constraints in accessing all relevant articles, Walden library and its
document delivery system were quite helpful in this context. This meta-analysis included
research published only in English. Although some related researches are published in
languages other than English, such as Arabic, Persian, and other native languages,
because of resource constraints, translations of these researches could not be obtained.
Methodology
Population of Study
This meta-analysis included the population of countries of the EMR. Although
there are variations in socioeconomic conditions, these countries share many cultural
practices and lifestyle patterns (Jahan, 2008). The WHO Eastern Mediterranean Region
comprises 22 countries with a population of approximately 583 million (WHO, n.d.a).
The Eastern Mediterranean Regional Office (EMRO) comprises a group of WHO
member states in one of its six geographical regions. The 22 Middle Eastern countries of
EMRO include Afghanistan, Bahrain, Djibouti, Egypt, Iran, Iraq, Jordan, Kuwait,
Lebanon and Libya. In addition, Morocco, Oman, Pakistan, Palestine, Qatar, Saudi
Arabia, Somalia, Sudan, Syria, Tunisia, United Arab Emirates, and Yemen are also
included in the WHO EMRO (World Health Organization, n.d.b).
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The population size and health indicators of Middle Eastern countries are variable
and differ from country to country. During 2011, the population of the member countries
of WHO EMRO ranged from 865,000 in Djibouti to 177,100,000 in Pakistan which has
the largest population in the region (WHO, 2012). During the same period, crude birth
rate in the region varied from as low as 11.9 per thousand in Qatar to as high as 44 per
thousand in Somalia while total fertility rate was 0.9 per woman in Kuwait which was the
lowest while it was 6.4 per woman in Somalia which was the highest in the region
(WHO, 2012). My dissertation included available relevant published studies in English
from the member countries, and the results of the study reflected the situation in the
above mentioned population.
Sampling and Sampling Procedures
All original research studies conducted to determine the association between
GDM/PGDM and pregnancy outcomes among women in the Eastern Mediterranean
countries were searched by a comprehensive search strategy, stated in the next section.
Many studies conducted to determine the effect of GDM/PGDM on pregnancy outcomes
had small sample size and few adverse outcomes. These studies might be having low
power to detect the association of GDM/PGDM with adverse outcomes. For example, the
study conducted by Sobande et al. (2000) had a power of 41.7% at an alpha level of 0.05,
to determine statistically significant difference between women with GDM/PGDM and
those without GDM/PGDM and perinatal deaths. Synthesizing the results of these studies
by meta-analysis increased the sample size which lead to increased precision of the
results (The Cochrane Collaboration, 2008). I combined all the sample sizes of all the
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published relevant and eligible research in English from the EMR which helped in
increasing the precision of the results and in identifying statistically significant
associations.
Meta-analysis increases the statistical power by reducing the standard error of the
weighted average effect size. It also decreases the confidence interval, representing
increased precision, around effect size (Cohn & Becker, 2003). Effect size is defined as
the magnitude of a difference measured on a standardized scale. It is a metric-free
measure and can be used for comparison of results of different studies (Sun, Pan, &
Wang, 2010). As small sample sizes from primary studies are pooled into a large one,
statistical power is higher in meta- analyses as compared to primary studies (Cohn &
Becker, 2003). Statistical power of a study refers to the chances of identifying an
underlying association within the population. By pooling the samples of primary studies,
a meta-analysis can increase the likelihood of detecting true estimates of effect size in the
underlying population (Cohn & Becker, 2003).
At the planning stage of meta-analysis, it is important to estimate the chances of
detecting a significant effect by that meta-analysis (Cafri, Kromrey, & Brannick, 2009).
This estimation can be done by conducting a power analysis prior to the study (Cafri et
al., 2009). Theoretically, statistical power in meta-analysis and in primary studies is
similar, as it is a function of sample size, an estimation of population effect size, and the
Type I error rate in both cases (Valentine, Pigott, & Rothstein, 2010). Increasing any one
of these variables without changing the others increases power of the study (Valentine et
al., 2010). Table 2 shows the estimation of power of a meta-analysis with a random
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effects model, under various assumptions regarding different factors of the meta-analysis.
The calculations in Table 2 assume α = 0.05 for Type I error.
Table 2
Illustration of the Random Effects of Statistical Power (One-Tailed) as a Function of
Different Assumptions About Review Parameters
Within-study sample Number of
Effect size
Degree of
Power
size (per group)
studies to be
to detect
heterogeneity
included
20
40
0.15
Moderate
0.68
30
40
0.15
Moderate
0.75
40
40
0.15
Moderate
0.79
20
25
0.15
Moderate
0.51
20
40
0.15
Moderate
0.68
20
65
0.15
Moderate
0.83
20
40
0.05
Moderate
0.18
20
40
0.25
Moderate
0.97
20
40
0.35
Moderate
~ 1.00
20
40
0.15
Large
0.44
20
40
0.15
Small
0.83
Note. Adapted with permission of the author from "How Many Studies Do You Need? A
Primer on Statistical Power for Meta-Analysis" by J. C. Valentine, T. D. Pigott, and H. R.
Rothstein, 2010, Journal of Educational and Behavioral Statistics, 35(2), p. 221.
Copyright 2010 by the American Educational Research Association.
While reviewing the literature for this dissertation, I found within study sample
size (per group) of more than 40, in most of the studies conducted for determining the
association between GDM/PGDM and pregnancy outcomes among women in the EMR.
Based on the criteria stated in Table 2, a meta-analysis of 40 studies with moderate
heterogeneity, will have a power of 0.79 to detect an effect size of 0.15 in my study.
All relevant studies conducted for determining the association between
GDM/PGDM and pregnancy outcomes among women in the EMR were considered for
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possible inclusion in meta-analysis, based on inclusion and exclusion criteria listed in the
following section.
Criteria for Inclusion and Exclusion of Studies in the Meta-analysis
It is important to set explicit criteria for the inclusion and exclusion of studies in
the meta-analysis. Inclusion criteria for studies can be based on various characteristics of
the research studies. The following criteria were used for the inclusion of studies in the
meta-analysis for estimating the association of GDM/PGDM with adverse maternal and
fetal outcomes.
Types of Studies. The observational studies regarding pregnancy outcomes in
women with diabetes were systematically reviewed. I included studies with a prospective
or retrospective cohort, case-control, and cross- sectional designs. Cohort and casecontrol studies, which examined pregnancy outcomes in women with diabetes, were
included. Those cross-sectional studies were included where pregnant women with
diabetes were compared with those without diabetes and measures of association were
calculated or there is data available for these calculations.
Types of participants. Pregnant women with GDM and/or PGDM.
Types of settings. Population-based as well as hospital- based studies were
included in this meta-analysis.
Types of outcomes measures. The research study should provide information on
at least one outcome included in the meta-analysis. Fetal outcomes including macrosomia
and perinatal death, ascertained through registry review, birth/medical records, and
physical examination of the newborn, were accepted.
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Geographical context. This dissertation included studies conducted in countries
of the EMR as classified by WHO (n.d.b). The meta-analysis was limited to articles
written in English.
Timeframe. Publication period ranged from the inception of the research
database to November 2013.
Exclusion Criteria
I excluded the studies with following attributes:
x

case report or case series;

x

review articles;

x

studies from countries other than members of the EMR;

x

not published in English;

x

a conference proceeding or abstract, letter to the editor, or commentary;

x

no assessment of an outcome relevant to the research questions;

x

animal studies.

Procedures for Data Collection
Review of the Literature. A meta-analysis identifies, evaluates, and combines
relevant studies on a specific topic (Petticrew & Roberts, 2006, p.2). This meta-analysis
included all stages of research synthesis including problem statement, literature search,
data evaluation, data analysis, data interpretation and writing of the results (Cooper &
Hedges, 2009). The background, research questions and methods of meta-analysis;
inclusion and exclusion criteria for primary studies; search strategy for finding relevant
research; and statistical procedures were stated (Victor, 2008). Background of the study,
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and inclusion and exclusion criteria for primary studies are stated in the above sections
while rest of the components are described in the sections below.
Independent and Dependent Variables
In this meta-analysis, independent variables were GDM/PGDM. The dependent
variable for maternal outcome was delivery by cesarean section. The dependent variables
for neonatal outcomes were (a) macrosomia, which means that the birth weight was
greater than 4000 g (large for gestational age or LGA) or that the (birth weight was
greater than the 90th percentile for their gestational age), and (b) perinatal mortality. I
defined the outcomes as follows:
x

Cesarean delivery was defined according to the primary study definition.

x

Large for gestational age births and macrosomia were included as defined by the
authors of the primary study.

x

Perinatal mortality included stillbirth and early neonatal death.
To identify relevant literature including the above mentioned independent and

dependent variables, a comprehensive literature search strategy was developed which is
described in the next section.
Search Strategy for Relevant Studies
A review of studies conducted on GDM/PGDM in the EMR was conducted to assess the
relevant literature. For meta-analyses, it is important to conduct a literature search in a
systematic manner to identify all available relevant research. It requires a comprehensive
literature search in several research databases, such as ProQuest Family Health, ProQuest
Health & Medical, ProQuest Health Management, ProQuest Nursing & Allied Health
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Source, ProQuest Science Journals, Academic Search Complete, CINAHL Plus, and
MEDLINE. Moreover, relevant journals and the reference lists of relevant papers should
also be hand searched (Crombie, & Davies, 2009). Explicit criteria for inclusion or
exclusion of studies must be used for meta-analyses (Crombie, & Davies, 2009).
Important keywords capable of identifying relevant research should be used as search
terms.
Search Terms. A comprehensive search for relevant studies using important
keywords was conducted. The index terms for search were diabetes mellitus, type I
diabetes, type 2 diabetes mellitus, NIDDM, pregnancy, pregestational diabetes,
gestational diabetes, diabetic pregnancy, diabetes in pregnancy, pregnancy
complications, outcome, macrosomia, cesarean, cross- sectional, case control, and
cohort studies. The search terms were combined using the term “AND” to create a
complete list of articles for this meta-analysis. These terms were also searched with the
names of individual member countries of the EMR. These countries include Afghanistan,
Bahrain, Djibouti, Egypt, Iran, Iraq, Jordan, Kuwait, Lebanon; Libya, Morocco, Oman,
Pakistan, Palestine, Qatar, Saudi Arabia, Somalia, Sudan, Syria, Tunisia, United Arab
Emirates, and Yemen. The limitation applied was the English language. The search limit
start-date was chosen by the earliest date the database had been available.
Electronic databases. The electronic databases searched included ABI/INFORM,
Academic Search Premier, CINAHL, Cochrane Database of Systematic Reviews
(CDSR), Educational Resource Information Center (ERIC), Emrmedex, Journals at Ovid,
Library Information Science and Technology Abstract (LISTA), Medline, Proquest,
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PsychINFO, and publishers’ databases such as Elsevier and Springer. The databases were
searched from inception to November 2013 to identify relevant citations.
Hand searching. The medical journals of EMR such as Eastern Mediterranean
Health Journal by World Health Organization, Annals of Saudi Medicine, Saudi Medical
Journal and Saudi Journal of Family and Community Medicine were hand-searched.
These journals are likely to publish articles relevant to the topic of this meta- analysis.
Hand searching was performed by scanning the table of contents of the journals most
likely to publish articles on the topic and scanning reference lists from included articles
and review articles on GDM/PGDM.
Internet searching. Internet searches were conducted using the keywords
mentioned above, through search engines such as googlescholar.com and google.com.
Websites such as WHO EMRO, and websites of Ministry of Health of member countries
of EMRO were also searched for relevant researches. Individual websites of journals of
the EMR such as Eastern Mediterranean Health Journal by World Health Organization,
Annals of Saudi Medicine, Saudi Medical Journal and Saudi Journal of Family and
Community Medicine were explored for relevant articles.
Reference lists. In addition to electronic database searches, articles cited in metaanalyses and systematic reviews on GDM and PGDM, were reviewed. The reference lists
of relevant literature were also examined, to identify studies eligible for inclusion in the
present study.
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Documenting the Search Process
A complete record of literature search and data collection process was maintained.
The record included information about search time periods; research databases; search
engines; keywords; and search results. Studies were searched mainly through the Walden
University library system. If electronic copies were not available, print copies of the
journal articles were obtained. A record of excluded studies along with the reason for
exclusion was maintained.
Details of Study Included in the Meta-analysis
For maintaining details of studies included in the meta-analysis, the guidelines for
reporting meta- analysis of observational studies (Appendix A) was followed (Stroup et
al., 2000). A summary table helps in displaying individual study characteristics in an
organized manner. A summary table (Appendix B) was created to record the main
elements of each study such as relevant bibliographic information, the studies’ design,
type(s) of diabetes mellitus, age group/ mean age of women and outcome data (Glasziou
et al., 2001). In addition, any other pertinent information about the study was also
included.
Steps in Search Strategy
x

All titles and abstracts were considered for eligibility.

x

I screened the title and abstract of each study identified by the search and apply
the inclusion and exclusion criteria.
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x

Whenever an abstract seemed that the journal article may meet the inclusion
criteria, the corresponding full-text article was reviewed and the inclusion and
exclusion criteria applied.

x

References of review articles were searched for additional relevant studies.

x

Bibliographies of relevant retrieved studies were hand-searched for additional
publications.

x

Studies identified through additional search activities were reviewed to identify
duplicates of articles retrieved earlier.

x

Data on characteristics of study participants and outcomes (caesarean section,
macrosomia and perinatal mortality) listed in research questions were abstracted.

Data Abstraction
Articles were selected by reviewing the abstract and assessing if it met the
selection criteria for meta-analysis. When an abstract potentially fulfilled the criteria, the
corresponding full text was reviewed to find out if it fitted into the designated criteria.
The citations of all identified articles were entered into an electronic database for record
keeping and for removing the duplicates. I reviewed each article that met the selection
criteria and abstracted the data by using data abstraction form (Appendix C). I extracted
information about the general study characteristics (study design, study period, country of
study, and year of publication), study participants (number of study participants, maternal
age, type of diabetes); and designated maternal and fetal outcomes.
The relative risks (RRs) and odds ratios (ORs) for the association with adverse
pregnancy outcomes were abstracted, if stated. The unadjusted and adjusted RRs or ORs
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and 95% confidence intervals (CIs) were extracted as reported by authors. If not stated,
then the RRs and ORs were calculated from information stated in each study. When raw
quantitative data were not reported, values were obtained from the provided information.
Dichotomous data reported as percentages were converted to counts and OR and RR
were calculated. For each study, I constructed separate two-by-two tables to compute the
ORs or RRs and 95% CIs of each outcome. Association of caesarean section with
GDM/PGDM was observed for maternal outcome while macrosomia and perinatal
mortality (stillbirths and neonatal deaths) were focused for fetal outcome. All information
from the article review process was entered and analyzed in Comprehensive Meta
Analysis (CMA) software, Version 2.
It is important to write the report of meta-analysis according to standard
international guidelines. For reporting of meta- analysis, I followed the Meta-analysis of
Observational Studies in Epidemiology (MOOSE) guidelines (Stroup et al., 2000),
attached as Appendix A and Preferred Reporting Items for Systematic reviews and MetaAnalyses (PRISMA) guidelines (Moher et al., 2009) included as Appendix D. An
important component mentioned in the guidelines for meta-analysis is the assessment of
quality of the included studies. In this meta-analysis, quality of studies was assessed by
various criteria. Quality assessment of the studies is discussed in the next section.
Quality Assessment of Studies
Quality assessment of the studies (Appendix E) included in meta-analysis was
done. To assess individual observational studies, quality criteria were laid down by
organizations such as the Agency for Healthcare Research and Quality (AHRQ) (Myers

88
et al., 2008). These criteria addressed issues related to the methods employed to select the
study population, the appropriateness of the sample size, the methods for determining
outcomes, and the appropriateness of the statistical analysis.
Researchers have argued the utility of assigning a summary quality score to
individual observational studies. There is lack of evidence regarding substantial impact
on the results of meta-analysis by using a quality scoring system (Jüni, Witschi, Bloch, &
Egger, 1999). It is reported that instead of determining a cumulative quality score,
identifying quality issues such as inadequate sample size or inappropriate statistical
methods may be more helpful in guiding future research (Agency for Health Care
Research and Quality [AHRQ], 2010; Myers et al., 2008). Thus, quality scoring was not
done in my study, however, to assess the quality of the included studies various criteria
were observed and reported (Appendix E).
I conducted quality assessment of the studies by selecting elements from the
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE)
guideline (Von Elm et al., 2007). For quality assessment, STROBE guideline (Appendix
F) includes different criteria for various study designs. I used the following criteria for
various study designs to assess the quality of the studies (Myers et al., 2008; Von Elm et
al., 2007).
Cohort study:
• Appropriate cohort selection
• Appropriate sample size
• Properly described cohort
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• Clear description of diagnostic criteria for GDM/PGDM
• Clear definition of the outcomes
• Description of the methods for ascertaining outcomes
• Description of lost to follow up
• Appropriateness of statistical analyses
Case-control study:
• Selection of cases in an appropriate and unbiased manner
• Selection of controls in an appropriate manner
• Matching of cases and controls regarding potential confounders
• Description of diagnostic criteria
• Clear definition of outcomes
• Address the potential sources of bias
• Appropriateness of statistical analyses
Cross-sectional study:
• Adequate sample size
• Appropriate methods of selection of participants
• Description of diagnostic criteria
• Clear definition of outcomes
• Appropriate sources of data and methods of assessment for outcomes
• Address the potential sources of bias
• Appropriateness of statistical analyses

90
Data Analysis Plan
Meta- analysis was conducted using the software Comprehensive Meta Analysis,
v2. Various statistical procedures were conducted in this software. This section describes
statistical procedures including effect size computation, random effects model and fixed
effects model, subgroup analysis, assessing heterogeneity, sensitivity analysis,
publication bias, and a brief description of software used for computation of data in the
meta- analysis. The description of each of these components is as follows:
Effect Size Computation
Most meta-analyses focus on relationships between variables (Borenstein et al.,
2009; p. 17). These relationships or associations are expressed as indices such as relative
risk (RR) or odds ratio (OR). Both OR and the RR can be given as the summary measure.
Although technically different, usually the ORs and the RRs have the same interpretation
(Davies, Crombie, & Tavakoli, 1998). In meta-analysis, the results from primary studies
are combined by statistical technique. There are different techniques for combining
relative risks, odds ratios and other effect estimates, but the basic principle is the same.
An estimate, weighted by the precision of the estimate is obtained from each study
(Crombie, & Davies, 2009). For some indices that are similar such as ORs and the RRs, it
is acceptable to combine them under certain conditions. ORs and the RRs are
approximately equal and can readily be combined, if the event is rare (Borenstein et al.,
2009; p. 21). In my study ORs and the RRs were combined to calculate the effect size as
the outcomes of interest such as perinatal death are rare.
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An effect size is a number that expresses the magnitude of the association
between two variables (Cooper & Hedges, 2009). There are various types of effect size
measures; r type in which effect size measured in terms of strength of association when
both the independent and dependent variables are ordered; and d type when the
independent variable is dichotomous and the dependent variable is ordered (Kraemer et
al., 2003). In meta-analysis, computation of effect size is the cornerstone as it synthesizes
the results related to outcomes of interest (Borenstein, 2009). The effect size computation
depends on three factors: (a) the measures for variables of outcomes of interest, (b) the
study designs of primary studies included in meta-analysis, and (c) the data analyses of
the primary studies (Lipsey & Wilson, 2001). In my dissertation, the studies included in
meta-analysis were observational studies with cohort, case-control and cross-sectional
designs. Thus, RRs and ORs were the indices measuring outcomes of interest in these
studies, both of which could be used for calculation of effect size in meta-analysis.
For the calculation of effect sizes in this study, OR is the primary metric, as the
OR has certain statistical properties which make it the best index for a meta-analysis
(Borenstein et al., 2009, p. 36). A weighted average of the ORs in the studies was
computed. In meta-analysis, odds ratios need to be transformed, followed by computation
of a weighted mean for the transformed values and then conversion of this mean back
into an odds ratio to report the combined value. Log scale is used for computations. The
log odds ratio, and the standard error of the log odds ratio, are computed and are used for
all calculations in the meta-analysis (Borenstein et al., 2009, p. 36). For my study, all
these statistical procedures were conducted by using the data analysis software.
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Odds ratios are analyzed in log units. Following is the computational formula for the
odds ratio (Borenstein et al., 2009; p. 36):
Odds ratio = AD/BC
log odds ratio: LogOddsRatio = ln(OddsRatio)
With approximate variance: VLogOddsRatio = 1/A + 1/B + 1/C + 1/D
An important step in conducting meta-analysis is to select the method for merging
effect sizes. Two types of models, fixed effects model and random effects model, can be
used for merging effect sizes. Selection of the model depends on certain characteristics of
primary studies such as heterogeneity. Decision about model selection should be taken
before conducting meta-analysis. A brief description of both these models along with the
decision about selection of model for this study follows in the next section.
Random Effects Model and Fixed Effect Model
Random effects model is a technique for merging effect sizes. It assumes that
reported effect sizes among studies may vary, due to both sampling error as well as actual
difference in population parameters (Cooper & Hedges, 2009). In contrast, the fixedeffect model takes an average of the primary study estimates and computes a pooled
effect estimate. It weights each study estimate by the inverse of its variance. The fixedeffect model assumes that there is no heterogeneity between studies. On the other hand,
some aspects of heterogeneity are incorporated in random effect models, and are
preferred to the fixed effect method when the studies are heterogeneous. Both models
give almost similar results, except that the confidence interval is generally wider in the
random effect model as compared to the fixed-effect model (Sutton et al., 2000, p. 360).
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In this meta-analysis, random effects model is used because of potential diversity among
the studies. Comprehensive Meta-Analysis (Version 2) software provided options for
analyzing data both by fixed-effect model and random effects model.
Random effects model is appropriate when the primary studies belong to different
populations. In my dissertation, the population of various studies included in metaanalysis was heterogeneous and differed from one another. Thus, random effects model
was the choice for calculating effect sizes. I prespecified use of the random effects model
because the studies were from different populations and had different designs such as
cohort and case-control studies (Flenady et al., 2011). Random effects model addresses
variation in study effects, due to variation in the effect sizes across primary studies as a
result of various factors such as ages and ethnicities of the study population. Moreover, a
random effects model balances weights across large and small primary studies in a more
appropriate manner (Borenstein et al., 2009). Various researchers have used random
effects models for meta-analysis on similar topics (Chu et al., 2007; Poel et al., 2012;
Wendland et al., 2012). Thus, random effects model was the most appropriate choice for
this study. Effect estimates were combined with random effects method in the software,
which yielded pooled adjusted odds ratios (aOR) and associated 95% CIs. I pooled
outcomes from primary studies calculating the OR for each outcome, and statistical
significance for overall effect was tested by Z test with the conventional significance
level of p < 0.05. CMA software has the option of calculating Z test according to
specified significance levels.
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Subgroup Analysis
Some studies included in the meta-analysis reported outcome measures according
to various sub-groups such as outcome measures according to type of diabetes. Thus,
sub-group meta-analyses for the main outcomes was performed. For each outcome, the
sub-groups were defined as those with different types of diabetes. The results were
considered statistically significant at the conventional value of p < 0.05.
Assessing Heterogeneity
Heterogeneity is the extent of variation of effect sizes among primary studies
(Peticrew & Roberts, 2006). A meta-analysis addresses a broader question than those
addressed by the included primary studies. Thus, there is expected diversity among the
included studies. It is important to anticipate this diversity and interpret the findings of
the meta-analysis accordingly (Borenstein et al., 2009, p.358). For this purpose, statistical
tests such as Cochrane’s Q statistic and I-squared are used to assess heterogeneity.
Cochrane’s Q statistic tests the statistical significance of the inconsistency among
studies. If the results are statistically significant, the studies are considered
heterogeneous. The Q statistic determines the sum of the between-studies variance
relative to within-studies variance. If the effects are homogeneous, that is, if the total
variance is no more than expected on the basis of the variance within-studies, then the
expected value of Q would equal the degrees of freedom (the number of studies minus 1;
Borenstein et al., 2009). For a statistically non-significant Q statistic, studies are
considered homogeneous. Although Q statistic is commonly used for assessment of
heterogeneity among studies, the test has certain limitations.
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Experts have expressed reservations about the use of Q statistic because of both
technical and conceptual problems (Huedo-Medina, Sánchez-Meca, Marín-Martínez, &
Botella, 2006). One technical problem is the fact that the Q statistic is not intuitive. A Q
value of 10 could represent a high amount of dispersion in a meta- analysis with fewer
studies, and little or no dispersion in another with a greater number of studies. Therefore,
Q does not lend itself to simple interpretation. Moreover, the Q statistic serves as a test of
the null, and like other tests of significance, it may not be significant because of low
statistical power. In contrast, it may be statistically significant if many studies are
included in the meta-analysis even if the dispersion is minimal (Borenstein et al., 2009).
Because of these limitations, certain alternative for assessing heterogeneity among
studies may also be considered.
An alternative statistic for assessment of heterogeneity is I-squared (Borenstein et
al., 2009). It measures the extent of total variation across primary studies because of
heterogeneity. It describes the heterogeneity in percentage. I-squared is an index, defined
as variance (between studies) /variance (total). This is equivalent to true/total variance.
The strength of this index is that the number of studies in the meta-analysis do not
directly affect it. The index is multiplied by 100 and reported on a scale of 0 to 100
(Borenstein et al., 2009). Various researchers have used Q statistic as well as I-squared to
assess heterogeneity in the meta-analysis (Balsells, García-Patterson, Gich, & Corcoy,
2012; Flenady et al., 2011; Horvath et al., 2010; Poel et al., 2012; Tobias et al., 2010;
Wendland et al., 2012). In the current study, to assess heterogeneity in the meta-analysis,
I used both Q statistic and I-squared, computed by the data analysis software. The Q
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statistic tests the existence of heterogeneity while I-squared also determines the extent of
heterogeneity and quantifies its magnitude. It is crucial to assess heterogeneity in metaanalysis because the decision to select the fixed or random-effects model in a metaanalysis may be based on the result of a homogeneity test (Huedo-Medina et al., 2006).
For this meta-analysis, the decision to use random-effects model was made apriori
because of the diversity of the population studied, however, assessment of heterogeneity
helped in providing statistical support to this decision. Moreover, quantification of
magnitude of heterogeneity by I-squared was helpful in interpreting the results of the
meta-analysis. For example, a value of 50% for I-squared means that sampling error is
responsible for half of the total variability among effect sizes while half of it is caused by
true heterogeneity between studies.
Sensitivity Analysis
A sensitivity analysis is a technique employed to examine the robustness of the
results of analysis of data (Borenstein et al., 2009). In a meta-analysis, study design and
sample size should be taken into account as potential sources of biased results. Extremely
large or small sample sizes or effect size on extremes can lead to skewed results
(Borenstein et al., 2009). Sensitivity analysis is carried out to explore the ways in which
selection of the studies and synthesis of data may have affected the overall results. It also
explores the effect of excluding various categories of studies. It may also examine the
extent of consistency of the results across various subgroups (Crombie & Davies, 2009).
Thus, sensitivity analysis is an important component of meta-analysis, to assess the
robustness of the results.
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Sensitivity analysis can be used to examine the changes in results by using varied
study inclusion rules. An outlier study may be examined to see its effects on the results of
meta-analysis. Thus, it can show the variation in results on omitting a single study or
some studies. Sensitivity analysis may also examine the effect of selection of the
statistical methods used on the overall results of the analysis. For example, examining the
difference in the overall result on using a different effect size measure such as a risk ratio
in comparison to an odds ratio. Sensitivity analysis may also examine if the overall
results would be the same if fixed-effect models had been used instead of random-effects
models (Borenstein et al., 2009). In this study, sensitivity analyses was performed to
assess variation in effect size caused by study design, sample size and country of study.
The influence of outliers was also evaluated to determine the affect of their omission on
overall results (Tobias et al., 2010).
Assessment of Publication Bias
A key concern in meta-analysis is publication bias, as the researches with nonsignificant or negative findings are less likely to be accepted for publication (Palma &
Delgado-Rodriguez, 2005). Possible presence of publication bias can be evaluated by
funnel plot (Egger et al., 1997). In funnel plot, the studies included in the meta-analysis
are displayed in a plot of effect size against sample size. Funnel plot should display the
picture of a symmetrical inverted funnel as chance variability is more in smaller studies
as compared to studies with larger sample size. If the plot is asymmetric, this suggests
that some studies might have been missed in the meta-analysis. The funnel plot has some
limitations, such as difficulty in visual detection of asymmetry (Terrin, Schmid, & Lau,
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2005). Certain statistical methods are also available to test for heterogeneity. Egger’s
regression test is commonly used to test for publication bias (Crombie & Davies, 2009).
In this study, publication bias was assessed using both funnel plot and Egger’s test
(Wendland et al., 2012). For publication bias, a visual inspection of the funnel plot was
performed, looking for an asymmetric picture (Tobias et al., 2010). Funnel plot
asymmetry was assessed with statistical methods (Balsells et al., 2012; Mao, Li, & Gao,
2012). Egger’s test, using a significance level of p < 0.05, was used to determine
significant asymmetry.
Software
Comprehensive Meta-analysis (CMA) [Version 2] was used for computation of
effect sizes as well as for computation of statistics such as p-values, confidence intervals,
Q statistics and I-squared. Forest plot and funnel plots were also created utilizing this
software.
Data Analysis Plan for Individual Research Questions
Data analysis plan for each research question along with the hypothesis is
described below:
Research Question 1. Is there an association between the presence of GDM/
PGDM and delivery by cesarean section among women in the EMR?
H01 - There is no association between the presence of GDM/ PGDM and delivery by
cesarean section among women in the EMR
HA1 - There is an association between the presence of GDM/PGDM and delivery by
cesarean section among women in the EMR
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Data analysis plan. Odds ratio was the primary metric for the calculation of effect
size regarding the association between GDM/PGDM and delivery by cesarean section
among women in the EMR. A weighted average of the ORs in the studies was computed.
For combining effect sizes of primary studies, random effects model was used because of
potential diversity among the studies. Effect estimates were combined with random
effects method in Comprehensive Meta Analysis (CMA) software [Version 2], which
yielded pooled adjusted odds ratios (aOR) and associated 95% CIs. I will pool outcome
regarding caesarean section from primary studies calculating the OR, and statistical
significance for overall effect was tested by Z test with significance level at p < 0.05.
Some studies included in the meta-analysis reported occurrence of caesarean
section according to type of diabetes (GDM and PGDM). Sub-group meta-analyses for
the occurrence of caesarean section according to the type of diabetes was performed. The
results were considered statistically significant at p < 0.05. A sensitivity analysis was
employed to examine the robustness of the results. Sensitivity analyses was performed to
assess variation in effect size caused by study design, sample size and country of study.
The influence of outliers was also be evaluated to determine the affect of their omission
on overall results.
Research Question 2. Is there an association between GDM/PGDM and adverse
fetal outcomes among women in the EMR?
Research Question 2a. Is there an association between GDM/PGDM and
macrosomia among women in the EMR?
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H02a - There is no association between GDM/PGDM and macrosomia among
women in the EMR
HA2a - There is an association between GDM/PGDM and macrosomia among
women in the EMR
Data analysis plan. Odds ratio was the primary metric for the calculation of effect
size regarding the existence of association between GDM/PGDM and macrosomia among
women in the EMR. Random effects model was used for merging effect sizes because of
potential diversity among the studies. Effect estimates were combined with random
effects method in the data analysis software, which yielded pooled adjusted odds ratios
(aOR) and associated 95% CIs. I pooled outcome regarding macrosomia from primary
studies calculating the OR, and statistical significance for overall effect will be tested by
Z test with significance level at p < 0.05.
Sub-group meta-analyses for the occurrence of macrosomia according to the type
of diabetes was performed. The sub-groups were defined as those with different types of
diabetes. The results were considered statistically significant at p < 0.05. A sensitivity
analysis was employed to examine the robustness of the results, and to assess variation in
effect size caused by study design and sample size.
Research Question 2b. Is there an association between GDM/PGDM and
perinatal mortality among women in the EMR?
H02b - There is no association between GDM/PGDM and perinatal mortality
among women in the EMR
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HA2b - There is an association between GDM/PGDM and perinatal mortality
among women in the EMR
Data analysis plan. Odds ratio was the primary metric for the calculation of effect
size regarding the existence of association between GDM/PGDM and perinatal mortality
among women in the EMR. Random effects model was used for merging effect sizes.
Pooled adjusted odds ratios (aOR) and associated 95% CIs were obtained by combining
effect estimates with random effects method in the data analysis software. The statistical
significance for overall effect was tested by Z test with significance level at p < 0.05.
Sub-group meta-analyses for the occurrence of perinatal mortality according to
the type of diabetes was performed. The sub-groups were defined as those with different
types of diabetes. The results were considered statistically significant at p <0.05.
Sensitivity analyses was performed to assess variation in effect size caused by study
design, sample size and country of study. The influence of outliers was also evaluated to
determine the affect of their omission on overall results.
Threats to Validity
Meta-analyses have limitations like all other types of research (Garg et al., 2008).
There are threats to the validity by factors that might lead to incorrect inferences (Cooper,
Hedges, & Valentine, 2009). There may be threats to construct validity, internal validity,
statistical conclusion validity, and external validity. These threats to validity are
discussed as follows:
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Construct Validity
It is important for meta-analysis that the effect sizes calculated from various
measures can be compared directly (Nugent, 2009). For this purpose, definitions of
variables should be consistent in the primary studies and meta-analysis. In my study,
there were certain threats to construct validity, as the definitions used in the primary
studies were not consistent. For example, the criteria for diagnosis of GDM were not
consistent in primary studies. This is because of lack of consensus on the diagnostic
criteria and due to changing criteria for GDM in different periods of time. Similarly,
definition of macrosomia varied in primary studies; some studies using the cut-off weight
of 4,000 grams while others using 4,500 grams for defining macrosomia. These threats to
construct validity were addressed by discussing various definitions stated in primary
studies while writing results in chapter 4, and while discussing the results in chapter 5.
Internal Validity
Internal validity refers to the validity of associations inferred from the results of
the primary studies. Meta-analysis includes diverse studies differing in their designs and
study participants. The meta-analysis cannot rectify issues with the design and
implementation of the primary studies. It also cannot correct the biases in the primary
studies (Garg et al., 2008). In addition to these general limitations of meta-analysis, there
are certain specific limitations related to the types of study designs included in the metaanalysis. Meta-analysis of observational studies have certain specific limitations which
are threats to internal validity. Estimates of association in observational studies may not
depict true association because of various factors. In addition to the role of chance,
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confounding factors, biases, or both may affect the results in observational studies. The
exposed study participants may be different in various ways which are related to the risk
of developing the outcome of interest (Egger, Smith, & Schneider, 2008). The effect of
residual confounding is another threat to the validity of meta-analysis of observational
studies (Flenady et al., 2011). This study included observational studies in meta-analysis.
Thus, it had threats to internal validity because of general limitations related to metaanalysis as well as limitations specific to the meta-analysis of observational studies.
To address the threats to internal validity, it is important to adopt comprehensive
search strategy to avoid bias in study identification and selection; and to assess the
quality of the primary studies using appropriate criteria (Crombie & Davies, 2009).
Following standard guidelines for reporting of meta-analysis such as MOOSE (Appendix
A) and PRISMA (Appendix D) guidelines is important in addressing the threats to
internal validity. All these measures were taken into consideration for my dissertation to
address the threats to internal validity. Specific discussions relating to internal validity
will be presented in chapter 5.
Statistical Conclusion Validity
Statistical conclusion validity refers to the application of appropriate statistical
tests in primary studies (Cooper et al., 2009). The quality and reliability of the overall
effect size and conclusions of meta-analysis depends on the reliability and
appropriateness of methods used by the primary studies. The statistical results of the
meta-analysis depend upon the statistical analysis conducted in primary studies. The
statistical conclusion validity also implies correct application of analytic procedures in

104
meta-analysis, such as control of confounding factors by using logistic regression. To
address the threat to statistical conclusion validity, it is important to assess the quality of
the primary studies using appropriate criteria including statistical tests used for analysis.
It is also important to use appropriate statistical methods for calculation of the combined
effect size, and to consider and test for heterogeneity (Crombie & Davies, 2009). All
these measures were taken into consideration for my dissertation to address the threat to
statistical conclusion validity.
External Validity
External validity refers to the generalization of the results of meta-analysis
(Cooper et al., 2009). Meta-analysis includes diverse studies differing in their study
participants enrolled from various geographical regions. This study generalizes the results
to the population of the EMR. The studies selected for inclusion in meta-analysis did not
include studies from all countries in the EMR, leading to the threat to the external
validity. To address this issue, an exhaustive literature search was conducted to include
available studies from different countries of the region. In addition to electronic searches,
local libraries were contacted. When required, the authors of relevant journal articles
were also contacted to obtain the relevant article.
Ethical Procedures
This study is a meta-analysis which provides an opportunity to learn more from
the published data and increase the benefits of conducted studies. Thus, time and efforts
of the human participants involved in the primary studies entering into the meta-analysis
are said to be more justified when their data enter into a meta-analysis (Rosenthal, 1994).
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The meta-analysis increases the utility of the primary studies. Other costs of primary
studies such as those of funding, researcher time and effort, and other resources are also
said to be more justified because the utility of primary studies is enhanced by the strength
obtained by combining the results from other studies (Rosenthal, 1994).
This study used data obtained from previously published studies. Thus, the issues
of confidentiality and anonymity were not relevant as these issues were already addressed
by the authors, reviewers and editors of the published articles. There were no associated
conflicts of interest. Although ethical concerns were minimal, ethical review board
approval was obtained before proceeding with data management. I obtained Walden
Institutional Review Board approval (number: 11-11-13-0137511) for my study.
Summary
This chapter contained an explanation of the research study, research questions
and hypotheses, and other pertinent issues related to the meta-analysis. Meta-analysis is a
statistical method for synthesizing the results of relevant primary studies by utilizing
scientific literature search strategies. This meta-analysis included studies from most
countries of the EMR, conducted in various periods of time in varied settings. A
comprehensive search strategy with explicit criteria for the inclusion and exclusion of
studies was used. Several research databases, such as MEDLINE, ProQuest and
EBSCOhost, were used to obtain primary studies for inclusion in meta-analysis. Journal
articles were selected by reviewing the abstract and assessing if it meets the selection
criteria for meta-analysis. When an abstract potentially met the criteria, the full text
article was reviewed to find out if it fitted into the designated criteria. The data were
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abstracted by using data abstraction form. For reporting of meta- analysis, I followed the
Meta-analysis of Observational Studies in Epidemiology (MOOSE) guidelines (Stroup et
al., 2000) and Preferred Reporting Items for Systematic reviews and Meta-Analyses
(PRISMA) guidelines (Moher et al., 2009).
Description of literature search strategy, selection criteria for the studies, data
abstraction, and quality assessment of studies for inclusion in the meta-analysis were
provided in this chapter. Important statistical aspects including effect size computation,
assessment of heterogeneity, sub-group analysis, and sensitivity analysis were explained.
Furthermore, limitations of meta-analysis and various measures to address these
limitations were also discussed. Chapter 4 will discuss the data analysis and results of the
study.
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Chapter 4: Results
Introduction
The purpose of this study was to determine the association of GDM/PGDM with
adverse pregnancy outcomes among women in the EMR. Given the rising prevalence of
PGDM and GDM in the Middle Eastern countries, it is important to be aware of the
severity and seriousness of the problem. Determining the magnitude of association
between adverse pregnancy outcomes and GDM/PGDM is an important initial step for
developing appropriate interventions. Proper interventions for improvement of outcomes
in GDM/PGDM will result in healthier mothers and children in Middle Eastern countries
and thus leading to a healthier and more productive community. To determine the
magnitude of association between adverse pregnancy outcomes in GDM/PGDM, certain
outcomes were specified, and the research questions were constructed around them.
There were two research questions for this study First question was related to
adverse maternal outcome and determined an association between GDM/PGDM and birth
by caesarian section among women in the EMR. Second question was whether there is an
association between GDM/PGDM and adverse fetal outcomes among women in the
EMR. Two adverse fetal outcomes were explored for association with GDM/PGDM
among women in EMR. These adverse fetal outcomes included macrosomia and perinatal
mortality.
This chapter presents findings on the pregnancy outcomes of 118,652 women,
including (a) 9,288 women with GDM/PGDM and (b) 109,364 without GDM/PGDM, all
of whom were participants in 33 observational studies that examined the pregnancy
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outcomes of women with GDM/PGDM in the Eastern Mediterranean countries. This
chapter explains the procedures for data collection, describes studies included in the
meta-analysis, and discusses the results of the meta-analysis, including sub-group
analysis, moderator analysis, and public bias.
Data Collection
Procedures for Data Collection
I conducted a systematic review of published journal articles providing original
data on pregnancy outcomes in GDM/PGDM among women in the EMR. According to
the standard protocol outlined by MOOSE (Stroup et al., 2000) and PRISMA guidelines
(Moher et al., 2009), the background; research questions and methods of meta-analysis;
inclusion and exclusion criteria for primary studies; search strategy for finding relevant
research; and statistical procedures were stated in chapter 3.
In this meta-analysis, independent variables are GDM and PGDM. The dependent
variables for maternal outcome are delivery by cesarean section. The dependent variables
for neonatal outcomes are macrosomia (birth weight > 4000 g)/large for gestational age
(LGA; birth weight > 90th percentile for their gestational age), and perinatal mortality.
To identify relevant literature including these independent and dependent variables, I
followed a comprehensive literature search strategy which is described in the next
section.
Search Strategy for Relevant Studies
To identify all available relevant research, I conducted a comprehensive literature
search in several research databases in a systematic manner, for studies published on
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GDM/PGDM in the EMR. Moreover, relevant journals and the reference lists of relevant
papers were also hand searched. Explicit criteria for inclusion or exclusion of studies
were used for meta-analyses. Important keywords capable of identifying relevant
research were used as search terms. As discussed in detail in Chapter 3, important
keywords were used to search electronic databases, search engines and relevant websites.
The medical journals of the EMR such as Eastern Mediterranean Health Journal by
World Health Organization, Annals of Saudi Medicine, Saudi Medical Journal and Saudi
Journal of Family and Community Medicine were hand-searched in the local libraries.
The reference lists of relevant literature were also examined, to identify studies eligible
for inclusion in the present meta-analysis.
Studies were included if they fulfilled the inclusion criteria. The criteria used for
the exclusion and inclusion of studies in the meta-analysis for estimating the association
of GDM/PGDM with adverse maternal and fetal outcomes were discussed in Chapter 3.
The steps in literature search strategy are listed as follows:
Steps in Search Strategy
x

All titles were considered for eligibility.

x

I screened the abstract of relevant title identified by the search for possible
inclusion in the meta-analysis.

x

Whenever an abstract seemed that the journal article may meet the inclusion
criteria, the corresponding full text was reviewed, and the inclusion and exclusion
criteria applied.
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x

References of review articles and bibliographies of relevant retrieved studies were
searched for additional relevant studies.

x

Studies identified through additional search activities were reviewed to identify
duplicates of articles retrieved earlier.

x

Data on characteristics of study participants and outcomes (caesarean section,
macrosomia and perinatal mortality) listed in research questions were abstracted.

Documenting the Search Process
I maintained a complete record of literature search and data collection process.
The record included information about search time periods; research databases; search
engines; keywords; and search results. Studies were searched mainly through the Walden
University library system. Journal articles not available in Walden Library were
requested by document delivery system. If electronic copies were not available, print
copies of the journal articles were obtained from local libraries or by personal request to
the authors of that journal article. Two articles (Al Teheawt & Farida, 1995; Denguezli et
al., 2007) could not be obtained by document delivery system. One of them (Al Teheawt
& Farida, 1995) was obtained by personal request, from the local library in Egypt. The
other (Denguezli et al., 2007) was obtained by requesting the author via e- mail. The
author emailed scanned copy of the requested journal article.
The search strategy retrieved 12,188 records. I considered all titles for eligibility.
The abstracts of all relevant titles were reviewed. Whenever an abstract seemed that the
journal article could meet the inclusion criteria, I assessed the corresponding full text, to
find out if it fits into the designated criteria. On title review, 170 abstracts were eligible
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for review. On reviewing the abstracts, 69 full-text journal articles seemed to meet
inclusion criteria. Thus, 69 full-text journal articles were examined for inclusion criteria.
Of these studies, 36 (52.2%) did not qualify for the meta-analysis and were excluded. The
search strategy is summarized in Figure 1.
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Records identified through
database searching
(n = 1995 )

Additional records identified
through other sources
(n = 10193)

Search results combined
(n = 12188 )

Journal titles screened
(n = 12188)

Journal titles excluded
(n = 12018 )

Abstracts of articles
assessed for eligibility
(n = 170 )

Abstracts of articles
excluded
(n = 101 )

Full- text articles assessed
for eligibility
(n = 69 )

Full- text articles excluded
(n = 36 )

Studies included in meta analysis
(n = 33 )

Studies examining GDM
and pregnancy outcomes
(n = 17 )

Studies examining
GDM /PGDM and
pregnancy outcomes
(n = 15 )

Studies examining P GDM
and pregnancy outcomes
(n = 1 )

Figure 1. Flow chart of article elimination for journal articles in meta-analysis.
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I maintained a record of excluded studies along with the reason for exclusion.
Table 3 shows brief information about each article and the reasons for exclusion of that
article. The most common reason of exclusion of articles (18 or 50%) was that they did
not have a control or comparison group. Other reasons were that the articles discussed the
prevalence and/or incidence of PGDM/GDM and their risk factors, or the specific
outcomes of interest were not measured or were excluded from the study. For some
excluded articles, abstract was available in English while the full text was only available
in Persian language.
Table 3
Thirty Six Studies of GDM/PGDM Outcome Excluded from Meta-Analysis
Study
Akhlaghi &
Hamedi,
2005

Data of interest
Studied maternal and fetal
outcomes in 73 women with GDM
and 27 women with PGDM.

Al Busaidi,
Al-Farsi,
Ganguly, &
Gowri, 2012
Al Mahroos,
Nagalla,
Yousif, &
Sanad, 2005
Al Najashi &
Al Umran,
1997

Caesarean section as an obstetric
outcome, was studied ; one of the
risk factors for caesarean section
was PGDM.
Studied birth weight of children and
macrosomia born to women with
GDM.

Al-Dabbous,
Owa,
Nasserallah,
& al-Qurash,
1996
Al-Hakeem,
2006
Almarzouki,

466 women with GDM/PGDM
were studied; fetal outcome
(congenital anomalies among
infants of diabetic mothers) was
studied.
Studied perinatal mortality in 133
women with GDM and PGDM.

685 women with GDM were
studied; maternal outcome
(caesarean section) and fetal
outcome (still birth) reported.
78 women with GDM were studied;

Reason excluded
Compared pregnancy outcome of women
with GDM with those of PGDM; did not
have a control/ comparison group of
women without GDM/PGDM
Case-control study with cases as women
delivered by caesarean section while
controls as women who did not deliver by
caesarean section.
Did not have a control/ comparison group
of women without GDM.
Did not study outcomes of interest
included in this dissertation.

Compared perinatal mortality in the study
population with perinatal mortality of the
hospital during the same duration of study,
however, the sample size for control group
(total number of deliveries in the hospital)
was not available.
Did not have a control/ comparison group
of women without GDM.
Did not have a control/ comparison group
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Study
2012

Al-Sultan,
Anan, &
Ahmed,
2004)
Ayaz, Saeed,
Farooq, Ali
Bahoo, &
Hanif, 2009
Beigi,
Yazdani, &
salehi, 2007
El-Gilany &
Hammad,
2010
Elnour &
McElnay,
2010

Data of interest
maternal outcome (caesarean
section) and fetal outcome
(macrosomia and perinatal
mortality) reported.
76 women with GDM were studied;
risk factors for GDM and reasons
for hospital admission were studied

Reason excluded
of women without GDM.

76 women with GDM were studied;
maternal and fetal outcomes
according to the gestational age at
the time of diagnosis studied.

Study population divided into three groups
according to the gestational age at the time
of diagnosis; these three groups were
compared in terms of pregnancy outcomes;
did not have a control/ comparison group
of women without GDM.
Full text article in Persian language.

70 women with GDM were studied;
maternal and fetal outcomes were
studied and compared with women
without GDM.
787 pregnant women (normal
weight, overweight and obese) were
studied; GDM and caesarean
section as outcomes of body mass
index (BMI) were stated.
165 women with GDM were
studied; caesarean section and
macrosomia was studied.

Garshasbi,
Faghihzadeh,
Naghizadeh,
& Ghavam,
2008
Hindi,
Gazzaz,
Barhamin,
Dhafar, &
Farooq, 2012
Hosseinnezhad et al.,
2011

1804 pregnant women were
screened for GDM; and 124 women
with GDM were studied.

Hussain,
Irshad,
Khattak, &
Khan, 2011
Jaber, 2006

42 women with GDM and PGDM
were studied; caesarean section,
macrosomia and perinatal mortality
rate were studied.
47 newborns of women with GDM
and PGDM were studied; caesarean
section rates and plasma leptin level
of the newborns were the outcome
of interest.

Did not study outcomes of interest
included in this dissertation

GDM and caesarean section in relation to
BMI were studied.

Effect of various values of diagnostic
criteria on pregnancy outcomes discussed;
did not have a control/ comparison group
of women without GDM.
Prevalence and risk factors of GDM were
studied; outcomes of interest in relation to
women with GDM and those without
GDM was not studied.

118 women with GDM and PGDM
were studied. Caesarean section
rate was studied.

Caesarean section rate among women with
GDM and PGDM was studied. Did not
have a control/comparison group of
women without GDM and PGDM.

293 women with GDM were
studied. Pregnancy-induced
hypertension was studied as
maternal outcome.

Comparison of incidence of hypertensive
disorders in pregnant women with GDM
and those without GDM. Did not study
outcomes of interest included in this
dissertation.
Did not have a control/comparison group
of women without GDM and PGDM.
Study population was newborns admitted
in nursery according to the diabetic status
of the mother. The study discussed
caesarean section rates in this group but
the enrollment is of children admitted in
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Data of interest

Kadiki,
Reddy,
Sahli,
Shawar, &
Rao, 1993
Kamali,
Shahnam,
Poormemari,
2003
Keshavarz &
Babaei, 2004

988 women with GDM and PGDM
were studied. Caesarean section
rates and perinatal mortality
discussed in relation to level of
control of diabetes.
13 women with GDM were studied.
Macrosomia and still birth were
studied.

Khan, 2012

Kheir,
Berair,
Gulfan,
Karrar, &
Mohammed,
2012
Marssussi &
Darban
Hosseini,
1999
Mazhar,
Saleh, &
Rennie, 2003

Meher-unnisa, Aslam,
Ahmed,
Rajab, &
Kattea, 2009

Misra,
Rashid,
Grundsell, &
Sedagathian,
2001

Reason excluded
the neonatology ward.
Women with GDM and PGDM were
divided into two groups of well- controlled
diabetes and poorly controlled diabetes.
Did not have a control/comparison group
of women without GDM and PGDM.
Full text article in Persian language.

63 women with GDM were studied.
Caesarean section rates,
macrosomia and still birth were
studied.
229 newborns with birth weight >
3,500 grams born to women with
GDM/PGDM (72) and those
without GDM/PGDM (157) were
studied. Caesarean section rates and
perinatal mortality were studied.
50 newborns born to women with
GDM/PGDM were studied.
Caesarean section rates were
studied.

Full text article in Persian language.

56 women with GDM/PGDM were
studied. Macrosomia was studied.

Full text article in Persian language.

386 women were studied (17 with
type 1 diabetes; 86 with type 2
diabetes; and 116 with GDM).
Discussed caesarean section rate
and perinatal mortality rate in the
study population.
1000 pregnant women divided into
5 groups depending upon their BMI
(< 18.5, 18.5-24.9, 25-29.9, 30-39.9
&>40, classified as underweight,
normal weight, overweight, obese
& morbidly obese respectively),
were studied. Caesarean section
rates and macrosomia were studied.
129 women were studied (82 with
GDM and 47 with PGDM). The
article compared GDM and PGDM
outcomes including caesarean
section, macrosomia and perinatal
mortality

The article had no comparison group but
had given the background figures for
hospital, however, the denominator for
total number of deliveries in the hospital
was not available. Thus, the sample size
for control group was not available.
Effect of various values of BMI on
pregnancy outcomes discussed. Did not
have a control/ comparison group of
women without GDM/PGDM.

Caesarean section rates and perinatal
mortality in relation to macrosomia were
studied.

Did not have a control/ comparison group
of women without GDM and PGDM.

The article compared GDM and PGDM
outcomes. A table illustrated comparison
of all diabetic pregnancies with normal
pregnancies, however, the denominator for
total number of deliveries in the hospital
was not available. Thus, the sample size
for control group was not available.
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Study
Najafian &
Cheraghi,
2012

Data of interest
1800 newborns with macrosomia
were studied.

Narchi &
Kulaylat,
1997

1870 infants born to women with
GDM/PGDM were studied; Down's
syndrome was studied as fetal
outcome.
212 women with impaired glucose
tolerance test were studied.
macrosomia was studied.

Nasrat,
Augensen,
Abushal, &
Shalhoub,
1994
Nili &
Mahdaviani,
2004
Rajab &
Mehdi, 1998
Rajab, Issa,
Hasan,
Rajab, &
Jaradat, 2012
Randhawa,
Moin, &
Shoaib, 2003
Saleh et al.,
2008

Sobande,
Eskandar,
Eskander, &
Archibong,
2005
Yaseen et
al., 1999

Reason excluded
Macrosomic infants as cases and nonmacorosomic infants as controls, were
studied. Association of macrosomia with
diabetes mentioned but diabetes was
considered a risk factor for macrosomia.
Down's syndrome and its association with
diabetes was studied. Did not study
outcomes of interest included in this
dissertation.
Outcomes of pregnancy in patients with
impaired glucose tolerance test were
studied.

107 infants born to women with
GDM/PGDM were studied.
Macrosomia was studied.
725 pregnant women with raised
blood glucose level (>7.7 mmol/l)
were studied. Pregnancy outcomes
such as macrosomia was discussed .
4982 pregnant women with GDM
were studied.

Did not have a control/ comparison group
of women without GDM/PGDM.

50 women with GDM/PGDM were
studied; still births and neonatal
deaths discussed.
766 newborns with macrosomia
were studied.

Did not have a control/ comparison group
of women without GDM/PGDM.

155 women with GDM/PGDM
were studied. Pregnancy outcomes
such as caesarean section and
perinatal mortality rate was
compared between women with
Type 1, type 2 and GDM.
188 newborns of women with
GDM/PGDM were studied.
Macrosomia was studied.

Macrosomia was discussed in relation to
various categories of raised blood glucose
levels.
Incidence and risk factors of GDM were
studied; Did not study outcomes of interest
included in this dissertation.

Study population was newborns with
macrosomia. Newborns with macrosomia
were grouped according to being born to
women with GDM/PGDM or women
without GDM/PGDM.
Did not have a control/ comparison group
of women without GDM/PGDM.

Did not have a control/ comparison group
of women without GDM/PGDM;
determined the predictive factors of
morbidity in infants of women with
GDM/PGDM.
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Details of the Studies Included in the Meta-analysis
For maintaining details of studies included in the meta-analysis, the guidelines for
reporting meta- analysis of observational studies was followed (Stroup et al., 2000). A
summary table was created to record the main elements of each study such as relevant
bibliographic information, the studies’ design, type(s) of diabetes mellitus, age group/
mean age of women and outcome data. In addition, any other pertinent information about
the study was also included (Table4).
Description of Included Studies
Thirty three articles fulfilled the inclusion criteria and were included in the metaanalysis. Countries of origin of included journal articles were Egypt, Iran, Jordan,
Kuwait, Oman, Pakistan, Qatar, Saudi Arabia, Sudan, Tunisia, and United Arab Emirates.
A total of 17 studies included women with GDM while 15 included women with
GDM/PGDM and one study included women with PGDM only. Out of the 15 studies
including women with both GDM and PGDM, 8 studies discussed and analyzed the
outcomes in GDM and PGDM separately while 7 studies did not differentiate between
GDM and PGDM, and mentioned the participants as women with diabetes. A total of
118,652 pregnant women were included in these studies. The studies including women
with GDM had a total of 53,744 pregnant women while those including women with
GDM/PGDM included 62,320 pregnant women. There were 2,588 pregnant women in
the study including women with PGDM. A total of 27 studies examined the association
of GDM/PGDM with caesarean section while 26 studied macrosomia and 24 studies
observed perinatal deaths.
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Table 4 illustrates the information on authors and year of article publication,
country of study, duration of study; maternal characteristics (age and type of diabetes);
and selected maternal and fetal outcomes described in the study. All 33 studies included
in this meta-analysis were published in scholarly, peer-reviewed journals. Their
publication year ranged from 1988 to 2013. The attributes of the studies included in the
meta-analysis are described as follows:
Country of origin. Twelve (37%) studies were conducted in Saudi Arabia, five
(15%) in Iran, five (15%) in Pakistan, two (6%) in Kuwait, two (6%) in Qatar, two (6%)
in Sudan, one (3%) in Egypt, one (3%) in Jordan, one (3%) in Oman, one (3%) in
Tunisia, and one (3%) in UAE. Thus, out of a total of 22 countries in the EMR,11(50%)
countries are represented in this meta-analysis.
Duration of study. The duration of the studies ranged from a minimum of 3
months (Diejomaoh et al., 2009) to a maximum of 30 years (Badakhsh et al., 2012). In
two studies (Abolfazl et al., 2008; Al Teheawt & Farida, 1995) year in which study was
conducted was mentioned, however, the duration of the study was not mentioned. One of
the studies (Ezimokhai, Joseph, & Bradley-Watson, 2006) was conducted for two 18month periods, 5 years apart.
Research design. A total of 33 studies were included in this meta-analysis, of
which 14 (42.4%) case- control, 10 (30.3%) cross-sectional including retrospective
review of the hospital/ medical records and 9 (27.3%) cohort studies were included in the
meta-analysis. All studies were hospital-based. All studies except one (Fadwa, Shawqi,
Asma, Nabil, Adel, & Kamel, 2013) collected data from hospital records. Fadwa et al.
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(2013) collected data from women with diabetes and those without diabetes through
structured questionnaires.
Study participants. There were a total of thirty three studies, and 118,652
participants were included in this meta-analysis. Minimum number of participants in any
single study was 138 (Abdelgadir et al., 2003) while the maximum number was 37,997
women (Badakhsh et al., 2012). A total of 28 studies mentioned the sample size for GDM
patients. Total number of women with GDM in these studies was 6,192 with a minimum
number of women with GDM as 19 (Abdelgadir et al., 2003) while the maximum number
of women with GDM was 972 women (El Mallah, Narchi, Kulaylat, & Shaban, 1997). A
total of 11 studies stated the sample size for PGDM patients. Total number of women
with PGDM in these studies was 929, with a minimum number of women with PGDM as
18 (Jawad & Irshaduddin, 1996) while 161 women was the maximum number of women
with PGDM (Johnstone, Nasrat, & Prescott, 1990). Four studies did not differentiate
between GDM and PGDM and labeled the study participants as women with diabetes and
those without diabetes. These studies included 1,026 women in the study by Al-Mejhim
& Al-Najashi, 1998; while Fadwa et al. (2013) included 750 women with diabetes;
Denguezli et al., (2007) studied 200 women; and Nasrat et al. (1993) had a total of 193
women with diabetes in their study.
Majority of the studies had mentioned the mean age of study participants. The
mean age of women without GDM/PGDM ranged from 25.2 ± 5.1 to 33.2 ± 6.8 years.
The mean age of women with GDM ranged from 29.3 ± 5.7 to 33.5 ± 5.7 years. Two
studies stated the age of women with PGDM. Wahabi et al. (2012) stated the mean age of

120
women with PGDM as 34.95 ± 5.66 years, while Abdelgadir et al. (2003) mentioned the
mean age of women with Type I diabetes as 28.8 ±5.8; while those with Type II diabetes
as 34.4 ±4.0 years. Fadwa et al. (2013) did not differentiate between PGDM and GDM
and mentioned the mean age of women with diabetes as 34.7 ± 4.67 years in comparison
to those without diabetes as 32.9 ± 5.26 years.
Table 4
Characteristics of Observational Studies of Pregestational/Gestational Diabetes and
Adverse Pregnancy Outcomes in Eastern Mediterranean Region Included in MetaAnalysis
Author

Count
ry

Study
Design

Time
Period

Sample
size(n)

Type of
Maternal
Diabetes

Outcome
Maternal

Fetal

Abdelgadir
, Elbagir,
Eltom,
Eltom, &
Berne,
2003

Suda
n

Casecontrol
study

Duration
2 years;
year of
study not
mentione
d

Macrosomia
(Large for
gestational
age)
Perinatal
mortality
(Intrauterine
fetal death
and neonatal
death)

Iran

Cohort
study

2006

Gestation
al
Diabetes
Mellitus
(GDM )
and
Pregestat
ional
Diabetes
Mellitus
(PGDM)
GDM

C-section

Abolfazl,
Hamidreza
, Narges,
&
Maryam,
2008
AlKhalifah,
AlFaleh,
AlSubaihin,
Al-Kharfi,
& AlAlaiyan,
2012

138 women;
88 with
diabetes (19
with GDM;
38 with type
1 diabetes;
and 31 with
type 2
diabetes);
50 without
diabetes
420 women;
70 with
diabetes and
350 without
diabetes

C-section

Macrosomia
Perinatal
mortality
(Still births)

Saudi
Arabi
a

Casecontrol
Study

January
2007Decembe
r 2007

766 women;
419 GDM
and 347
without
GDM

GDM

C-section

Macrosomia
(Large for
gestational
age)

121
Author

Count
ry

Study
Design

Time
Period

Sample
size(n)

Type of
Maternal
Diabetes

Outcome
Maternal
C-section

Fetal
Macrosomia
Large for
gestational
age
Perinatal
mortality
Perinatal
mortality

GDM &
Impaired
Glucose
Toleranc
e Test

C-section

Macrosomia

GDM
and
PGDM

C-section

Macrosomia
Perinatal
mortality

Almarzouk
i, 2013

Saudi
Arabi
a

Casecontrol
Study

June 01,
2008 Novemb
er 30,
2008

GDM = 69;
High risk
without
GDM = 80

GDM

Al-Mejhim
& AlNajashi,
1998

Saudi
Arabi
a

Crosssectional
Study

January
1987 Decembe
r 1996

GDM
and
PGDM

Al-Shawaf,
Moghraby,
& Akiel,
1988

Saudi
Arabi
a

Crosssectional
Study

June
1984 Decembe
r 1986

Al
Teheawt &
Farida,
1995

Egypt

Case Control
Study

1992

Badakhsh
et al., 2012

Iran

Cohort
study

GDM

C-section

Barakat,
Youssef, &
Al-Lawati,
2010

Oman

Case Control
Study

January
01, 1980
Decembe
r 31,
2009
January
1, 2004Decembe
r 31,
2004

28,507
women;
1026 with
GDM/PGD
M
218 women;
177 with
impaired
glucose
tolerance; 41
with GDM
406 women;
203 cases
(132 PGDM;
71 GDM);
and 203
controls
37,997
women; 312
with GDM

5394
women;
225 with
GDM; 56
with PGDM

GDM
and
PGDM

C-section

Bener et
al., 2013

Qatar

Crosssectional
Study

1432
women; 227
with GDM

GDM

C-section

Bener,
Saleh, &
Al-Hamaq,
2011

Qatar

Cohort
study

1608
women;
262 with
GDM and
1346
without
GDM

GDM

C-section

January
2010April
2011
January
2010 April
2011

Macrosomia
(High birth
weight)
Perinatal
mortality
(Still birth)

Macrosomia
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Author

Count
ry

Study
Design

Time
Period

Dafallah &
Yousif,
2004

Suda
n

Case Control
Study

January
1998 Decembe
r 2001

Denguezli
et al., 2007

Tunis
ia

CaseControl
Study

Diejomaoh
et al., 2009

Kuwa
it

Case Control
Study

January
01, 1999
Decembe
r 31,
2003
April
2005 –
June
2005

El Mallah,
Narchi,
Kulaylat,
& Shaban,
1997
Ezimokhai,
Joseph, &
BradleyWatson,
2006

Saudi
Arabi
a

Crosssectional
Study

January
1991 April
1994

Unite
d
Arab
Emira
tes

Crosssectional
Study

Two 18month
periods;
5 years
apart
(June
1996 Decembe
r 1997
and June
2001 Decembe
r 2002)

Sample
size(n)

Type of
Maternal
Diabetes

Outcome
Maternal

Fetal
Perinatal
mortality
(Still birth,
Early
Neonatal
deaths)

1280
women;
660 cases
(130 PGDM;
230 GDM;
330
impaired
glucose
tolerance
test);
620 controls
400 women;
200 with
diabetes and
200 without
diabetes

GDM
and
PGDM

GDM
and
PGDM

C-section

Macrosomia

177 with
DM (128
with GDM;
49 PGDM)
and 177
controls
972 women
with GDM;
71 women
PGDM

GDM
and
PGDM

C-section

Macrosomia
Perinatal
mortality
(Intrauterine
fetal death)

GDM
and
PGDM

C-section

Macrosomia
Perinatal
mortality
(Still births)

11738
women; 905
with
diabetes
(802 with
GDM; 103
PGDM)

PGDM
and
GDM

C-section

Macrosomia
Perinatal
mortality
(Intrauterine
fetal death)
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Author

Count
ry

Study
Design

Time
Period

Sample
size(n)

Type of
Maternal
Diabetes

Outcome
Maternal
C-section

Fetal
Macrosomia
Perinatal
mortality
(Intrauterine
fetal death;
Still birth;
Neonatal
Death)
Macrosomia
Perinatal
mortality

Fadwa,
Shawqi,
Asma,
Nabil,
Adel, &
Kamel,
2013

Jorda
n

Crosssectional
Study

Septemb
er 2007 January
2008

1500
women; 750
with
diabetes

PGDM
and
GDM

Gasim,
2012

Saudi
Arabi
a

Case Control
Study

January
2001 Decembe
r 2008

GDM

C-section

HosseinNezhad,
Maghbooli
, Vassigh,
& Larijani,
2007
Jawad &
Irshaduddi
n, 1996

Iran

Cross
sectional
study

2 years:
study
years not
mentione
d

440 women;
220 with
GDM and
220 without
GDM
2,416
women; 114
with GDM

GDM

C-section

Pakist
an

Cross
sectional
study

Perinatal
mortality

Kuwa
it

Case control
study

5559
women;
192 with
GDM
731 cases
and 731
controls

GDM

Johnstone,
Nasrat, &
Prescott,
1990

January 1
990 Decembe
r 1992
1984 1986

GDM
and
PGDM

Keshavarz
et al.,
2005

Iran

Cohort
Study

Decembe
r 1999 January
2001

GDM

C-section

Khan, Ali,
& Khan,
2013

Pakist
an

Cohort
Study

February
2012 to
Decembe
r 2012

1310
women;
63 with
GDM and
1247
without
GDM
200 women;
103 with
GDM and 97
without
GDM

Macrosomia
Perinatal
mortality
(Still birth,
early
neonatal
death,
perinatal
death and
intrauterine
fetal death)
Macrosomia
Perinatal
mortality
(Still birth)

GDM

C-section

Macrosomia
Perinatal
mortality
(Still births)

Macrosomia
Perinatal
mortality
(Still birth)
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Author

Count
ry

Study
Design

Time
Period

Khan,
Hashmi, &
Rizvi,
1995

Pakist
an

Casecontrol
study

June
1988June
1992

Khoshniat
nikoo et
al., 2010

Iran

Cohort
study

July
2004 Septemb
er 2005

Nasrat,
Abalkhail,
Fageeh,
Shabat, &
el Zahrany,
1997

Saudi
Arabi
a

Crosssectional
study

January
1991 Decembe
r 1992

Nasrat,
Fageeh,
Abalkhail,
Yamani, &
Ardawi,
1996

Saudi
Arabi
a

Case control
study

January
1991 to
Decembe
r 1992

Sample
size(n)

1292
women; 292
women with
abnormal
GTT ;
177 with
GDM and
115 with
Impaired
Glucose
Tolerance
Test
1801
women;
412
abnormal
GCT/normal
OGTT;
67 with
Impaired
Glucose
Tolerance
Test; 133
with GDM
51 newborns
of women
with GDM;
501
newborns of
women
without
GDM
510 women;
173 with
GDM; 337
without
diabetes

Type of
Maternal
Diabetes
GDM

Outcome
Maternal
C-section

Fetal
Macrosomia

GDM

Macrosomia

GDM
and
PGDM

Macrosomia

GDM

C-section

Macrosomia
(fetal weight
> the 90th
centile of
weight for
gestational
age)
Perinatal
mortality
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Author

Count
ry

Study
Design

Time
Period

Nasrat,
Salleh,
Ardawi, &
Ghafouri,
1993

Saudi
Arabi
a

Case control
study

Rizvi,
Rasul,
Malik,
Rehamatua
llh, &
Khan,
1992

Pakist
an

Case control
study

January
01, 1988Decembe
r 31,1989

Sobande,
Al-Bar, &
Archibong,
2000

Saudi
Arabi
a

CaseControl
Study

January
1991Decembe
r 1992

Tahir,
Zafar, &
Thontia,
2011

Pakist
an

Crosssectional
study

August
2007 August
2009

Wahabi,
Esmaeil,
Fayed, AlShaikh, &
Alzeidan,
2012
Wahabi,
Esmaeil,
Fayed, &
Alzeidan,
2013

Saudi
Arabi
a

Cohort
Study

January
01, 2008Decembe
r 31,
2008

Saudi
Arabi
a

Cohort
Study

January
01, 2010Decembe
r 31,
2010

Sample
size(n)

Type of
Maternal
Diabetes

Outcome
Maternal
C-section

Fetal
Macrosomia
Perinatal
mortality
(neonatal
death)

GDM

C-section

Perinatal
mortality

GDM
and
PGDM

C-section

Perinatal
mortality
(Still birth,
Early
Neonatal
deaths)

GDM

C-section

Macrosomia
Perinatal
mortality
(Neonatal
deaths and
intrauterine
fetal death)

384
newborns;
191 of
women with
diabetes and
193 of
women
without
diabetes
2,230
women;
780 with
GDM and
424 with
impaired
glucose
tolerance
test
166 women;
83 with
diabetes (26
with PGDM
and 57 with
GDM);
83 without
diabetes
228 women;
111 without
diabetes;
42 with mild
gestational
hyperglycem
ia, 75 with
GDM
3,157
women; 116
women with
PGDM

GDM
and
PGDM

PGDM

C-section

Macrosomia
Perinatal
mortality
(intrauterine
fetal death)

3,041
women; 569

GDM

C-section

Macrosomia
Perinatal
mortality
(intrauterine
fetal death)

women
with GDM
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Data Abstraction
I reviewed each selected article that met the inclusion criteria and abstracted the
data by using data abstraction form (Appendix C). I extracted information about the
general study characteristics (study design, study period, country of study, and year of
publication), study participants (number of study participants, maternal age, type of
diabetes); the diagnostic criteria for GDM; and designated maternal and fetal outcomes.
The study characteristics of included studies were entered and analyzed in Epi Info
version 3.5.4.
The relative risks (RRs) and odds ratios (ORs) for the association with adverse
pregnancy outcomes were abstracted, if stated. The unadjusted and adjusted RRs or ORs
and 95% confidence intervals (CIs) were extracted as reported by authors. If not stated,
then the RRs and ORs were calculated from information stated in each study. When raw
quantitative data was not reported, values were obtained from the provided information.
Dichotomous data reported as percentages were converted to counts and OR and RR
were calculated. For each study, I constructed separate two-by-two tables to compute the
ORs or RRs and 95% CIs of each outcome. Association of GDM/PGDM with caesarean
section was observed for maternal outcome while macrosomia and perinatal mortality
(intrauterine fetal deaths, stillbirths and neonatal deaths) were focused for fetal outcome.
All information from the article review process were entered and analyzed in the data
analysis software.
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Issues during Data Abstraction
Several special situations arose while data abstraction. For this meta-analysis,
subtypes of diabetes were classified as PGDM and GDM. However, various studies had
used different classifications for diabetes, such as “Type I diabetes,” or “insulindependent diabetes mellitus” “adult onset diabetes,” “type II diabetes,” or “noninsulindependent diabetes mellitus. All these categories were classified as PGDM for this metaanalysis. Some studies reported outcome data on women with type 2 DM and type 1 DM
(Abdelgadir et al., 2003; Wahabi et al., 2012). In these cases, I merged the data of women
with type 2 DM and type 1 DM and analyzed as PGDM. Some studies included women
with impaired glucose tolerance test as cases (Al-Shawaf et al., 1988; Dafallah & Yousif,
2004; Johnstone et al., 1990; Khoshniat nikoo et al., 2010; Rizvi, Rasul, Malik,
Rehamatuallh, & Khan, 1992), however, the analysis of these cases was presented
separately. So women with IGTT were not included in this meta-analysis. Tahir et al.
(2011) stated a category of mild hyperglycemia in 42 cases, but the data were analyzed
separately and were not included in this meta-analysis. However, in two studies
(Diejomaoh et al., 2009; Khan, Hashmi, & Rizvi, 1995) it was not possible to exclude the
data of women with IGTT as the data analysis was not presented separately for these
groups. In the study of Diejomaoh et al. (2009), among 177 cases with diabetes mellitus,
25 cases of IGTT were also included. Khan et al. (1995) had included 292 women with
abnormal GTT in their study; out of which 177 were with GDM while 115 were with
IGTT.
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Some issues were faced regarding study participants. Researchers in a casecontrol study (Almarzouki, 2013) had included women with GDM as cases while the
controls were high- risk women without GDM. Another special situation was noted in the
study by Nasrat, Abalkhail, Fageeh, Shabat, & El Zahrany (1997). The aim of this study
was to examine the clinical significance of subcutaneous deposition of fat in fetuses of
mothers with gestational diabetes, however, the study stated the proportion of
macrocosmic children in women with diabetes as well as those without diabetes in
pregnancy. The data were extracted from that information.
The method of diagnosis of GDM varied across the studies. Various studies used
different criteria for diagnosing GDM. Out of 32 studies including women with GDM, 6
(18.8%) had used WHO criteria; 4 (12.5%) had used Carpenter and Coustan criteria; 3
(9.4%) used O'sullivan's criteria; 2 (6.3%) used American Diabetes Association criteria; 2
6.3%) National Diabetes Data Group (NDDG) criteria; while one (3.1%) had used
O'sullivan and Mahan criteria. Nine studies had given details of the diagnosis of GDM
mentioning the cut-off points but did not name the criteria; while five studies did not state
details of diagnosis.
Discrepancies in Definition of Outcome
Out of the total 33 studies, 26 had included macrosomia as fetal outcome. Twenty
four studies stated definition of macrosomia. Various studies used different definitions of
macrosomia. Ten studies defined macrosomia as birth weight more than 4 kg while six
studies defined it as more than or equal to 4 kg. Two studies had defined macrosomia as
more than 4.5 kg (Barakat et al., 2010; Johnstone et al., 1990). Some studies had used the
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term of large for gestational age (Abdelgadir et al., 2003; Al-Khalifah et al., 2012;
Almarzouki, 2013). Most studies defined large for gestational age as birth weight more
than 90th percentile.
Out of the total of 33 studies, 24 studies discussed perinatal deaths. Twenty
studies included a description of perinatal deaths. Various studies used different
descriptions for perinatal deaths. Only one study (Almarzouki, 2013) defined perinatal
mortality as fetal or neonatal death from 22 weeks of pregnancy to 4 weeks after birth.
Al-Mejhim & Al-Najashi (1998) defined perinatal deaths as all stillbirths and all live
babies who weighed 500 g or more and died in the first week of life. Still
births/intrauterine fetal deaths and early neonatal deaths were described in 7 studies
(Abdelgadir et al., 2003; Dafallah & Yousif, 2004; Fadwa et al., 2013; Jawad &
Irshaduddin, 1996; Johnstone et al., 1990; Sobande et al., 2000; Tahir et al., 2011). Ten
studies (Abolfazl et al., 2008; Barakat et al., 2010; Diejomaoh et al., 2009; El Mallah et
al., 1997; Ezimokhai et al., 2006; Hossein-Nezhad et al., 2007; Keshavarz et al., 2005;
Khan, Ali, & Khan, 2013; Wahabi et al., 2012; Wahabi, Esmaeil, Fayed, & Alzeidan,
2013) had included only still births/intrauterine fetal deaths. Nasrat et al. (1993) had
included only neonatal deaths.
An important step in conducting meta-analysis is the assessment of quality of the
included studies. In this meta-analysis, quality of studies was assessed by various criteria,
outlined in Chapter 3. These criteria address issues related to the methods employed to
select the study population, the appropriateness of the sample size, the methods for
determining outcomes, and the appropriateness of the statistical analysis (Appendix E).
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Quality Assessment of the Studies
Quality assessment of individual studies was performed using criteria based on
various aspects of the study related to methods and results of the study. Quality scores
were not generated as assigning quality score is largely an arbitrary and subjective
process. Generally, quality scoring is based on reported information which may not be an
accurate measure of the truth about an element of quality. Moreover, the reliability and
validity of the quality rating scales have not been well evaluated (Taylor, 2005).
In this meta-analysis, the included studies were assessed for quality, however, no
study was rejected on the basis of quality criteria. Separate criteria were laid down for
case-control, cohort and cross- sectional study designs. Criteria such as adequate sample
size; description of diagnostic criteria; clear definition of outcomes; appropriate statistical
analyses; and power of the study were common for all study designs, and had similar
definitions as described below:
Description of Diagnostic Criteria
The description of diagnostic criteria was considered appropriate if the author had
provided the name of the method used for diagnosis of GDM such as WHO Criteria or
American Diabetes Association Criteria. The description was also considered appropriate
if the authors mentioned the procedure and cut-off values for diagnosing GDM even if
the name of the diagnostic criteria were not mentioned. However, if the details were not
provided clearly, then the description was considered “partially” appropriate. The
description was considered inappropriate if no description for diagnosing GDM were
provided.
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Clear Definition of Outcomes
Out of the three outcomes studied in this meta-analysis, macrosomia and perinatal
death were examined for a clear definition in the article. If one of these outcomes was
defined, then it was considered to meet the criteria "partially", and if both the outcomes
were clearly defined then this criterion was labeled as yes. If none of these outcomes was
defined in the article then the criterion was labeled as no.
Power of the Study
Power of the study to detect statistically significant association of adverse
outcomes among women with GDM/PGDM was calculated by using G-Power software.
The power of each study was calculated by using the sample size of the smallest group
for an outcome. If the sample size was similar in more than one outcome, then the group
having the smallest number of events was used to calculate the power of the study. The
criteria used in G-Power software, for calculation of power were as follows:
x

type of power analysis: 'Post hoc: compute achieved power - given alpha, sample
size and effect size;

x

test family: z-test;

x

statistical test: 'Proportions: Difference between two independent proportions'; and

x

alpha: 0.05.

Adequate Sample Size
If the power of the study was > 80%, then the sample size was labeled as
adequate; for 60-80% power, sample size was considered 'partially' adequate while for
power <60% the sample size was considered inadequate.
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Appropriate Statistical Analyses
If the authors used appropriate statistical tests such as logistic regression or x2 test
for comparing proportions and had also adjusted for confounding factors, then the
statistical analysis was considered appropriate. If statistical tests were appropriate, but no
adjustment for confounding factors was done, then the statistical analysis was considered
"partially" appropriate.
Above mentioned criteria were used for all study designs, however, some criteria
were specific to a single study design. These criteria are discussed in the following
section under discussion of quality assessment of studies according to their study designs.
Case-control studies. Quality criteria specific to case-control studies included
appropriate selection of cases and controls, and description of matching criteria. If the
eligibility criteria and the sources of cases and controls were stated properly, it was
considered 'appropriate' selection of cases and controls. For matched studies, describing
matching criteria and stating the number of controls per case was examined and noted
down. Table 5 displays the findings of quality assessment of case-control studies. Most of
the studies did not have an adequate sample size and the power to detect statistically
significant association was low. All studies had used appropriate statistical tests, but the
majority of them had reported crude odds ratio and had not adjusted odds ratio for the
confounding factors (Table 5).
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Table 5
Quality Assessment of Case-Control Studies Included in the Meta-analysis
Author

Abdelgadir
et al.,
2003
Al-Khalifah
et al., 2012
Almarzouki,
2013
Al Teheawt
& Farida,
1995
Barakat et
al., 2010
Dafallah &
Yousif,
2004
Denguezli
et al., 2007
Diejomaoh
et al., 2009
Gasim,
2012
Johnstone et
al., 1990
Nasrat et
al., 1996
Nasrat et
al., 1993
Rizvi et al.,
1992
Sobande et
al., 2000

Appropriate
selection of
cases

Appropriate
selection of
controls

Adequate
sample
size

Description
of
diagnostic
criteria
Yes

Clear
definition
of
outcomes
Yes

Address
potential
sources
of bias
Yes

Appropriate
statistical
analyses

No

Matching
of cases
and
controls
Yes

Yes

Yes

Yes

Partially

(%)
39.30

Yes

No

No

Yes

Yes

Partially

Partially

28.02

Yes

Partially

No

No

Yes

Yes

No

Partially

5.00

Yes

Yes

No

No

No

Partially

Yes

Partially

28.15

Yes

Yes

No

Yes

Yes

Yes

Yes

Yes

13.37

Yes

Yes

Yes

No

Yes

Yes

Yes

Partially

97.54

Yes

Yes

Yes

No

Yes

Yes

Partially

Yes

99.97

Yes

Yes

No

Yes

No

Yes

Yes

Partially

12.07

Yes

Yes

No

Yes

Yes

Partially

Yes

Yes

0.05

Yes

Yes

Yes

No

Yes

Yes

Yes

Partially

98.62

Yes

Yes

No

Yes

Yes

Partially

Yes

Yes

9.95

Yes

Yes

No

No

Yes

Yes

Yes

Partially

9.55

Yes

Yes

No

Yes

Yes

Partially

Yes

Partially

18.25

Yes

Yes

Partially

Yes

Yes

Yes

Yes

Partially

66.72

Cohort studies. Quality criteria specific to cohort studies included appropriate
selection of cohorts, description of methods of ascertaining outcomes and description of
lost to follow-up. Cohort selection was considered appropriate if the authors described
eligibility criteria, and the sources, methods of selection of participants. If matching
criteria and number of exposed and unexposed were stated, it was considered a properly
described cohort. Table 6 displays the findings of quality assessment of cohort studies
included in the meta-analysis. An important finding was regarding the description of lost

Power
of the
Study
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to follow-up. As most of the studies were retrospective cohort studies, description of lost
to follow up was not provided in most of them.
Table 6
Quality Assessment of Cohort Studies Included in the Meta-analysis
Author

Appro
priate
cohort
selecti
on

Adequ
ate
sample
size

Properly
describe
d cohort

Clear
descript
ion of
diagnos
tic
criteria

Clear
definition
of the
outcomes

Descriptio
n of lost to
follow up

Appropriate
ness of
statistical
analyses

Power
of the
Study
(%)

Partially

Descriptio
n of the
methods
for
ascertaini
ng
outcomes
Yes

Abolfazl et
al., 2008
Badakhsh et
al., 2012
Bener et al.,
2011
Keshavarz
et al.,
2005
Khan et al.,
2013
Khan et al.,
1995
Khoshniat
nikoo et al.,
2010
Wahabi et
al., 2012

Yes

Partiall
y
Yes

Yes

No

No

Partially

78.26

Yes

Yes

Yes

Yes

No

Yes

100.00

Yes

Partiall
y
Yes

Yes

Yes

Yes

Yes

No

Yes

63.98

Yes

Yes

Yes

Yes

No

Yes

88.62

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Partially

81.29

Yes

Yes

Yes

Yes

Yes

No

Partially

64.31

Yes

Partiall
y
Yes

Yes

Yes

Yes

Yes

No

Partially

99.99

Yes

No

Yes

Not
Applicab
le

Yes

Yes

No

Yes

52.36

Wahabi et
al., 2013

Yes

No

Yes

Yes

Yes

Yes

No

Partially

5.00

Yes
Yes

Cross-sectional studies. Quality criteria specific to cross-sectional studies
included appropriate method of selection of participants, and appropriate sources of data
and methods of assessment for outcomes. If the authors described the eligibility criteria,
and the sources and methods of selection of participants, it was considered appropriate
methods of selection of participants. All of these studies were hospital-based and in all
studies except one (Fadwa et al., 2013) the source of data for outcomes were medical
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records, which are considered credible sources of information. Table 7 displays the
findings of quality assessment of cross-sectional studies included in the meta-analysis.
Table 7
Quality Assessment of Cross-sectional Studies Included in the Meta-analysis
Author

Adequ
ate
sampl
e size

Descriptio
n of
diagnostic
criteria

Clear
definitio
n of
outcome
s

Yes

Appropriat
e methods
of
selection
of
participant
s
Yes

Address
the
potential
sources of
bias

Appropriate
ness of
statistical
analyses

Power
of the
Study
(%)

Yes

Appropriat
e sources
of data and
methods of
assessment
for
outcomes
Yes

Al-Mejhim
& AlNajashi,
1998
Al-Shawaf
et al., 1988
Bener, A. et
al., 2013
El Mallah et
al., 1997
Ezimokhai
et al., 2006
Fadwa et
al., 2013
HosseinNezhad et
al., 2007
Jawad &
Irshaduddin,
1996)
Nasrat et al.,
1997
Tahir et al.,
2011

No

No

Partially

100.00

Yes

Yes

Yes

Yes

Yes

No

Partially

95.10

No

Yes

No

Yes

Yes

Yes

Partially

54.30

No

Yes

Yes

Yes

Yes

Yes

Partially

44.92

Partial
ly
Yes

Yes

Yes

Partially

Yes

Yes

Partially

73.63

Yes

No

Yes

Partially

Yes

Yes

100.00

Yes

Yes

Yes

Yes

Yes

No

Yes

100.00

Yes

Yes

Yes

Yes

Yes

No

Partially

85.82

No

Yes

Yes

Yes

Yes

No

Partially

43.32

No

Yes

Yes

Yes

Yes

Yes

Partially

26.30

To sum up, quality assessment of studies included in the meta-analysis revealed
important findings. In many studies, the cases (women with GDM/PGDM) and
comparison groups (women without GDM/PGDM) differed not only in the type of DM
but also in some associated characteristics, such as age of the women. Most of the studies
had not mentioned matching criteria of the two groups, however, all of these studies were
hospital-based, and in most cases the researchers had mentioned some criteria for
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selection. For example, woman without GDM/PGDM delivered next to the enrolled
woman with GDM/PGDM was included in the study for comparison. All outcomes of
interest were not defined in some studies (Ezimokhai et al., 2006; Abolfazl et al., 2008;
Al Teheawt & Farida, 1995; Gasim, 2012; Nasrat et al., 1996; Rizvi et al., 1992). Few
studies adjusted for the potential confounding factors in their analysis (Badakhsh et al.,
2012; Barakat et al., 2010; Bener et al., 2011; Denguezli et al., 2007; Fadwa et al., 2013;
Gasim, 2012; Hossein-Nezhad et al., 2007; Keshavarz et al., 2005; Nasrat et al., 1996;
Wahabi et al., 2012). In spite of the above mentioned issues with the quality of the
studies, none of the selected articles fulfilling inclusion/exclusion criteria was rejected
because of quality assessment. The next section presents the results of meta-analysis of
these studies.
Meta-Analysis Results
This meta-analysis investigated adverse maternal and fetal outcomes in women
with GDM/PGDM in comparison to women without GDM/PGDM. Caesarean section
was studied as the adverse maternal outcome, which was reported in 27 (81.8%) out of
the total 33 studies. Out of these 27 studies, 16 (59.3%) examined the association of
GDM with caesarean section, 10 (37.0%) examined the association of both GDM and
PGDM while one (3.7%) study examined the association of PGDM with caesarean
section. Adverse fetal outcomes studied in this meta-analysis included macrosomia and
perinatal death. Macrosomia was reported in 26 (78.8%) studies; out of which 14 (53.8%)
examined the association of GDM with macrosomia, 11 (42.3%) examined the
association of both GDM and PGDM with macrosomia while one (3.8%) study examined
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the association of PGDM with macrosomia. Perinatal death was reported in 24 (72.7%)
studies. Out of the total 24 studies, 13 (54.2%) studied the association of both GDM and
PGDM with perinatal death, 10 (41.7%) examined the association of GDM with perinatal
death while one (4.2%) study examined the association of PGDM with perinatal death.
Measures of association (odds ratios, or relative risks) and their 95% confidence
intervals (CIs) were abstracted or derived from published data. The maternal and fetal
outcomes were expressed as odds ratios and 95% confidence intervals were calculated for
individual study. Comprehensive Meta-Analysis software (CMA) [Version 2] was used
to calculate individual effect sizes for each study. I pooled outcomes from primary
studies calculating the odds ratio of an outcome occurring, and significance for combined
effect was tested with a z- test. Because of expected statistical heterogeneity within
primary studies, random-effects model was employed to combine the data, setting
statistical significance at a p value <0.05. The random effects model was selected a priori
as it allows for variation of the different effect sizes in each study (Borenstein et al.,
2009). It allows for the difference in the observed effect sizes due to both sampling error
and true variability in population parameters (Cooper & Hedges, 2009). Factors varying
from study to study included sample size, method of GDM diagnosis, definition of
outcome measures, study design, as well as the country of origin of study.
A test of heterogeneity, Cochran's Q test, was performed for each outcome. It was
conducted to assess the variance of the true effect sizes using the Q statistic, a measure of
weighted standard deviations. To express the percentage of total variation among studies
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attributable to heterogeneity, I used the I2 statistic, which explains the proportion of total
variation in study estimates due to heterogeneity.
Subgroup analysis involves calculating a summary estimate for subgroups of
studies (The Cochrane Collaboration, 2008). In this meta-analysis, the outcomes among
women with GDM and PGDM were analyzed as sub-groups.
Sensitivity analysis tests the robustness of the overall findings of the metaanalysis with respect to different assumptions or inclusion of certain studies. It is an
important tool for investigating heterogeneity (Taylor, 2005). I assessed the influence of
individual studies by estimating the summary estimate of effect in the absence of each
study.
Moderator analysis examines heterogeneity by observing the influence of various
differences in studies such as study design and year of publication (Huedo-Medina et al.,
2006). Heterogeneity was examined by classifying studies according to potential sources
of variation and analyzing these subgroups of studies. Three moderators were analyzed to
determine their influence on the pooled odds ratio. These moderators included
publication period, study design and country of origin of the study. Regarding publication
period, the studies were divided into two groups; those published before the year 2000
and those published in the year 2000 and after.
Various methods were used to assess the publication bias for association between
GDM/PGDM and adverse outcomes, including funnel plot, Duval and Tweedie trim and
fill procedure, Egger's regression test, fail safe N, and Orwin's fail safe N tests
(Borenstein, 2005). Association of each of the maternal and fetal outcome among women
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with GDM/PGDM in comparison to women without GDM/PGDM is discussed in the
next sections.
Association Between GDM/PGDM and Delivery by Cesarean Section Among
Women in the Eastern Mediterranean Region
The analysis for examining the association of caesarean section and GDM/PGDM
included 27 studies with a total of 7,102 women with GDM/PGDM. Out of these, 5,341
had GDM, 620 had PGDM while 1,141 women were labeled as diabetics having either
GDM or PGDM. The study was used as the unit of analysis for overall pooling of data for
the groups GDM, PGDM and those labeled as diabetics. Thus, the data analysis software
was used to calculate a pooled estimate for association of caesarean section in each of
those studies where the researchers had reported separate odds ratios for women with
GDM and for women with PGDM. This overall pooling of the data showed that odds of
undergoing caesarean section in women with GDM/PGDM were 2.56 times more than
those without GDM/PGDM (OR = 2.56, 95% CI [2.13 - 3.07], p < 0.0001; Figure 2). The
Q statistic was statistically significant (Q = 150.78, df = 26, p < 0.0001, I2 = 82.76%),
and variance in effect sizes can be attributed to both sampling error and heterogeneity
among studies (Borenstein et al., 2009). Figure 2 shows effect sizes across 27 studies and
a corresponding forest plot visually depicting the effect sizes and weight of each of the
studies. The size of the squares on the plot indicate the weight assigned to the study based
on sample size, with a smaller square representing smaller weights and a larger square
representing larger weights. The central vertical line is at the null value (OR = 1.0).

140
Figure 2 displays that virtually all studies except one (Nasrat et al., 1996) reported
increased odds of caesarean section in women with GDM/PGDM as compared to those
without GDM/PGDM, although the associations were not always statistically significant.
However, 24 studies found a significantly increased rate of caesarean section among
women with GDM/PGDM compared with those without GDM/PGDM, with significant
odds ratios ranging from 1.44 (Bener et al., 2013) to 10.01 (Badakhsh et al., 2012).

Study name

Nasrat, 1996
Al-Khalifah, 2012
Bener, 2013
Wahabi, 2013
Al-Shawaf, 1988
Diejomaoh, 2009
Abolfazl, 2008
Khan, 2013
Gasim, 2012
Hossein-Nezhad, 2007
Fadwa, 2013
Tahir, 2011
Almarzouki, 2013
El Mallah, 1997
Khan, 1995
Ezimokhai, 2006
Denguezli, 2007
Abdelgadir, 2003
Al Teheawt, 1995
Rizvi, 1992
Bener, 2011
Barakat, 2010
Wahabi, 2012
Nasrat, 1993
Keshavarz, 2005
Sobande, 2000
Badakhsh, 2012
Overall

Statistics for each study
Odds
ratio

Lower
limit

Odds ratio and 95% CI

Upper
limit

p-Value

0.97
1.32
1.44
1.49
1.72
1.98
2.06
2.15
2.27
2.28
2.30
2.41
2.47
2.52
2.60
2.66
2.72
2.91
3.02
3.14

0.57
0.93
1.03
1.20
0.70
1.22
1.12
1.01
1.37
1.48
1.79
1.31
1.05
2.12
1.88
2.25
1.80
1.36
2.12
1.25

1.64
1.87
2.00
1.84
4.22
3.21
3.80
4.59
3.77
3.50
2.96
4.45
5.80
2.99
3.60
3.14
4.11
6.23
4.28
7.88

0.9094
0.1232
0.0328
0.0003
0.2341
0.0059
0.0203
0.0474
0.0016
0.0002
0.0000
0.0048
0.0377
0.0000
0.0000
0.0000
0.0000
0.0059
0.0000
0.0150

3.25
3.33
3.50
4.39
5.07
5.22
10.01
2.56

2.39
1.77
2.34
2.29
2.39
2.01
7.27
2.13

4.42
6.26
5.24
8.44
10.72
13.59
13.78
3.07

0.0000
0.0002
0.0000
0.0000
0.0000
0.0007
0.0000
0.0000
0.01

0.1

1

10

100
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Figure 2. Forest plot of the odds ratio (OR) of delivery by caesarean section among
women with GDM/PGDM in the Eastern Mediterranean Region. The odds ratio for
delivery by caesarean section is reported for each study (black square) along with its 95%
confidence interval (horizontal lines). The size of the square is proportional to the
statistical weight of the study based on random effects model. Summary line represents
the overall pooled estimate and its 95% CI. The diamond represents the summary odds
ratios obtained from random effects pooled analysis with 95% confidence interval
demonstrated by its width.
Subgroup Analysis
The pooled odds ratio for women with GDM and the outcome of caesarean
section showed that in women with GDM, the odds of being delivered by caesarean
section were 2.39 times in comparison to those without GDM (OR = 2.39, 95% CI [1.843.1], p < 0.0001; Figure 3). Out of 20 studies analyzing the association of GDM with
caesarean section, four studies (Nasrat et al., 1996; Al-Khalifah et al., 2012; Al-Shawaf et
al., 1988; Abdelgadir et al., 2003) had statistically non-significant association. Nasrat et
al. (1996) reported the lowest odds ratio of 0.97 (95% CI, 0.57 - 1.64, p = 0.91) while
Badakhsh et al. (2012) reported the highest odds ratio of 10.01 (95% CI, 7.27 - 13.78, p <
0.0001). As random effects model was used, the relative weight of the studies was
balanced. The lowest relative weight for a single study was 2.44% (Abdelgadir et al.,
2003) while the highest relative weight was 6.42% (El Mallah et al., 1997). The Q
statistic was statistically significant (Q = 137.05, df = 19, p < 0.0001, I2 = 86.14%) and
variance in effect sizes can be attributed to both sampling error and heterogeneity among
studies (Borenstein et al., 2009).
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Study name

Nasrat, 1996

Statistics for each study

Odds ratio and 95% CI

Odds
ratio

Lower
limit

Upper
limit

p-Value

0.97

0.57

1.64

0.9094

Al-Khalifah, 2012

1.32

0.93

1.87

0.1232

Bener, 2013

1.44

1.03

2.00

0.0328

Wahabi, 2013

1.49

1.20

1.84

0.0003

Al-Shawaf, 1988

1.72

0.70

4.22

0.2341

Abolfazl, 2008

2.06

1.12

3.80

0.0203

Khan, 2013

2.15

1.01

4.59

0.0474

Gasim, 2012

2.27

1.37

3.77

0.0016

Hossein-Nezhad, 2007

2.28

1.48

3.50

0.0002

Tahir, 2011

2.41

1.31

4.45

0.0048

Almarzouki, 2013

2.47

1.05

5.80

0.0377

El Mallah, 1997

2.52

2.09

3.03

0.0000

Khan, 1995

2.60

1.88

3.60

0.0000

Abdelgadir, 2003

2.62

0.69

9.91

0.1561

Barakat, 2010

2.70

1.17

6.23

0.0199

Al Teheawt, 1995

2.72

1.56

4.75

0.0004

Rizvi, 1992

3.14

1.25

7.88

0.0150

Bener, 2011

3.25

2.39

4.42

0.0000

Keshavarz, 2005

5.07

2.39

10.72

0.0000

Badakhsh, 2012

10.01

7.27

13.78

0.0000

2.39

1.84

3.10

0.0000

Overall

0.01

0.1

1

10

100

Figure 3. Forest plot of the odds ratio of delivery by caesarean section among women
with GDM in the Eastern Mediterranean Region. The odds ratio for delivery by caesarean
section is reported for each study (black square) along with its 95% confidence interval
(horizontal lines). The size of the square is proportional to the statistical weight of the
study based on random effects model. Summary line represents the overall pooled
estimate and its 95% CI. The diamond represents the summary odds ratios obtained from
random effects pooled analysis with 95% confidence interval demonstrated by its width.

Five studies reported association of PGDM with delivery by caesarean section.
The pooled estimate for women with PGDM and the outcome of caesarean section was
3.24 (95% CI, 2.51 - 4.17, p < 0.0001; Figure 4). All studies had statistically significant
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association. El Mallah et al. (1997) reported the lowest odds ratio of 2.51 (95% CI, 1.344.69, p = 0.004) while Barakat et al. (2010) reported the highest odds ratio of 4.39 (95%
CI, 1.68-11.48, p = 0.003). The lowest relative weight for a single study was 6.45%
(Abdelgadir et al., 2003) while the highest relative weight was 39.62% (Wahabi et al.,
2012). The Q statistic was not significant statistically (Q = 1.197, df = 4, p = 0.879, I2 =
0.0%) and variance in effect sizes can be attributed to sampling error only (Borenstein et
al., 2009).

Figure 4. Forest plot of the odds ratio of delivery by caesarean section among women
with PGDM in the Eastern Mediterranean Region. The odds ratio for delivery by
caesarean section is reported for each study (black square) along with its 95% confidence
interval (horizontal lines). The size of the square is proportional to the statistical weight
of the study based on random effects model. Summary line represents the overall pooled
estimate and its 95% CI. The diamond represents the summary odds ratios obtained from
random effects pooled analysis with 95% confidence interval demonstrated by its width.
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Sensitivity Analyses
I performed a sensitivity analysis investigating whether the results are influenced
by the effect of certain specific studies. Sensitivity analyses indicated that none of the
studies seemed to contribute more to the analysis. I assessed the relative influence of each
study by omitting one study at a time from the pooled analysis. Excluding individual
studies did not substantially affect the estimates. The pooled odds ratio for association
between GDM/PGDM and delivery by caesarean sections after leaving out one study at a
time ranged from 2.37 to 2.65 which is close to the pooled estimate of 2.56. Sensitivity
analyses, excluding the study with the highest odds ratio (Badakhsh et al., 2012),
produced results [OR = 2.38, 95% CI (2.08-2.72)] similar to the pooled odds ratio
estimated for all included studies.
Moderator Analysis
Three moderators were analyzed to determine their influence on the pooled odds
ratio for caesarean section. These moderators included; publication period, study design
and country of origin of the study.
Regarding publication period, the studies were divided into two groups; those
published before the year 2000 and those published in the year 2000 and after. By
random effects analysis, the pooled odds ratio for the studies published before the year
2000 was 2.4 (95% CI, 1.64-3.52, p < 0.0001), while those published in the year 2000
and after had a pooled odds ratio of 2.62 (95% CI, 2.1-3.27, p < 0.0001). Although the
studies published in the 2000s showed a higher pooled odds ratio, the difference was not
statistically significant (p = 0.702).
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To assess the relationship between study design and odds ratio, I analyzed
differences in effect sizes between three subgroups representing cross-sectional, casecontrol and cohort study designs. The pooled odds ratio for cross-sectional studies was
2.18 (95% CI, 1.53-3.12, p < 0.0001), for case control studies 2.44 (95% CI, 1.8-3.29, p
< 0.0001) and for the cohort studies 3.17 (95% CI, 2.25-4.46, p < 0.0001). Although
pooled odds ratio varied between three study design, the differences were not statistically
significant (p = 0.308).
The studies were assessed for differences in effect sizes according to the country
of origin of study. A total of 11 countries were represented in this meta-analysis.
Although pooled odds ratio varied among countries between the lowest of 1.98 (95% CI,
0.69-5.62, p < 0.0001) from Kuwait to the highest of 4.05 (95% CI, 2.38-6.9, p = 0.201)
from Iran, the differences among countries were not statistically significant (p = 0.917).
Publication Bias
Various methods were used to assess the publication bias for association between
GDM/PGDM and delivery by caesarean section, including funnel plot, Duval and
Tweedie trim and fill procedure, Egger's regression test, fail safe N, and Orwin's fail-safe
N tests were applied. A funnel plot was generated to evaluate the potential for publication
bias. On visual inspection, the funnel plot (Figure 5) depicts a mostly symmetrical
diagram of studies about the effect size, resembling a funnel shape. This depiction
implies an absence of publication bias (Borenstein et al., 2009). In case of publication
bias, the bottom of the plot would display a greater concentration of studies on one side
of the mean as compared to the other. A tendency of the studies to congregate towards
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the bottom of the plot reflects the fact that the chances of publication of smaller studies
are higher if they have greater than average effects, and hence a greater likelihood of
yielding statistical significance. The Duval and Tweedie trim and fill procedure showed
no indication of publication bias (Duvall and Tweedie adjusted OR = 2.48, 95% CI, 2.322.66, number of imputed studies = 0). Egger's regression test also showed no indication
of publication bias (Egger test intercept = 0.42; SE = 0.99; p = .67).
This meta-analysis incorporated data from 27 studies, which yield a z-value of
23.35 and corresponding 2-tailed p value of less than 0.0001. The fail-safe N is 3,807.
This means that we would be required to find and include 3,807 'null' studies for the
pooled 2-tailed p value to exceed 0.05. Thus, 141.0 missing studies would be required for
every observed study for the effect to be nullified. The Orwin's fail safe N is the number
of missing studies that, when added to the analysis, will bring the pooled odds ratio
below a specified threshold (Borenstein, 2005). On specifying threshold of OR equal to
1.2, the Orwin's fail-safe N is 108. This means that we would be required to find 108
studies with mean odds ratio of 1 to bring the combined odds ratio under 1.2. To sum up,
all tests applied for the assessment of publication bias did not provide evidence of
publication bias.
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Funnel Plot of Standard Error by Log odds ratio
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Figure 5. Funnel plot of studies included in meta-analysis on association of delivery by
Caesarean section and GDM/PGDM among women in Eastern Mediterranean Region.
The diagonal lines represent the 95% confidence interval (CI) around the overall effect
estimate, which is indicated by the vertical line. The effect of each study is marked by a
circle. Observed and adjusted pooled estimates are calculated using Duval and Tweedie's
trim and fill method. The observed pooled estimate is shown in an open diamond, while
pooled estimate adjusted for publication bias is shown in filled diamond. The summary of
estimates obtained before (open diamond) and after the adjustment (filled diamond)
indicates that there are no missing studies.

Association Between Macrosomia and GDM/PGDM Among Women in the Eastern
Mediterranean Region
The analysis for examining the association of macrosomia and GDM/PGDM
included 26 studies with a total of 7,000 women with GDM/PGDM. Out of these, 5,104
had GDM, 755 had PGDM while 1,141 women were labeled as diabetics having either
GDM or PGDM. The study was used as the unit of analysis for overall pooling of data for
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the groups GDM, PGDM and those labeled as diabetics. Thus, the data analysis software
was used to calculate a pooled estimate for association of macrosomia in each of those
studies where the researchers had reported separate odds ratios for women with GDM
and for women with PGDM. Overall pooling of all data for macrosomia showed the odds
of having a macrosomic baby in women with GDM/PGDM 3.5 times as compared to
those without GDM/PGDM. The pooled odds ratio for macrosomia and GDM/PGDM
among women was 3.51 (95% CI, 2.73-4.51, p < 0.0001; Figure 6). Six studies had
statistically non-significant association. Nasrat et al. (1993) reported the lowest odds ratio
of 1.72 (95% CI, 0.79- 3.75.69, p = 0.171) while Khoshniat nikoo et al. (2010) reported
the highest odds ratio of 16.96 (95% CI, 8.27-34.79, p < 0.0001). The Q statistic was
statistically significant (Q = 148.41, df = 25, p < 0.0001, I2 = 83.15%) and variance in
effect sizes can be attributed to both sampling error and heterogeneity among studies.
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Al-Khalifah, 2012
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Figure 6. Forest plot of the odds ratio of macrosomia among women with GDM/PGDM
in the Eastern Mediterranean Region. The odds ratio for macrosomia is reported for each
study (black square) along with its 95% confidence interval (horizontal lines). The size of
the square is proportional to the statistical weight of the study based on random effects
model. Summary line represents the overall pooled estimate and its 95% confidence
interval. The diamond represents the summary odds ratios obtained from random effects
pooled analysis with 95% confidence interval demonstrated by its width.
Subgroup Analysis
Analysis according to diabetes type showed that in women with GDM, the odds
of having a macrosomic baby is 3.8 times in comparison to those without diabetes. The
pooled odds ratio for women with GDM and the outcome of macrosomia was 3.83 (95%

150
CI, 2.83 - 5.18, p < 0.0001; Figure 7). Out of 19 studies analyzing the association of
GDM with macrosomia, four studies (Khan et al., 1995; Al-Khalifah et al., 2012; Tahir et
al., 2011; Abdelgadir et al., 2003) had statistically non-significant association. Wahabi et
al. (2013) reported the lowest odds ratio of 1.75 (95% CI, 1.14-2.71, p = 0.011) while
Khoshniat nikoo et al. (2010) reported the highest odds ratio of 16.96 (95% CI, 8.2734.79, p < 0.0001). As random effects model was used, the relative weight of the studies
was balanced. The lowest relative weight was 2.65% (Abdelgadir et al., 2003) while the
highest relative weight was 7.40% (El Mallah et al., 1997). The Q statistic was
statistically significant (Q = 80.51, df = 18, p < 0.000, I2 = 77.64%), and variance in
effect sizes can be attributed to both sampling error and heterogeneity among studies.
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Figure 7. Forest plot of the odds ratio of macrosomia among women with GDM in the
Eastern Mediterranean Region. The odds ratio for macrosomia is reported for each study
(black square) along with its 95% confidence interval (horizontal lines). The size of the
square is proportional to the statistical weight of the study based on random effects
model. Summary line represents the overall pooled estimate and its 95% confidence
interval. The diamond represents the summary odds ratios obtained from random effects
pooled analysis with 95% confidence interval demonstrated by its width.

Six studies reported association of PGDM with macrosomia. The pooled estimate
for women with PGDM and macrosomia was 3.51 (95% CI, 2.22-5.57, p < 0.0001)
(Figure 8). Two studies had statistically non-significant association (Abdelgadir et al.,
2003; Al Teheawt & Farida, 1995). Al Teheawt and Farida (1995) reported the lowest
odds ratio of 1.60 (95% CI, 0.72-3.56, p = 0.253) while Barakat et al. (2010) reported the
highest odds ratio of 7.20 (95% CI, 2.3-22.57, p < 0.0001). The lowest relative weight
was 10.34% (Abdelgadir et al., 2003) while the highest relative weight was 22.03% (El
Mallah et al., 1997). The Q statistic was not significant statistically (Q = 9.66, df = 5, p =
0.085, I2 = 48.262%) and variance in effect sizes can be attributed to the sampling error,
and heterogeneity among studies is low.
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Figure 8. Forest plot of the odds ratio of macrosomia among women with PGDM in the
Eastern Mediterranean Region. The odds ratio for macrosomia is reported for each study
(black square) along with its 95% confidence interval (horizontal lines). The size of the
square is proportional to the statistical weight of the study based on random effects
model. Summary line represents the overall pooled estimate and its 95% confidence
interval. The diamond represents the summary odds ratios obtained from random effects
pooled analysis with 95% confidence interval demonstrated by its width.

Sensitivity Analyses
I performed a sensitivity analysis investigating whether the results are influenced
by the effect of certain specific studies. Sensitivity analyses indicated that none of the
studies seemed to contribute more to the analysis. I assessed the relative influence of each
study by omitting one study at a time from the pooled analysis. Excluding individual
studies did not substantially affect the estimates. The pooled estimates after leaving out
one study at a time ranged from 3.27 (95% CI, 2.65-4.05, p < 0.0001) to 3.63 (95% CI,
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2.81- 4.69, p < 0.0001) which is close to the pooled estimate of 3.5 (95% CI, 2.73-4.51, p
< 0.0001). Sensitivity analyses, excluding the study with the highest odds ratio
(Khoshniat nikoo et al., 2010), produced results (OR = 3.18, 95% CI, 2.89-3.49) similar
to the pooled estimated of all included studies.
Moderator Analysis
Three moderators were analyzed to determine their influence on the pooled odds
ratio for macrosomia. These moderators included; publication period, study design and
country of origin of the study.
Regarding publication period, the studies were divided into two groups; those
published before the year 2000 and those published in the year 2000 and after. By
random effects analysis, the pooled odds ratio for the studies published before the year
2000 was 3.13 (95% CI, 1.95-5.00; p < 0.0001), while those published in the year 2000
and after had a pooled odds ratio of 3.71 (95% CI, 2.68-5.13; p < 0.0001). Although the
studies published in the 2000s showed a higher pooled odds ratio, the difference was not
statistically significant (p = 0.560).
To assess the relationship between study design and odds ratio for macrosomia, I
analyzed differences in effect sizes between three subgroups representing cross-sectional,
case-control and cohort study designs. The pooled odds ratio for cross-sectional studies
was 4.37 (95% CI, 2.65-7.21, p < 0.0001), for case- control studies 3.14 (95% CI, 2.084.74, p < 0.0001) and for the cohort studies 3.33 (95% CI, 2.06-5.37, p < 0.0001).
Although pooled odds ratio varied between three study design, the differences were not
statistically significant (p = 0.585).
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The studies examining macrosomia as an adverse fetal outcome were assessed for
differences in effect sizes according to the country of origin of study. A total of 11
countries were represented in this meta-analysis. The pooled odds ratio varied among
countries between the lowest of 1.82 (95% CI, 0.93-3.56, p = 0.082) from Qatar to the
highest of 14.56 (95% CI, 7.71-27.49, p < 0.0001) from Jordan. The differences among
countries was statistically significant (p < 0.0001).
Publication Bias
Various methods were used to assess the publication bias for association between
GDM/PGDM and macrosomia, including funnel plot, Duval and Tweedie trim and fill
procedure, Egger's regression test, fail safe N, and Orwin's fail safe N tests. A funnel plot
was generated to evaluate the potential for publication bias. On visual inspection, the
funnel plot (Figure 9) depicts a mostly symmetrical diagram of studies about the effect
size, resembling a funnel shape. This depiction implies an absence of publication bias.
The Duval and Tweedie trim and fill procedure showed no indication of publication bias
(Duvall and Tweedie adjusted OR = 3.24 [95% CI, 2.96-3.56]), number of imputed
studies = 0]). Egger's regression test also showed no indication of publication bias (Egger
test intercept = 0.85; SE = 0.96; p = 0.39).
The meta-analysis for macrosomia incorporated data from 26 studies, which yield
a z-value of 22.74 and corresponding 2-tailed p-value of less than 0.0001. The fail-safe N
is 3,474. This means that we would be required to find and include 3,474 "null" studies
in order for the pooled 2-tailed p-value to exceed 0.050. In other words, 133.6 missing
studies would be required for every observed study for the effect to be nullified. The
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Orwin fail-safe N is the number of missing studies that, when added to the analysis, will
bring the pooled odds ratio below a specified threshold (Borenstein, 2005). On specifying
threshold of OR equal to 1.2, the Orwin's fail-safe N is 142. This means that we would
need to locate 142 studies with mean odds ratio of 1 to bring the combined odds ratio
under 1.2.
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Figure 9. Funnel plot of studies included in meta-analysis on association of macrosomia
and GDM/PGDM among women in Eastern Mediterranean Region. The diagonal lines
represent the 95% confidence interval (CI) around the overall effect estimate, which is
indicated by the vertical line. The effect of each study is marked by a circle. Observed
and adjusted pooled estimates are calculated using Duval and Tweedie's trim and fill
method. The observed pooled estimate is shown in an open diamond, while pooled
estimate adjusted for publication bias is shown in filled diamond. The summary of
estimates obtained before (open diamond) and after the adjustment (filled diamond)
indicates that there are no missing studies.
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Association Between Perinatal Death and GDM/PGDM Among Women in the
Eastern Mediterranean Region
The analysis for examining the association of perinatal death and GDM/PGDM
included 24 studies with a total of 7,352 women with GDM/PGDM. Out of these, 4,456
had GDM, 929 had PGDM while 1,967 women were labeled as diabetics having either
GDM or PGDM. The study was used as the unit of analysis for overall pooling of data for
the groups GDM, PGDM and those labeled as diabetics. Thus, CMA software [Version
2] was used to calculate a pooled estimate for association of caesarean section in each of
those studies where the researchers had reported separate odds ratios for women with
GDM and for women with PGDM. This overall pooling of the data showed that odds of
perinatal death in women with GDM/PGDM was 2.46 times more than those without
GDM/PGDM (OR = 2.46, 95% CI [1.81-3.34], p < 0.0001; Figure 10). The Q statistic
was statistically significant (Q = 65.257, df = 23, p < 0.0001, I2 = 64.75%) and variance
in effect sizes can be attributed to both sampling error and heterogeneity among studies.
Figure 10 shows effect sizes across 24 studies and a corresponding forest plot visually
depicting the effect sizes and weight of each of the studies. The size of the squares on the
plot indicate the weight assigned to the study based on sample size, with a smaller square
representing smaller weights and a larger square representing larger weights. The central
vertical line is at the null value (OR = 1.0). Thirteen studies showed statistically nonsignificant association. Diejomaoh et al. (2009) reported the lowest odds ratio of 0.33
(95% CI, 0.03-3.2, p = 0.338) while Khan et al. (2013) reported the highest odds ratio of
19.60 (95% CI, 1.13-341.57, p = 0.041). As random effects model was used, the relative
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weight of the studies was balanced. The lowest relative weight was 0.83% (Nasrat et al.,
1993) while the highest relative weight was 8.66% (Al-Mejhim & Al-Najashi, 1998).

Study name
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Wahabi, 2012
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Dafallah, 2004
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Johnstone, 1990
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Khan, 2013
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Figure 10. Forest plot of the odds ratio of perinatal death among women with
GDM/PGDM in the Eastern Mediterranean Region. The odds ratio for perinatal death is
reported for each study (black square) along with its 95% confidence interval (horizontal
lines). The size of the square is proportional to the statistical weight of the study based on
random effects model. Summary line represents the overall pooled estimate and its 95%
confidence interval. The diamond represents the summary odds ratios obtained from
random effects pooled analysis with 95% confidence interval demonstrated by its width.

158
Subgroup Analysis
The pooled odds ratio for women with GDM and the outcome of perinatal death
was 2.23 [(95% CI (1.40-3.54), p = 0.0007] (Figure 11). Out of 18 studies analyzing the
association of GDM with perinatal death, 12 studies had statistically non-significant
association. Nasrat et al. (1996) reported the lowest odds ratio of 0.39 [95% CI (0.028.1), p = 0.540] while Khan et al. (2013) reported the highest odds ratio of 19.60 (95% CI
[1.125 - 341.568], p = 0.041). As random effects model was used, the relative weight of
the studies was balanced. The lowest relative weight for a single study was 1.73%
(Abdelgadir et al., 2003) while the highest relative weight was 9.47% (Johnstone et al.,
1990). The Q statistic was statistically significant (Q = 39.647, df = 17, p < 0.001, I2 =
57.12%) and variance in effect sizes can be attributed to both sampling error and
heterogeneity among studies.
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Figure 11. Forest plot of the odds ratio of perinatal death among women with GDM in
the Eastern Mediterranean Region. The odds ratio for perinatal death is reported for each
study (black square) along with its 95% confidence interval (horizontal lines). The size of
the square is proportional to the statistical weight of the study based on random effects
model. Summary line represents the overall pooled estimate and its 95% CI. The
diamond represents the summary odds ratios obtained from random effects pooled
analysis with 95% confidence interval demonstrated by its width.

Nine studies reported association of PGDM with perinatal death. The pooled odds
ratio for women with PGDM and perinatal death was 3.71 (95% CI [2.09-6.57], p <
0.0001; Figure 12). Four studies had statistically non-significant association. Barakat et
al. (2010) reported the lowest odds ratio of 0.75 (95% CI [0.09-6.37], p = 0.793) while
Sobande et al. (2000) reported the highest odds ratio of 10.70 (95% CI [1.06-107.75], p =
0.044). The lowest relative weight was 3.33% (Abdelgadir et al., 2003) while the highest
relative weight was 18.22% (Johnstone et al., 1990). The Q statistic was statistically
significant (Q = 18.294, df = 8, p = 0.019, I2 = 56.27%). Thus, the studies included in
this sub-group meta-analysis were shown to be heterogeneous, and variance in effect
sizes can be attributed to both sampling error and heterogeneity among studies.
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Figure 12. Forest plot of the odds ratio of perinatal death among women with PGDM in
the Eastern Mediterranean Region. The odds ratio for perinatal death is reported for each
study (black square) along with its 95% confidence interval (horizontal lines). The size of
the square is proportional to the statistical weight of the study based on random effects
model. Summary line represents the overall pooled estimate and its 95% CI. The
diamond represents the summary odds ratios obtained from random effects pooled
analysis with 95% confidence interval demonstrated by its width.

Sensitivity Analyses
I performed a sensitivity analysis investigating whether the results were
influenced by the effect of certain specific studies. Sensitivity analyses indicated that
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none of the studies seemed to contribute more to the analysis. I assessed the relative
influence of each study by omitting one study at a time from the pooled analysis.
Excluding individual studies examining perinatal deaths did not substantially affect the
estimates. The pooled estimates after leaving out one study at a time ranged from 2.46
(95% CI [1.86-3.24], p < 0.0001) to 2.74 (95% CI [2.08-3.61], p < 0.0001) which is close
to the pooled estimate of 2.59 (95% CI [1.95-3.43], p < 0.0001). Sensitivity analyses,
excluding the study with the highest odds ratio (Khan et al., 2013), produced results (OR
= 2.54, 95% CI [1.91-3.37]) similar to the pooled estimated of all included studies.
Moderator Analysis
Three moderators were analyzed to determine their influence on the pooled odds
ratio. These moderators included; publication period, study design and country of origin
of the study.
Regarding publication period, the studies were divided into two groups; those
published before the year 2000 and those published in the year 2000 and after. By
random effects analysis, the pooled odds ratio for the studies published before the year
2000 was 2.67 (95% CI [2.20-3.24], p < 0.0001), while those published in the year 2000
and after had a pooled odds ratio of 2.91 (95% CI [2.35-3.60], p < 0.0001). Although the
studies published in the 2000s showed a higher pooled odds ratio, the difference was not
statistically significant (p = 0.28).
To assess the relationship between study design and odds ratio, I analyzed
differences in effect sizes between three subgroups representing cross-sectional, casecontrol and cohort study designs. The pooled odds ratio for cross-sectional studies was
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3.03 (95% CI [2.53-3.63], p < 0.0001), for case- control studies 2.27 (95% CI [1.752.95], p < 0.0001) and for the cohort studies 2.97 (95% CI [1.69-5.21], p = 0.0001).
Although pooled odds ratio varied between three study design, the differences were not
statistically significant (p = 0.315).
The studies were assessed for differences in effect sizes according to the country
of origin of study. A total of 9 countries were represented in this meta-analysis. The
pooled odds ratio varied among countries with the lowest of 0.61( 95% CI [0.11-3.36], p
= 0.567) from Oman to the highest of 8.39 (95% CI [3.02-23.33], p < 0.0001) from Iran.
The difference among countries was statistically non-significant (p = 0.145).
Publication Bias
Various methods were used to assess the publication bias for association between
GDM/PGDM and perinatal death, including funnel plot, Duval and Tweedie trim and fill
procedure, Egger's regression test, fail safe N, and Orwin's fail safe N tests were applied.
A funnel plot was generated to evaluate the potential for publication bias. On
visual inspection, the funnel plot (Figure 13) depicts a mostly symmetrical diagram of
studies about the effect size, resembling a funnel shape. This depiction implies an
absence of publication bias (Borenstein et al., 2009). The Duval and Tweedie trim and fill
procedure showed no indication of publication bias (Duvall and Tweedie adjusted
OR = 2.78; 95% CI, 2.41-3.20; number of imputed studies = 0). Egger's regression test
also showed no indication of publication bias (Egger test intercept = -0.53; SE = 0.57; p =
0.36).
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This meta-analysis for perinatal deaths incorporated data from 24 studies, which
yielded a z-value of 10.17 and corresponding 2-tailed p value of less than 0.0001. The
fail safe N is 623. This means that we would be required to find and include 623 'null'
studies in order for the pooled 2-tailed p value to exceed 0.050. Put another way, 26.0
missing studies would be required for every observed study for the effect to be nullified.
The Orwin's fail safe N is the number of missing studies that, when added to the analysis,
will bring the pooled odds ratio below a specified threshold (Borenstein, 2005). On
specifying threshold of OR equal to 1.2, the Orwin's fail safe N is 111. This means that
we would need to locate 111 studies with mean odds ratio of 1 to bring the combined
odds ratio under 1.2.
Funnel Plot of Standard Error by Log odds ratio
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Figure 13. Funnel plot of studies included in meta-analysis on association of perinatal
death and GDM/PGDM among women in Eastern Mediterranean Region. The diagonal
lines represent the 95% confidence interval (CI) around the overall effect estimate, which
is indicated by the vertical line. The effect of each study is marked by a circle. Observed
and adjusted pooled estimates are calculated using Duval and Tweedie's trim and fill

164
method. The observed pooled estimate is shown in an open diamond, while pooled
estimate adjusted for publication bias is shown in filled diamond. The summary of
estimates obtained before (open diamond) and after the adjustment (filled diamond)
indicates that there are no missing studies.
Summary and Transition
This chapter contained a description of the meta-analysis results. It included a
summary of research questions and hypotheses, details of literature search and data
collection procedures, quality assessment of studies, data abstraction, attributes of the
studies included in the meta-analysis, and findings of the meta-analysis. The metaanalysis included sub-group analysis, sensitivity analysis, moderator analysis, and tests
for publication bias.
Scientific literature search strategies were utilized for synthesizing the results of
relevant primary studies. A comprehensive search strategy with explicit criteria for the
inclusion and exclusion of studies was used. The full text articles were selected on
meeting the designated criteria. The data was abstracted by using data abstraction form.
For reporting of meta- analysis, I followed the Meta-analysis of Observational Studies in
Epidemiology (MOOSE) guidelines (Stroup et al., 2000) and Preferred Reporting Items
for Systematic reviews and Meta-Analyses (PRISMA) guidelines (Moher et al., 2009).
The search strategy retrieved 12,188 records. On title review, 170 abstracts were
eligible for review. On reviewing the abstracts, 69 full-text journal articles seemed to
meet inclusion criteria. On examining full-text journal, 33 articles fulfilled the inclusion
criteria and were included in the meta-analysis. These articles represented 11 (50%)
countries of the Middle Eastern Region with the highest number of studies from Saudi
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Arabia [12 (37%)] followed by Iran and Pakistan each of which contributed five (15%)
studies in this meta-analysis. Out of the total 33 studies included in this meta-analysis, 17
studies included women with GDM, while 15 included women with GDM/PGDM and
one study included women with PGDM only. A total of 118,652 pregnant women were
included in these studies. The studies including women with GDM had a total of 53,744
pregnant women while those including women with GDM/PGDM included 62,320
pregnant women. There were 2,588 pregnant women in the study including women with
PGDM. This meta-analysis investigated caesarean section as the adverse maternal
outcome while macrosomia and perinatal death as adverse fetal outcome. A total of 27
(81.8%) studies examined the association of GDM/PGDM with caesarean section while
26 (78.8%) studied macrosomia and 24 (72.7%) studies observed perinatal deaths.
In this meta-analysis, the association of GDM/PGDM with adverse maternal and
fetal outcomes were expressed as odds ratios and 95% confidence intervals.
Comprehensive Meta-Analysis software (CMA) [Version 2] was used to calculate
individual effect sizes for each study. Because statistical heterogeneity was expected
within included studies, a random-effects model was employed to pool the data, setting
statistical significance at a p value < 0.05. To assess the variance of the true effect sizes
the Q statistic and I2 statistic were computed. Subgroup analysis for the outcomes among
women with GDM and PGDM was conducted to calculate a summary estimate for
subgroups of studies. Sensitivity analysis was done to assess the influence of individual
studies on the results of the meta-analysis. Moderator analysis examined heterogeneity by
observing the influence of differences in study design, year of publication and country of
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origin of the studies. Funnel plot, Duval and Tweedie trim and fill procedure, Egger's
regression test, fail safe N, and Orwin's fail safe N tests were applied to assess the
publication bias.
The pooling of the data showed that odds of undergoing caesarean section in
women with GDM/PGDM was 2.56 times more than those without GDM/PGDM [OR =
2.56, 95% CI (2.13-3.07), p < 0.0001)]. The pooled estimate for women with PGDM and
the outcome of caesarean section (OR = 3.24 95% CI [2.51-4.17], p < 0.0001) was
greater as compared to those with GDM (OR = 2.39, 95% CI [1.84-3.1], p <0.0001).
Overall pooling of all data for macrosomia showed the odds of having a macrosomic
baby in women with GDM/PGDM 3.5 times as compared to those without GDM/PGDM
(OR = 3.51, 95% CI [2.73-4.51], p < 0.0001). The pooled odds ratio for women with
GDM and the outcome of macrosomia (OR = 3.83, 95% CI [2.83-5.18], p < 0.0001) was
more as compared to women with PGDM (OR = 3.51 95% CI [2.22-5.57], p < 0.0001).
The overall pooling of the data showed that odds of perinatal death in women with
GDM/PGDM was 2.46 times more than those without GDM/PGDM (OR = 2.46, 95% CI
[1.81-3.34], p < 0.0001). The pooled odds ratio for women with PGDM and perinatal
death 3.71 (95% CI [2.09-6.57], p < 0.0001) was more as compared to those with GDM
(OR = 2.23, 95% CI [1.40 -3.54], p = 0.0007).
The tests for heterogeneity were statistically significant showing moderate
heterogeneity in most cases. However, there were statistically non-significant results, on
assessing the studies examining delivery by caesarean section and perinatal death, for the
differences in effect sizes according to study design, publication period and country of
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origin of the study. In case of macrosomia, statistically significant differences in effect
sizes were not found for study design and publication period; however, the results were
statistically significant for the difference in effect sizes according to the country of origin
of study. Chapter 5 will include the interpretation of the meta-analysis results, limitations
of this meta-analysis, recommendations and implications for positive social change of
this study.
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Chapter 5: Discussion, Conclusions, and Recommendations
Introduction
To determine the association of GDM/PGDM with adverse pregnancy outcomes
among women in the EMR, I performed a meta-analysis of the research studies
conducted in the EMR. Maternal and fetal outcomes were specified to determine the
magnitude of association between adverse pregnancy outcomes in GDM/PGDM. In this
meta-analysis, caesarean section was studied as adverse maternal outcome while
macrosomia and perinatal mortality were studied as adverse fetal outcomes.
The odds of having an adverse maternal outcome was greater in women with
GDM/PGDM as compared to those without GDM/PGDM. This meta-analysis indicated
that the odds of undergoing caesarean section in women with GDM/PGDM was 2.56
times more than those without GDM/PGDM. The odds of undergoing caesarean section
in women with PGDM was 3.24 times as compared to those without GDM/PGDM while
it was 2.39 times more in women with GDM in comparison to those without
GDM/PGDM.
The odds of having adverse fetal outcomes was greater in women with
GDM/PGDM as compared to those without GDM/PGDM. The odds of having a
macrosomic baby in women with GDM/PGDM was 3.5 times as compared to those
without GDM/PGDM. On subgroup analysis, the odds of having a macrosomic baby in
women with GDM was 3.83 times as compared to those without GDM/PGDM while it
was 3.51 times in women with PGDM as compared to those without GDM/PGDM. On
examining the association of perinatal deaths with GDM/PGDM, the odds of perinatal
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death in women with GDM/PGDM was 2.46 times more than those without
GDM/PGDM. The odds of having perinatal death was higher in women with PGDM
being 3.71 times more as compared to those without GDM/PGDM, while it was 2.23
times more in women with GDM in comparison to those without GDM/PGDM.
Interpretation of the Findings
The findings of this meta-analysis are in accordance with the findings of most of
the studies conducted worldwide as well as in the EMR. However, the results are more
precise and stable as compared to any single study conducted in the EMR. The
interpretation of findings of this meta-analysis and their comparison with the
international literature is discussed according to the 2 research questions, as follow.
Research Question 1
RQ1 asks the following question: Is there an association between delivery by
cesarean section and GDM/PGDM among women in the EMR?
In this meta-analysis, the odds of undergoing caesarean section in women with
GDM/PGDM was 2.56 times greater than those without GDM/PGDM (OR = 2.56, 95%
CI [2.13-3.07], p < 0.0001). This is in accordance with a case-control study conducted in
Kuwait where women with GDM/PGDM had significantly higher rate of caesarean
section (p = 0.008) as compared to those without GDM/PGDM (Diejomaoh et al., 2009).
Sobande et al. (2000) also found a statistically significant association between
GDM/PGDM and delivery by caesarean section. The researchers reported an odds ratio
of 5.22; however, the confidence intervals were wide with a 95% confidence interval of
1.90 to 16.48 (Sobande et al., 2000). To determine the association of GDM and PGDM
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with delivery by cesarean section among women in the EMR, I also conducted subgroup
analysis.
On subgroup analysis, among women with GDM, the odds of being delivered by
caesarean section was 2.39 times as compared to those without GDM (OR= 2.39, 95% CI
[1.84-3.1], p < 0.0001). This strength of association of caesarean section with GDM is
higher as compared to that found in a study from Sweden which was conducted to
determine maternal and neonatal outcomes for women with GDM during 1991-2003. It
was a population-based cohort study using the Swedish Medical Birth Register data. In
this study adjusted odds ratio for caesarean section was 1.46 (95% CI, 1.38-1.54; Fadl,
Östlund, Magnuson, & Hanson, 2010). The finding of this meta-analysis is supported by
various studies in the EMR. In Qatar, the cesarean section rate was significantly higher
in women with GDM as compared to those without GDM (27.9% vs. 12.4%; p <
0.001;Bener et al., 2011). Similarly, in a study of 228 pregnant women higher rate of
cesarean section (68%) was noted among women with GDM as compared to 46.8% (p =
0.009) in those without diabetes (Tahir et al., 2011). The findings of this meta-analysis
are also in accordance to the study by Hossein-Nezhad et al. (2007) in which the odds for
cesarean section were 2.28 times more in women with GDM as compared to those
without GDM. The results were statistically significant at p = 0.0002. In another study
including 420 Iranian women, there was a significant difference between women with
GDM and those without GDM in delivery by cesarean section (RR= 1.96, p < 0.05;
Abolfazl et al. 2008). In contrast to the above studies, certain studies did not show
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statistically significant association between GDM and delivery by caesarean section (AlKhalifah et al., 2012; Nasrat et al., 1997; Al-Shawaf et al., 1988).
In this meta-analysis, the pooled estimate of odds ratio for women with PGDM
and the outcome of caesarean section was 3.24 (95% CI, [2.51-4.17], p<0.0001), which
was higher as compared to those with GDM (OR = 2.39, 95% CI [1.84-3.1], p < 0.0001).
Other studies have also shown that women with PGDM have higher rates of caesarean
section as compared to those with GDM. Shand et al., (2008) studied outcomes of
pregnancies in 370,703 Australian women; out of which 1,248 women had PGDM while
17,128 had GDM. The odds of having delivery by caesarean section was reported in two
categories; caesarean before labor and caesarean after labor. Among women with PGDM,
the odds ratio for caesarean before labor was 4.83 (95% CI, 4.25-5.48) while for
caesarean after labor, it was 3.18 (95% CI, 2.72-3.71). Among women with GDM, the
odds ratio for caesarean before labor was 1.77 (95% CI, 1.70-1.85), while for caesarean
after labor, it was 1.48 (95% CI, 1.41-1.55). Similar results are reported by researchers
from the EMR. A prospective hospital-based study conducted among 100 women with
diabetes (27 women with GDM and 73 women with PGDM) showed that women with
PGDM had higher rate of cesarean section as compared to those with GDM (Akhlaghi &
Hamedi, 2005). In another hospital-based study conducted in Abu Dhabi, 129 records of
women with diabetes delivered over a two year period were reviewed. Of these, 82 had
GDM, and 47 had PGDM. Patients with PGDM had a significantly higher rate of
caesarean sections (p = 0.0147) as compared to those with GDM (Misra et al., 2001).
Similarly, Barakat, et al. (2010) observed a higher strength of association for cesarean
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delivery among women with PGDM (OR = 4.39; 95% CI [1.68-11.49]) as compared to
those with GDM (OR = 2.70; 95% CI [1.17-4.03]). Thus, this meta-analysis showed that
delivery by caesarean section is an important adverse outcome in women having
pregnancy with diabetes. Moreover, among women having pregnancy with diabetes, the
odds of having delivery by caesarean section are greater in women with PGDM as
compared to those with GDM. In addition to higher rates of caesarean section, adverse
fetal outcomes also occur in pregnancy with diabetes and are discussed as follows:
Research Question 2
RQ2 asks the following question: Is there an association between adverse fetal
outcomes and GDM/PGDM among women in the EMR?
RQ2a. Is there an association between macrosomia and GDM/PGDM among
women in the EMR?
The odds of having a macrosomic baby in women with GDM/PGDM was 3.5
times more as compared to those without GDM/PGDM. The pooled odds ratio for
macrosomia and GDM/PGDM among women was 3.51 (95% CI, 2.73-4.51, p < 0.0001).
Diejomaoh et al. (2009) found the incidence of fetal macrosomia in women with
GDM/PGDM double than those without GDM/PGDM (13.6 vs. 5.7%). The odds of
having a macrosomic baby in women with GDM/PGDM was 2.62 (95% CI, 1.213–
5.657) as compared to those without GDM/PGDM (Diejomaoh et al., 2009).
On sub-group analysis, in women with GDM, the odds of having a macrosomic
baby is 3.8 times in comparison to those without diabetes. The pooled odds ratio for
women with GDM and the outcome of macrosomia was 3.83 (95% CI, 2.83-5.18, p <

173
0.0001). Other authors have also reported similar association between macrosomia and
GDM. The finding of this meta-analysis is comparable to the study using the Swedish
Medical Birth Register data for the period 1991-2003, in which the adjusted odds ratios
for large for gestational age newborns among women with GDM was 3.43 (95% CI,
3.21-3.67; Fadl et al., 2010). In another study, live-born infants of Australian women
with GDM were 1.6 times more likely to have a birth weight greater than the 90th
percentile (OR = 1.65, 95% CI, 1.57-1.72; Shand et al., 2008). Similar results were
demonstrated in a cohort study in Iran in which women with GDM had a higher rate of
macrosomia (OR = 3.2; 95% CI [1.2-8.6]) as compared to those without GDM
(Keshavarz et al., 2005). In another study in Iran, Hossein-Nezhad et al. (2007) found
that the odds ratio for macrosomia (OR = 1.93, p = 0.0374) was significantly higher in
women with GDM as compared to those without GDM. Bener et al. (2011) studied a
cohort of 1,608 pregnant women in Qatar, and found that the newborns of women with
GDM were at increased risk of macrosomia (10.3% vs. 5.9%; p = 0.01) than those of
women without GDM. In a cohort study including 420 Iranian women, the newborns of
women with GDM were seven times more at risk of being macrosomic (RR = 7.38, p <
0.05) as compared to those born to women without GDM (Abolfazl et al., 2008).
In this meta-analysis, the pooled estimate of odds ratio for women with PGDM
and the outcome of macrosomia was 3.51 (95% CI, 2.22-5.57, p < 0.0001), which was
lower as compared to those with GDM (OR = 3.83, 95% CI [2.83-5.18], p < 0.0001).
This is in contrast to certain studies where on comparing the strength of association of
macrosomia, women with PGDM were found to be more prone to have a macrosomic
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baby. In a one-year retrospective review of records of 5,394 pregnant women registered
in Oman, 225 had GDM and 56 had PGDM. The risk of macrosomia was three-fold
among women with GDM (OR = 3.03; 95% CI [1.36-6.75]) and approximately sevenfold among those with PGDM (OR = 7.20; 95% CI [2.30-22.61]; Barakat et al., 2010).
Shand et al., (2008) found that the infants of Australian women with PGDM were 4.6
times more likely to have a birth weight greater than the 90th centile (OR = 4.6, 95% CI
4.1-5.2) compared with infants of mothers without diabetes. In the same study the odds of
having a newborn > 90th percentile among women with GDM was 1.65 (95% CI, 1.571.72; Shand et al., 2008).
In contrast to the findings of above studies, some researchers have reported
statistically non-significant association between macrosomia and pregnancy with
diabetes. In a study of 424 pregnant women in Saudi Arabia, infants of women with
diabetes were found to be heavier than those without diabetes, however, the proportion of
babies with birth weight ≥ 2 standard deviations above the mean, were equal in both
groups (Nasrat et al., 1994). In another study of 185 pregnant women with diabetes in
Saudi Arabia, there were 27 (14.6%) with type 1 diabetes forming group 1; 19 (10.2%)
with type 2 diabetes constituting group 2 and 139 (75.2%) with GDM making up group 3.
There were no statistically significant differences in the three groups regarding the mean
birth weight (p > 0.05) of newborns (Sobande et al., 2005). Another retrospective cohort
study among pregnant women with GDM in Saudi Arabia including 766 women (419
women with GDM and 347 without GDM), was also not able to demonstrate statistically
significant association between macrosomia and GDM (Al-Khalifah et al., 2012). To
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sum up, although researchers of primary studies have reported conflicting results
regarding association between macrosomia and GDM/PGDM, there is a clear positive
association between macrosomia and GDM/PGDM among women in the EMR, in this
meta-analysis.
RQ 2b: Is there an association between perinatal mortality and GDM/PGDM among
women in the EMR?
The odds of perinatal death in women with GDM/PGDM was 2.46 times more
than those without GDM/PGDM (OR = 2.46, 95% CI [1.81-3.34], p < 0.0001). The
Confidential Enquiry into Maternal and Child Health in the United Kingdom reported
that perinatal mortality was nearly four-fold in women with diabetes as compared to the
general population (Confidential Enquiry into Maternal and Child Health [CEMACH],
2005). In a cohort study including 420 Iranian pregnant women (70 women with diabetes
and 350 without diabetes), statistically significant difference in still births [RR = 8.87, p
< 0.05] between the two groups was observed (Abolfazl et al., 2008). Misra et al. (2001)
reviewed records of 129 women with diabetes in a hospital-based study in Abu Dhabi.
Perinatal mortality rate was 2.5 times higher among women with diabetes than in the
general population. In a case-control study conducted in Sudan, the perinatal mortality
rate was significantly higher (p < 0.01) among women with diabetes than the total
hospital population. The overall perinatal mortality rate in women with diabetes was 3.5
times more than that for women without diabetes (Dafallah & Yousif, 2004).
Unexplained intrauterine deaths were more common in PGDM (RR = 18.4; 95% CI [3.985.7]) than in GDM (RR = 13.4; 95% CI [29-61.6]; Dafallah & Yousif, 2004).
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In this meta-analysis, the pooled odds ratio for women with GDM and the
outcome of perinatal death was 2.23 (95% CI [1.40-3.54], p = 0.0007). This finding is
consistent with the results of various studies. On a review of pregnancy outcome in
116,303 pregnancies, at the Mercy Hospital for Women, GDM was found to be
associated with an increased risk of perinatal mortality (OR = 1.53, 95% CI [1.13-2.06];
Beischer et al., 1996). Similarly, Shand et al. (2008) found that Australian women with
PGDM and GDM were at increased risk of mortality in infants as compared to those
without diabetes. They found the odds of having a still birth among women with GDM as
1.17 (95% CI, 0.88-1.54). Studies from Middle Eastern region have also shown an
increased perinatal mortality rate in women with GDM/PGDM. In Iran, in a prospective
cohort study of 1,310 Iranian pregnant women, babies born to women with GDM had a
higher rate of stillbirth (OR = 17.1, 95% CI [4.5-65.5]; Keshavarz et al., 2005). Because
of less number of events in any single study, most of the studies from EMR did not have
statistically significant association between GDM and perinatal deaths (Almarzouki,
2013; Barakat et al., 2010; El Mallah et al., 1997; Gasim, 2012; Nasrat et al., 1996;
Wahabi et al., 2013). However, combining results of these studies by meta-analysis
showed statistically significant association of perinatal deaths and GDM.
In this meta-analysis, the pooled odds ratio for women with PGDM and perinatal
death was 3.71 (95% CI [2.09 - 6.57], p < 0.0001). Shand et al. (2008) found an odds
ratio of 2.90 (95% CI, 1.81-4.60) for still birth among Australian women with PGDM. In
an attempt to explore major risk factors for still births in high income countries, a metaanalysis of five studies showed that the odds of stillbirth increased nearly three times for
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women with PGDM (OR = 2.90, 95% CI, 2.05-4.09), however, the same study did not
demonstrate an increased risk of still birth among women with GDM (Flenady et al.,
2011). Because of few numbers of perinatal deaths in any single study, most of the
primary studies from the EMR did not report a statistically significant association
between perinatal deaths and PGDM (Abdelgadir et al., 2003; Al Teheawt& Farida,
1995; Barakat et al., 2010; Wahabi et al., 2012). However, merging the results of these
studies by meta-analysis lead to a statistically significant association found between
perinatal deaths and PGDM.
Researchers have compared outcomes of pregnancy in women with type 1
diabetes, type 2 diabetes and GDM. Greater risk of perinatal deaths, among women with
type 2 diabetes as compared to those with type 1 diabetes or GDM, are reported (Cundy
et al., 2000; Dunne et al., 2003; Jensen et al., 2004; Macintosh, 2006). In a meta-analysis
conducted to compare maternal and fetal outcomes in pregnant women with type 2 and
type 1 DM, the researchers found that women with type 2 DM had a greater risk of
perinatal mortality (OR = 1.50, 95% CI [1.15-1.96]; Balsells et al., 2009). Although
incidence of perinatal mortality is shown to vary according to the type of diabetes, in this
meta-analysis because of limited available data perinatal mortality could not be analyzed
according to the types of diabetes.
An increased perinatal mortality rate is especially important in settings where
appropriate obstetric care is not accessible to the whole population (IDF, 2009; Schmidt
et al., 2001). Because of poor socioeconomic conditions, some countries of the EMR
such as Somalia, Afghanistan and Pakistan, are not able to provide access to obstetric
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care to a substantial proportion of their population. Thus, it is important to determine the
perinatal mortality attributed to pregnancy with GDM/PGDM.
Meta-analysis Findings in Context of Conceptual Model
For this meta-analysis, epidemiologic triangle was used as the conceptual model.
The epidemiologic triangle is a traditional model examining the agent, the host, and the
environmental factors to examine causation of infectious disease (CDC, 2009). However,
it has also been used for chronic diseases and other health problems.
Agent
For GDM and its outcomes, the agent which is the cause of the condition, is
insulin. During pregnancy, some hormones (human placental lactogen, estrogen, and
cortisol) secreted by placenta can have a blocking effect on insulin, named as "insulin
resistance." GDM results if the insulin secretion is not adequate to counter the effect of
the placental hormones (Ohio State University, n.d.). Generally production of insulin
increases during pregnancy, however, there is less insulin secretion in women with GDM
as compared to those without GDM (Abayomi, Wood, Spelman, Morrison, & Purewal,
2013). Adverse outcomes of GDM/PGDM such as macrosomia, delivery by caesarean
section and perinatal mortality are associated with insulin resistance during pregnancy
(Young & Ecker, 2013).
Host
The host factors comprise of non-modifiable and modifiable factors. Nonmodifiable factors include age (women more than 25 years age are at a higher risk for
developing GDM than younger women); race (Asian American, American Indian,
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African-American, Hispanic/Latino, or Pacific Islander have a greater risk); having given
birth previously to macrosomic baby, or a still birth (Ben-Haroush et al., 2006; Ferrara,
2007). Modifiable factors include overweight/obesity; lifestyle factors including diet and
physical activity (Iqbal, 2005)..
Perinatal outcomes among women with GDM differ by ethnicity. These variations
may occur due to genetic factors as well as cultural traditions and diet during pregnancy
influencing glycemic control. Another factor is variation in prenatal care accessibility and
quality of available prenatal care (Nguyen et al., 2012). In the Middle Eastern region,
various important demographic, lifestyle, and health transitions have occurred during
previous decades. However, these transitions vary in different countries as the ethnicity,
socio-cultural conditions, and economic situation varies among the member countries
(Zabetian, Keli, Echouffo-Tcheugui, Narayan, & Ali, 2013). These variations could also
be seen among the studies included in this meta-analysis. Strength of association with
various adverse outcomes varied from country to country. The studies were assessed for
differences in effect sizes according to the country of origin of study. The pooled odds
ratio for adverse maternal and fetal outcomes varied among countries, however the
differences among countries were not significant statistically for delivery by caesarean
section and perinatal deaths while the differences among countries was statistically
significant (p < 0.0001) in case of macrosomia.
Environment
Environmental factors that contribute to GDM may include physical, social and
economic environment. Availability and affordability of healthy food; cultural values and
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accessibility to health care facilities are some of the environmental factors playing their
role in the etiology of GDM. In turn, these environmental factors are also related to
maternal and fetal outcomes of PGDM/GDM including macrosomia, caesarean delivery
and perinatal mortality (El-Chaar et al., 2013; Yogev & Visser, 2009).
GDM and PGDM are becoming more prevalent in pregnancy, however, it is
observed that women with diabetes often do not receive optimal pre-conception care and
antenatal care (Abayomi et al., 2013). The high incidence of some adverse pregnancy
outcomes associated with GDM in low- and middle-income countries may signify
inadequate care for women with GDM in these countries (Zabetian et al., 2013). It is
estimated that 98% of all perinatal deaths occur in low-income countries where perinatal
mortality rate is approximately five times higher than high-income countries (Cloke &
Pasupathy, 2013). In my meta-analysis study, there is greater strength of association for
perinatal deaths as compared to the findings of the studies conducted in developed
nations, as the EMR comprises both middle-income and low- income countries. One of
the reasons for higher perinatal death rate in low-income countries is that only around
40% of births in low-income countries are attended by trained health care workers in
comparison to almost 100% in the high income countries (Cloke & Pasupathy, 2013).
To sum up, the conceptual model for this study is epidemiologic triangle. Agent,
host and environment play an important role in the causation of diabetes mellitus,
PGDM/GDM, and their adverse maternal and fetal outcomes.
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Limitations of the Study
This study has limitations which correspond with the limitations of meta-analyses
in general (Garg et al., 2008). This meta-analysis includes diverse studies with different
settings, designs, and study participants. The quality and reliability of the overall effect
size and conclusions of this meta-analysis depends on the reliability and appropriateness
of methods used by the primary studies. Meta-analysis of observational studies has
certain specific limitations which are also reflected in my study. The role of chance,
confounding factors, or biases, may affect the results in primary observational studies
which could not be rectified in this meta-analysis (Egger et al., 2008). Another limitation
specific to this meta-analysis is the variability in defining the dependent and independent
variables in primary studies. Different diagnostic criteria were used for GDM in various
studies. Similarly, definition of macrosomia/large for gestational age also varied in
primary studies. In some studies, women with impaired glucose tolerance test (IGTT)
were also included along with women with GDM/PGDM. In most of these studies, data
for women with IGTT were separately analyzed. However, in two studies (Diejomaoh et
al., 2009; Khan et al., 1995), it was not done and women with IGTT were also included in
this meta-analysis. In the study of Diejomaoh et al. (2009), among 177 cases with
diabetes mellitus, 25 cases of IGTT were also included and the data were not analyzed
separately. Khan et al. (1995) had included 292 women with abnormal GTT in their
study; out of which 177 were with GDM while 115 were with IGTT. Data analysis was
not presented separately for these groups. As women with IGTT are less prone to have
adverse pregnancy outcomes, this inclusion of women with IGTT might have decreased
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the strength of association between exposure and outcome, observed in this metaanalysis.
Other limitations related to selection of participants in the primary studies might
have affected the results of this meta-analysis. Researchers in a case- control study
(Almarzouki, 2013) had included women with GDM as cases while the controls were
high risk women without GDM. This inclusion might have decreased the strength of
association between exposure and outcome as the high risk women are more prone to
have adverse pregnancy outcomes. Fadwa et al. (2013) collected data from women with
diabetes and those without diabetes through structured questionnaires. Women were
asked about history of various adverse pregnancy outcomes. The data collected in this
study may have limitations because of recall bias. Because of limitations of the primary
studies, this meta-analysis has certain threats to validity which are discussed in the next
section.
Threats to Validity
This meta-analysis has threats to the validity by factors that might lead to
incorrect inferences (Cooper et al., 2009). There are threats to construct validity, internal
validity, statistical conclusion validity, and external validity. These threats to validity are
discussed as follows:
Construct Validity
It is important for meta-analysis that the effect sizes calculated from various
measures can be compared directly (Nugent, 2009). For this purpose, definitions of
variables should be consistent in the primary studies and meta-analysis. In my study, the
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definitions used in the primary studies were not consistent. The criteria for diagnosis of
GDM were not consistent in primary studies. Some studies used WHO criteria; while
others used Carpenter and Coustan criteria; O'sullivan's criteria; American Diabetes
Association criteria; or National Diabetes Data Group (NDDG) criteria. Similarly,
definition of macrosomia varied in primary studies; some studies used the cut-off weight
of 4,000 grams (Bener et al., 2011; El Mallah et al., 1997; Khan, Ali, & Khan, 2013),
some used 4,500 grams (Barakat et al., 2010; Johnstone et al., 1990) for defining
macrosomia; while others used the term large for gestational age (Abdelgadir et al., 2003;
Al-Khalifah et al., 2012; Almarzouki, 2013). Similarly, various studies used different
descriptions for perinatal deaths. Only one study (Almarzouki, 2013) defined perinatal
mortality as fetal or neonatal death from 22 weeks of pregnancy to four weeks after birth.
Al-Mejhim & Al-Najashi (1998) defined perinatal deaths as all stillbirths and all live
babies who weighed 500 g or more and died in the first week of life. Some studies
reported still births/intrauterine fetal deaths and early neonatal deaths while others had
included only still births/intrauterine fetal deaths. Nasrat et al. (1993) had included only
neonatal deaths. The discrepancies in various variable definitions might have pushed
toward or pulled away the results from the null value.
Internal Validity
Internal validity refers to the validity of associations inferred from the results of
the primary studies. Meta-analysis of observational studies has certain specific limitations
which are threats to internal validity. Estimates of association in observational studies
may not depict true associations because of various factors. In addition to the role of
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chance, confounding factors, biases, or both may affect the results in observational
studies. The exposed study participants may be different in various ways which are
related to the risk of developing the outcome of interest (Egger et al., 2008). The effect of
residual confounding is another threat to validity of meta-analysis of observational
studies (Flenady et al., 2011). Many case- control studies in this meta-analysis had not
matched the cases and controls for important confounding factors, which may have
affected the results of those primary studies (Al-Khalifah et al., 2012; Almarzouki, 2013;
Al Teheawt & Farida, 1995; Barakat et al., 2010), in turn reflecting on the results of this
meta-analysis.
Statistical Conclusion Validity
Statistical conclusion validity refers to the application of appropriate statistical
tests in primary studies (Cooper et al., 2009). The quality and reliability of the overall
effect size and conclusions of meta-analysis depends on the reliability and
appropriateness of methods used by the primary studies. The statistical results of the
meta-analysis depend upon the statistical analysis conducted in primary studies, such as
control of confounding factors by using logistic regression. Most of the primary studies in
this meta-analysis did not use logistic regression or other statistical test to control
confounding factors which may have affected the results of this meta-analysis.
External Validity
External validity refers to the generalization of the results of meta-analysis
(Cooper et al., 2009). Meta-analysis includes diverse studies differing in their study
participants enrolled from various geographical regions. My study generalizes the results
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to the population of EMR. The studies selected for inclusion in meta-analysis did not
include studies from all countries in the EMR, leading to threats to the external validity.
None of the studies could be found from low-income countries such as Afghanistan,
Yemen and Somalia which may have a different picture of adverse pregnancy outcomes
among women with GDM/PGDM.
Recommendations
This meta-analysis has generated questions for future research beyond the scope
of this study. These questions concern five areas: (a) reasons for higher magnitude of
association of adverse pregnancy outcomes among women in the EMR as compared to
other parts of the world, (b) magnitude of association of adverse pregnancy outcomes
among women in those countries of EMR from where no studies were available, (c)
research to get a broader picture of the situation in the EMR by a multi-country study, (d)
population-based research for determining adverse pregnancy outcomes among women
deprived of care by an appropriate health care facility, and (e) research to determine the
health seeking patterns of women with GDM/PGDM, as in many countries of the EMR,
home deliveries are common. A large scale study with uniform definitions for
macrosomia and perinatal mortality may also be conducted in the Region so that valid
comparisons are possible and real picture of this important public health problem is
gained.
Implications
Filling gaps in the literature helps in creating positive social change which is an
important aspect of this study. This meta-analysis provides a broader perspective of
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adverse pregnancy outcomes associated with GDM/PGDM among women in the EMR.
By combining the results of small-scale published studies with small sample sizes and
few adverse outcomes among women in the EMR, this meta-analysis has filled the
literature gap through providing stable and statistically significant estimates of
association. This meta-analysis has also demonstrated the magnitude of association
between GDM/PGDM and adverse pregnancy outcomes among women in the EMR,
which is an important initial step prior to research efforts focusing on the epidemiology
of adverse pregnancy outcomes as they relate to PGDM and GDM in the EMR.
Information about the strength of association of GDM/PGDM with adverse pregnancy
outcomes is helpful in creating awareness about the severity and seriousness of the
problem. Disseminating the results of this study can lead to measures taken by the policy
makers and health care workers to develop intervention strategies for prevention of
complications related to GDM/PGDM. Thus, an implication for social change resulting
from this meta-analysis includes making health care providers aware of the magnitude of
problem related to GDM/PGDM. Awareness of the problem can enhance the ability of
the health care providers to identify, diagnose and properly manage the women with
GDM/PGDM.
In light of the findings of this meta-analysis, I suggest three recommendations.
The first recommendation is for health care workers to follow the guidelines for
screening and managing the pregnant women with GDM/PGDM. The second
recommendation is for health education workers to create awareness among women with
GDM/PGDM to follow the instructions by health care providers. Traditionally, home
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deliveries are practiced in some countries of the EMR. Encouraging women with
GDM/PGDM to receive antenatal check ups and delivery in a well-equipped health care
facility can play vital role in reducing adverse pregnancy outcomes and associated
complications (Koyanagi et al., 2013). The third recommendation is for the decision
makers to keep updating the policies and guidelines related to GDM/PGDM and to assure
implementation of these guidelines. Pre-conception care for women with PGDM is
associated with better outcomes (Canadian Diabetes Association Clinical Practice
Guidelines Expert Committee et al., 2013). Therefore, optimal pre-conception care may
be provided to women with PGDM. The policy makers should also consider providing
specialized health care for women with GDM/PGDM, during pregnancy and in the
postpartum period to reduce adverse maternal and fetal outcomes. These intervention will
also help women in making changes to their lifestyle, thus, improving their health in the
long term (Abayomi et al., 2013)
Conclusion
GDM/PGDM is associated with significant maternal and fetal morbidity,
including delivery by caesarean section, macrosomia and perinatal deaths (Carolan, 2013;
Cho, 2013). The number of women with GDM is increasing steadily, which may be
attributed to higher maternal age, increasing prevalence of obesity, and sedentary
lifestyles (Cho, 2013). In the EMR, these demographic and lifestyle changes have
occurred during previous decades (Zabetian et al., 2013). In this meta-analysis study
there was a strong association between adverse maternal and fetal outcomes and
GDM/PGDM and I recommend that health care providers and policy makers design
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intervention measures to create awareness among women. Moreover, guidelines and
protocols for care of women with diabetes should be developed and implemented to
decrease the adverse outcomes. Interventions during pregnancy provide important
opportunities to improve the health of mothers and children (Cho, 2013). Healthy
mothers and children are vital for a healthy and productive community, and for a
prosperous world.
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Appendix A: MOOSE Guidelines
MOOSE: (Meta-analysis of observational studies in epidemiology): A checklist for
authors, editors, and reviewers of meta-analyses of observational studies.
Reporting background should include
x

Problem definition

x

Hypothesis statement

x

Description

x

Type of exposure or intervention used

x

Type of study designs used

x

Study population

Reporting of search strategy should include
x

Qualifications of searches (e.g. librarians and investigators)

x

Search strategy, including time period included in the synthesis and keywords

x

Effort to include all available studies, including contact with authors

x

Databases and registries searched

x

Search software used, name and version, including special features

x

Use of hand searching (e.g. reference lists of obtained articles)

x

List of citations located and those excluded including justification

x

Method of addressing articles published in languages other than English

x

Method of handling abstracts and unpublished studies

x

Description of any contact with authors
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Reporting methods should include
x

Description of relevance or appropriateness of studies assembled for assessing the
hypothesis to be tested

x

Rationale for the selection and coding of data (eg, sound clinical principles or
convenience)

x

Documentation of how data were classified and coded (eg, multiple raters,
blinding, and interrater reliability)

x

Assessment of confounding (eg, comparability of cases and controls in studies
where appropriate)

x

Assessment of study quality, including blinding of quality assessors; stratification
or regression on possible predictors of study results

x

Assessment of heterogeneity

x

Description of statistical methods (eg, complete description of fixed or random
effects models, justification of whether the chosen models account for predictors
of study results, dose-response models, or cumulative meta-analysis) in sufficient
detail to be replicated

x

Provision of appropriate tables and graphics

x

Table giving descriptive information for each study included

Reporting of results should include
x

Graphic summarizing individual study estimates and overall estimate

x

Results of sensitivity testing (eg, subgroup analysis)

x

Indication of statistical uncertainty of findings
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Reporting of discussion should include
x

Assessment of quality of included studies

x

Justification for exclusion (eg, exclusion of non–English-language citations)

x

Quantitative assessment of bias (eg, publication bias)

Reporting of conclusions should include
x

Consideration of alternative explanations for observed results

x

Generalization of the conclusions (ie, appropriate for the data presented and
within the domain of the literature review)

x

Guidelines for future research

x

Disclosure of funding source

Note: Adapted with permission of the author from "Meta-analysis of observational
studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational
Studies in Epidemiology (MOOSE) group" by,. D. F. Stroup, J. A. Berlin, S. C. Morton,
I. Olkin, G. D.Williamson, D. Rennie, … S. B. Thacker, 2000, JAMA: The Journal of the
American Medical Association, 283(15), p.2010. Copyright 2000 by the American
Medical Association
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Appendix B: Dummy Table for Summary of Research Studies Included in Meta-Analysis
Characteristics of observational studies of Pregestational/ Gestational Diabetes and
Adverse Pregnancy Outcomes in Eastern Mediterranean Region
Study
No

Author

Country

Study
Design

Time
Period

Sample
size(n)

Type of
Maternal
Diabetes

Outcome
Maternal

Fetal
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Appendix C: Data Abstraction Form
Sr. No:
Author:
Journal Article Title:
Country:
Study Design:
Time Period during which study was conducted:
Sample Size:
Mean Maternal Age:
Type of Diabetes:
Pregnancy Outcomes
Fetal Outcome:
Macrosomia
Perinatal mortality
Maternal Outcome:
C-section
Comments:________________________________________________________________________
________________________________________________________________________

Quality Assessment:
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
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Reported Measures of Effect and Confidence Intervals
Caesarean Section:__________________________
Macrosomia: _______________________________
Perinatal Mortality:__________________________

Dummy 2X2 Tables for calculation of Measures of Effect and Confidence Intervals

Odds Ratio (95% Confidence Interval)=

Odds Ratio (95% Confidence Interval)=
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Odds Ratio (95% Confidence Interval)=

Odds Ratio (95% Confidence Interval)=
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Odds Ratio (95% Confidence Interval)=

Odds Ratio (95% Confidence Interval)=
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Odds Ratio (95% Confidence Interval)=

Odds Ratio (95% Confidence Interval)=
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Appendix D: PRISMA Checklist
Section/topic
Title
Title
Abstract
Structured
summary

Introduction
Rationale
Objectives

Methods
Protocol and
registration

Eligibility
criteria

Information
sources
Search

Study selection

# Checklist item
1 Identify the report as a systematic review, meta-analysis,
or both.
2 Provide a structured summary including, as applicable:
background; objectives; data sources; study eligibility
criteria, participants, and interventions; study appraisal
and synthesis methods; results; limitations; conclusions
and implications of key findings; systematic review
registration number.
3 Describe the rationale for the review in the context of
what is already known.
4 Provide an explicit statement of questions being
addressed with reference to participants, interventions,
comparisons, outcomes, and study design (PICOS).
5 Indicate if a review protocol exists, if and where it can
be accessed (e.g., Web address), and, if available,
provide registration information including registration
number.
6 Specify study characteristics (e.g., PICOS, length of
follow-up) and report characteristics (e.g., years
considered, language, publication status) used as criteria
for eligibility, giving rationale.
7 Describe all information sources (e.g., databases with
dates of coverage, contact with study authors to identify
additional studies) in the search and date last searched.
8 Present full electronic search strategy for at least one
database, including any limits used, such that it could be
repeated.
9 State the process for selecting studies (i.e., screening,
eligibility, included in systematic review, and, if
applicable, included in the meta-analysis).

Reported on
page #
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Data collection
process

Data items

Risk of bias in
individual
studies
Summary
measures
Synthesis of
results
Risk of bias
across studies
Additional
analyses
Results
Study selection

Study
characteristics
Risk of bias
within studies
Results of
individual
studies
Synthesis of
results
Risk of bias
across studies

10 Describe method of data extraction from reports (e.g.,
piloted forms, independently, in duplicate) and any
processes for obtaining and confirming data from
investigators.
11 List and define all variables for which data were sought
(e.g., PICOS, funding sources) and any assumptions and
simplifications made.
12 Describe methods used for assessing risk of bias of
individual studies (including specification of whether
this was done at the study or outcome level), and how
this information is to be used in any data synthesis.
13 State the principal summary measures (e.g., risk ratio,
difference in means).
14 Describe the methods of handling data and combining
results of studies, if done, including measures of
consistency (e.g., I2) for each meta-analysis.
15 Specify any assessment of risk of bias that may affect
the cumulative evidence (e.g., publication bias, selective
reporting within studies).
16 Describe methods of additional analyses (e.g.,
sensitivity or subgroup analyses, meta-regression), if
done, indicating which were pre-specified.
17 Give numbers of studies screened, assessed for
eligibility, and included in the review, with reasons for
exclusions at each stage, ideally with a flow diagram.
18 For each study, present characteristics for which data
were extracted (e.g., study size, PICOS, follow-up
period) and provide the citations.
19 Present data on risk of bias of each study and, if
available, any outcome level assessment (see item 12).
20 For all outcomes considered (benefits or harms),
present, for each study: (a) simple summary data for
each intervention group (b) effect estimates and
confidence intervals, ideally with a forest plot.
21 Present results of each meta-analysis done, including
confidence intervals and measures of consistency.
22 Present results of any assessment of risk of bias across
studies (see Item 15).
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Additional
analysis
Discussion
Summary of
evidence

Limitations

Conclusions

23 Give results of additional analyses, if done (e.g.,
sensitivity or subgroup analyses, meta-regression [see
Item 16]).
24 Summarize the main findings including the strength of
evidence for each main outcome; consider their
relevance to key groups (e.g., healthcare providers,
users, and policy makers).
25 Discuss limitations at study and outcome level (e.g., risk
of bias), and at review-level (e.g., incomplete retrieval
of identified research, reporting bias).
26 Provide a general interpretation of the results in the
context of other evidence, and implications for future
research.

Funding
Funding

27 Describe sources of funding for the systematic review
and other support (e.g., supply of data); role of funders
for the systematic review.
Note. Adapted from "Preferred Reporting Items for Systematic Reviews and MetaAnalyses: The PRISMA Statement" by D. Moher, A. Liberati, J. Tetzlaff, D. G. Altman,
& The PRISMA Group, 2009. PLoS Med, 6(7), e1000097.
doi:10.1371/journal.pmed.1000097
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Appendix E: Form for Quality Assessment of Studies
Cohort study
• Appropriate cohort selection
(The eligibility criteria, and the sources and methods of selection of participants are mentioned. Methods of
follow-up are described)

Yes

Partially

No

Can't tell

Partially

No

Can't tell

• Appropriate sample size
Yes
• Properly described cohort
(For matched studies, matching criteria and number of exposed and unexposed are stated)

Yes

Partially

No

Can't tell

• Clear description of diagnostic criteria for GDM/PGDM
Yes

Partially

No

Can't tell

No

Can't tell

• Clear definition of the outcomes
Yes

Partially

• Description of the methods for ascertaining outcomes
Yes

Partially

No

Can't tell

No

Can't tell

• Description of lost to follow up
Yes

Partially

• Appropriateness of statistical analyses
(Analysis with control for confounding factors taken into account)

Yes

Partially

No

Can't tell
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Case-control study
• Selection of cases in an appropriate and unbiased manner
(The eligibility criteria, and the sources and methods of case ascertainment are stated)

Yes

Partially

No

Can't tell

No

Can't tell

• Selection of controls in an appropriate manner
Yes

Partially

• Matching of cases and controls regarding potential confounders
(For matched studies, matching criteria and the number of controls per case are stated)

Yes

Partially

No

Can't tell

No

Can't tell

No

Can't tell

No

Can't tell

• Description of diagnostic criteria
Yes

Partially

• Clear definition of outcomes
Yes

Partially

• Address the potential sources of bias
Yes

Partially

• Appropriateness of statistical analyses
(Analysis with control for confounding factors taken into account)

Yes

Partially

No

Can't tell
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Cross-sectional study
x

Adequate sample size

(Calculation of sample size is explained)

Yes
x

Partially

No

Can't tell

Appropriate methods of selection of participants

(Eligibility criteria, and the sources and methods of selection of participants are stated)

Yes
x

Can't tell

Partially

No

Can't tell

No

Can't tell

Clear definition of outcomes
Yes

x

No

Description of diagnostic criteria
Yes

x

Partially

Partially

Appropriate sources of data and methods of assessment for outcomes

(For each outcome, sources of data and methods of assessment for outcome is described)

Yes
x

Partially

No

Can't tell

No

Can't tell

Address the potential sources of bias

(Efforts to address potential sources of bias are described)

Yes
x

Partially

Appropriateness of statistical analyses

(Analysis with control for confounding factors taken into account)

Yes

Partially

No

Can't tell
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Appendix F: STROBE Guidelines
STROBE Statement—checklist of items that should be included in reports of
observational studies
Item
No

Recommendation

Title and abstract

1

(a) Indicate the study’s design with a commonly used
term in the title or the abstract
(b) Provide in the abstract an informative and balanced
summary of what was done and what was found

Introduction
Background/rationale

2

Objectives

3

Explain the scientific background and rationale for the
investigation being reported
State specific objectives, including any prespecified
hypotheses

Methods
Study design
Setting

4
5

Participants

6

Variables

7

Data sources/
measurement

8*

Bias

9

Present key elements of study design early in the paper
Describe the setting, locations, and relevant dates,
including periods of recruitment, exposure, follow-up,
and data collection
(a) Cohort study—Give the eligibility criteria, and the
sources and methods of selection of participants.
Describe methods of follow-up
Case-control study—Give the eligibility criteria, and the
sources and methods of case ascertainment and control
selection. Give the rationale for the choice of cases and
controls
Cross-sectional study—Give the eligibility criteria, and
the sources and methods of selection of participants
(b) Cohort study—For matched studies, give matching
criteria and number of exposed and unexposed
Case-control study—For matched studies, give
matching criteria and the number of controls per case
Clearly define all outcomes, exposures, predictors,
potential confounders, and effect modifiers. Give
diagnostic criteria, if applicable
For each variable of interest, give sources of data and
details of methods of assessment (measurement).
Describe comparability of assessment methods if there
is more than one group
Describe any efforts to address potential sources of bias
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Study size
Quantitative variables

10
11

Statistical methods

12

Results
Participants

Descriptive data

Outcome data

Main results

Explain how the study size was arrived at
Explain how quantitative variables were handled in the
analyses. If applicable, describe which groupings were
chosen and why
(a) Describe all statistical methods, including those used
to control for confounding
(b) Describe any methods used to examine subgroups
and interactions
(c) Explain how missing data were addressed
(d) Cohort study—If applicable, explain how loss to
follow-up was addressed
Case-control study—If applicable, explain how
matching of cases and controls was addressed
Cross-sectional study—If applicable, describe analytical
methods taking account of sampling strategy
(e) Describe any sensitivity analyses

13* (a) Report numbers of individuals at each stage of study—eg
numbers potentially eligible, examined for eligibility, confirmed
eligible, included in the study, completing follow-up, and
analysed
(b) Give reasons for non-participation at each stage
(c) Consider use of a flow diagram
14* (a) Give characteristics of study participants (eg demographic,
clinical, social) and information on exposures and potential
confounders
(b) Indicate number of participants with missing data for each
variable of interest
(c) Cohort study—Summarise follow-up time (eg, average and
total amount)
15* Cohort study—Report numbers of outcome events or summary
measures over time
Case-control study—Report numbers in each exposure category,
or summary measures of exposure
Cross-sectional study—Report numbers of outcome events or
summary measures
16 (a) Give unadjusted estimates and, if applicable, confounderadjusted estimates and their precision (eg, 95% confidence
interval). Make clear which confounders were adjusted for and
why they were included
(b) Report category boundaries when continuous variables were
categorized
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Other analyses

17

Discussion
Key results
Limitations

18
19

Interpretation

20

Generalisability

21

Other information
Funding
22

(c) If relevant, consider translating estimates of relative risk into
absolute risk for a meaningful time period
Report other analyses done—eg analyses of subgroups and
interactions, and sensitivity analyses
Summarise key results with reference to study objectives
Discuss limitations of the study, taking into account sources of
potential bias or imprecision. Discuss both direction and
magnitude of any potential bias
Give a cautious overall interpretation of results considering
objectives, limitations, multiplicity of analyses, results from
similar studies, and other relevant evidence
Discuss the generalisability (external validity) of the study
results
Give the source of funding and the role of the funders for the
present study and, if applicable, for the original study on which
the present article is based

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed
and unexposed groups in cohort and cross-sectional studies.

Source: University of Bern. (2009). STROBE Statement: STROBE checklists. Retrieved
from http://www.strobe-statement.org/?id=available-checklists
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Permission for Table 2

Permission for Appendix A: MOOSE Guidelines
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